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	ABSTRACT	
	
Leber’s	hereditary	optic	neuropathy	(LHON)	 is	due	in	90%	of	cases	to	three	common	point	
mutations	affecting	complex	I	subunit	genes	encoded	by	the	mitochondrial	genome	(mtDNA).	
Besides	these	common	mutations,	there	is	a	long	and	complex	list	of	other	mutations	involved	
at	various	levels	in	the	pathogenesis	of	LHON.	On	this	scenario,	we	here	report	for	the	first	
time	on	 the	 existence	of	 LHON	associated	with	 peculiar	 combinations	 of	 individually	 non-
pathogenic	missense	mtDNA	variants,	affecting	the	MT-ND4,	MT-ND4L	and	MT-ND6	subunit	
genes	of	Complex	 I.	 The	pathogenic	potential	of	 these	mtDNA	haplotypes	 is	 supported	by	
multiple	evidences:	first,	the	LHON	phenotype	is	strictly	inherited	along	the	maternal	line	in	
one	very	large	family;	second,	the	combinations	of	mtDNA	variants	are	unique	to	the	maternal	
lineages	characterized	by	the	recurrence	of	LHON;	third,	the	Complex	I-dependent	respiratory	
and	oxidative	phosphorylation	defect	is	co-transferred	from	the	proband’s	fibroblasts	into	the	
cybrid	cell	model.	Finally,	all	but	one	of	these	missense	mtDNA	variants	clustered	along	the	
same	predicted	fourth	E-channel	deputed	to	proton	translocation	within	the	transmembrane	
domain	of	Complex	I,	involving	the	ND1,	ND4L	and	ND6	subunits.	
Hence,	the	definition	of	the	pathogenic	role	of	a	specific	mtDNA	mutation	becomes	blurrier	
than	ever	and	only	an	accurate	evaluation	of	mitogenome	sequence	variation	data	from	the	
general	population,	combined	with	functional	analyses	using	the	cybrid	cell	model,	may	lead	
to	 final	 validation.	 Our	 study	 conclusively	 shows	 that	 even	 in	 the	 absence	 of	 a	 clearly	
established	 LHON	 primary	 mutation,	 unprecedented	 combinations	 of	 missense	 mtDNA	
variants,	 individually	 known	 as	 polymorphisms,	 may	 lead	 to	 reduced	 OXPHOS	 efficiency	
sufficient	to	trigger	LHON.	
With	 this	 complexity	 in	mind,	mtDNA	genetic	 variation	 itself	may	play	 a	modifying	 role	 in	
LHON.	 Many	 studies	 reported	 the	 association	 of	 LHON	 and	 a	 specific	 mitochondrial	
haplogroup	classified	as	J.	Here	we	present	the	largest	sequence	survey	of	the	entire	mtDNA	
ever	 performed	 assessing	 119	 independent	 probands	 from	 all	 Europe	 carrying	 the	
m.14484T>C/MT-ND6	mutation.	Besides	the	occasional	finding	of	double	mutants,	we	confirm	
the	 association	with	 the	 haplogroup	 J	 root,	 but	 not	 with	 its	more	 recent	 sub-clades.	 The	
phylogenetic	 analysis	 suggests	 a	 possible	 double	 role	 of	 this	 haplogroup:	 it	 may	 act	 as	
predisposing	 factor	 to	 mutagenesis	 at	 m.14484T	 position,	 or	 preserving	 the	 pathogenic	
	mutation	 during	 evolution.	 On	 the	 clinical	 ground,	 the	 penetrance	 of	 LHON	 due	 to	
m.14484T>C/MT-ND6	 mutation	 increases	 on	 the	 haplogroup	 J	 background,	 especially	 in	
females,	and	multiple	founder	haplogroup	J	events	can	be	recognized	in	our	cohort.	
Considering	the	strong	association	of	mtDNA	haplogroups	with	LHON,	we	also	investigated	if	
a	similar	association	may	act	on	Dominant	Optic	Atrophy	(DOA).	This	is	another	inherited	optic	
neuropathy	 similar	 to	 LHON,	 caused	by	mutations	 in	 the	OPA1	gene,	which	encodes	 for	a	
protein	 essential	 for	 mitochondrial	 fusion	 and	 mitochondrial	 homeostasis.	 Our	 results	
indicated	that	the	relationship	of	DOA	with	mtDNA	genetic	variation	is	complex:	no	specific	
haplogroups	 resulted	 strongly	 associated	 with	 DOA,	 neither	 clearly	 modified	 its	 clinical	
outcome.	 We	 only	 documented	 a	 minor	 effect	 of	 the	 mitogenome	 variation	 in	 DOA,	 in	
particular	when	compared	with	what	it	seems	a	definitely	stronger	role	as	modifier	played	by	
nDNA.	
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INTRODUCTION	
	
Mitochondria:	origin,	structure	and	functions	
Mitochondria	are	unusual	organelles.	They	primarily	act	as	the	powerhouse	of	the	cell,	but	
they	 are	 also	 involved	 in	 programmed	 cell	 death,	 calcium	 homeostasis	 and	 several	
biosynthetic	pathways.	They	are	wrapped	by	two	membranes,	they	have	their	own	genome,	
an	 independent	 protein	 synthesis	 apparatus,	 and	 can	 change	 their	 shape	 to	 adapt	 to	 the	
different	metabolic	needs	of	the	cell,	from	discrete	isolated	organelles	to	a	large	network.	
Their	origin,	according	to	the	endosymbiotic	theory,	was	due	to	the	increasingly	oxygen-rich	
atmosphere	 and	 the	 primordial	 eukaryotic	 cell,	 unable	 to	 metabolize	 oxygen,	 acquired	
bacteria	much	better	adapted	to	oxygen	(Sagan,	1967;	DiMauro	et	al.,	2013).	
The	 mitochondrial	 genome	 (mtDNA)	 is	 present	 in	 multiple	 copies	 and	 codes	 for	 a	 few	
fundamental	protein	components	of	the	oxidative	phosphorylation	(OXPHOS)	(Anderson	et	
al.,	1981).	
The	 mitochondrial	 double-membrane	 is	 composed	 by	 the	 outer	 (OM)	 and	 inner	 (IM)	
membranes,	this	latter	separating	the	inner	membrane	space	(IMS)	from	the	internal	matrix.	
The	OM	has	similar	composition	to	the	cell	membrane;	many	transport	channels	(porin)	are	
present	and	make	 the	OM	permeable	 to	molecules	of	5000	dalton	or	 less	 (ions	and	 small	
proteins).	 Differently,	 the	 IM	 contains	 high	 levels	 of	 cardiolipin,	 making	 it	 especially	
impermeable	to	ions,	and	selective	transport	proteins	are	needed	to	transport	the	molecules	
necessary	 to	 matrix	 enzymes	 or	 their	 metabolites.	 This	 membrane	 is	 fundamental	 for	
maintenance	 of	 an	 electrochemical	 gradient	 between	 the	 matrix	 and	 the	 IMS	 (Frey	 and	
Mannella,	2000).	The	IM	is	also	organized	in	cristae,	which	can	shift	from	tubular	to	lamellar	
structures,	 depending	 on	 the	 conformational	 state	 (Frey	 and	Mannella,	 2000).	 All	 cristae	
connect	to	the	inner	boundary	membrane	via	a	tubular	structure,	named	crista	junctions,	that	
limits	 diffusion	 between	 the	 intracristal	 space	 and	 the	 intermembrane	 space	 (Frey	 and	
Mannella,	 2000;	 Rampelt	 et	 al.,	 2017).	 Cristae	 are	 the	 specialized	 compartment	 for	 the	
respiratory	chain	complexes	and	the	ATP	synthase	(Rampelt	et	al.,	2017).	
The	fundamental	mitochondrial	function	is	energy	conservation,	in	the	form	of	ATP	molecule,	
synthetized	 by	 the	 OXPHOS	 metabolism.	 Furthermore,	 other	 pathways	 take	 place	 in	
mitochondria:	 partial	 synthesis	 of	 steroids,	 heme-groups	 synthesis,	 Ca++	 intracellular	
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homeostasis,	 reactive	 oxygen	 species	 (ROS)	 production	 and	 detoxification	 and	 apoptosis	
regulation.	
	
Oxidative	Phosphorylation	
OXPHOS	 is	 the	 final	 step	 of	 cellular	 respiration	 and	 is	 a	 two-phases	 biochemical	 process:	
electron	transport	chain,	with	NADH	and	FADH2	redox	to	generate	a	proton	gradient,	and	ATP	
synthesis,	 exploiting	 the	 proton	 gradient.	 The	 OXPHOS	 uses	 the	 electrons	 flow	 that	 are	
transported	through	a	series	of	protein	complexes,	which	are	embedded	in	the	lipid	bilayer	of	
the	mitochondrial	IM,	to	provide	most	of	cellular	energy	in	the	form	of	ATP	(Balaban,	1990;	
Friedman	and	Nunnari,	2014).	
The	OXPHOS	system	is	composed	of	five	multimeric	enzymatic	complexes	(CI-V)	and	consists	
of	87	subunits,	13	directly	encoded	by	the	mitochondrial	DNA	(mtDNA)	(Figure	1).	
	
Figure	1.	Mitochondrial	respiratory	chain	(Schon	et	al.,	2012)	
	
All	complexes	are	integrated	in	the	lipid	bilayer	of	the	mitochondrial	IM	and	together	with	two	
mobile	 electron	 carriers,	 ubiquinone	 (CoQ)	 and	 cytochrome	 c	 (cyt	 c),	 they	 make	 up	 the	
electron	 transport	 chain.	 The	 electron	 transport	 is	 coupled	 to	 the	 generation	 of	 a	 proton	
gradient	across	the	IM	and	this	is	used	by	complex	V	to	synthesize	ATP	from	ADP	(Mitchell,	
1961).	The	electron	carriers,	nicotinamide	adenine	dinucleotide	(NADH)	and	flavin	adenine	
dinucleotide	(FADH2),	are	reduced	during	the	Krebs	cycle	or	the	β-oxidation	of	fatty	acids.	
CI	 is	 the	 largest	respiratory	complexes,	comprising	45	subunits,	only	seven	mitochondrially	
encoded	(Fiedorczuk	et	al.,	2016).	It’s	a	L-shape	structure	protein,	with	two	major	domains:	
the	hydrophilic	matrix	arm	comprises	flavin,	involved	in	electron	transfer,	and	the	membrane	
arm,	involved	in	proton	translocation	(Fiedorczuk	et	al.,	2016).	The	electrons	are	transported	
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via	 iron/sulphur	 clusters	 to	 CoQ,	 reduced	 to	 CoQH2	 (Fiedorczuk	 et	 al.,	 2016),	 with	 the	
simultaneous	translocation	of	four	protons	across	the	IM	into	the	inner	membrane	space.	
CII	is	formed	by	four	subunits,	completely	encoded	by	the	nucleus,	and	catalyzes	the	oxidation	
of	 succinate	 to	 fumarate.	 Reduced	 CoQ	 can	 move	 and	 transport	 the	 electrons	 to	 CIII	
(ubiquinone-cytochrome	c	oxidoreductase)	(Lancaster	and	Kröger,	2000).	CIII	is	a	functional	
dimer	and	transfers	electrons	from	CoQH2	to	cytochorme	c,	that	donates	electrons	to	complex	
IV	through	IMS	(Darrouzet	et	al.,	2001;	Dibrova	et	al.,	2013).	
CIV	is	the	terminal	enzyme	of	the	respiratory	chain,	composed	of	13	subunits,	of	which	three	
are	 encoded	 by	 the	mtDNA.	 This	 complex	 reduces	 O2	 to	 H2O,	 translocating	 protons	 from	
matrix	to	IMS.	During	the	electron	transfer,	the	energy	released	enables	the	proton	pumping	
against	gradient	from	the	matrix	to	the	IMS.	The	proton	transfer	occurs	only	in	CI,	III	and	IV.	
The	electrochemical	gradient,	positive	outside	and	negative	inside	the	IM,	is	used	by	complex	
V	(ATP	synthase)	to	synthesize	ATP.	
CV	consists	of	two	major	functional	domains,	a	large	extra-membranous	portion	(F1)	sector	
and	a	membrane-intrinsic	portion	(F0)	sector	joined	together	by	central	and	peripheral	stalks	
(Walker,	2013).	CV	has	two	subunits	encoded	by	mtDNA	(MT-ATP6	and	MT-ATP8),	which	take	
part	 to	 the	 membrane-bound	 portion	 (F0)	 of	 the	 complex,	 and	 about	 13	 other	 subunits	
encoded	by	nDNA	(Abrahams	et	al.,	1994).	Protons	from	the	intermembrane	space	enter	CV	
through	the	F0	complex	leading	to	the	rotation	of	the	catalytic	complex.	The	rotational	energy	
of	 the	motor	 is	 transmitted	 to	 the	catalytic	domain	by	 the	central	 stalk,	which	 is	attached	
directly	to	the	rotary	motor,	and	then	used	for	ATP	synthesis	(Walker,	2013).	ATP	formation	
requires	 a	 sufficient	 supply	 of	 ADP	 and	 phosphate,	 and	 specific	 carriers	 transport	 both	
substrates	across	the	mitochondrial	membranes:	the	adenine	nucleotide	translocator	(ANT)	
and	the	phosphate	carrier	(Seelert	and	Dencher,	2011).	
	
Morphology	
Mitochondria	appear	as	a	dynamic	network	in	balance	between	the	processes	of	fusion	and	
fission	of	both	OM	and	IM	(Chan,	2012;	Liu	et	al.,	2009).	During	fusion	the	membranes	of	two	
discrete	mitochondria	merge,	 uniting	 and	mixing	 their	 content.	 Opposite,	 during	 fission	 a	
single	mitochondrion	splits	into	two	organelles.	Continuous	rounds	of	fusion	and	fission	are	
necessary	 to	maintain	mitochondrial	 homeostasis	 (Chan,	 2012),	 in	 particular	 to	meet	 the	
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energetic	needs	(Gomes	et	al.,	2011;	Mishra	et	al.,	2014).	A	wide	mitochondrial	network	is	
present	in	metabolically	active	cells	and	acts	electrically	as	a	unique	system	able	to	transmit	
mitochondrial	membrane	potential,	allowing	energy	distribution	and	dissipation	(Skulachev,	
2001).	
A	“mitochondria-shaping”	machinery,	 including	both	pro-fusion	and	pro-fission	proteins,	 is	
involved	 in	 a	 dynamic	 control	 of	 the	 mitochondrial	 network,	 to	 efficiently	 maintain	 the	
mitochondrial	population.	During	mitochondrial	fission,	the	dynamin	protein	Drp1	is	recruited	
from	cytosol	to	the	mitochondrial	surface,	self-assembles	into	ring-like	oligomeric	structures	
that	encircle	and	pinch	the	outer	mitochondrial	membrane	at	sites	of	fission	(Lee	et	al.,	2017).	
Drp1	is	essential	for	mitochondrial	fission	provoked	by	events	like	mitosis	or	stress,	and	for	
development	of	the	nervous	system	(Ishihara	et	al.,	2009;	Wakabayashi	et	al.,	2009).	Drp1	is	
recruited	at	the	mitochondrial	surface	by	integral	OM	proteins	(Fis1,	Mff,	MiD49	and	MiD51).	
In	mammals	Fis1	can	directly	bind	Drp1,	although	in	yeast	the	recruitment	requires	Fis1	and	
the	 two	WD40-containing	 adaptors	 (Griffin	 et	 al.,	 2005;	Wells	 et	 al.,	 2007).	Moreover,	 in	
mammals	three	other	receptor	proteins	involved	in	fission	events	are	reported:	Mff,	MiD49	
and	MiD51	(Losón	et	al.,	2013;	Otera	et	al.,	2005).	Mitochondrial	fission	plays	a	key	role	in	
both	cell	 life	and	death.	Fission	occurs	 in	 the	programmed	cell	death	pathway	(apoptosis),	
before	the	release	of	cytochrome	c	and	caspase	activation	(Youle	and	Karbowski,	2005),	and	
in	cellular	division,	for	correct	distribution	of	mitochondria	to	daughter	cells	(Kashatus	et	al.,	
2011).	Fission	carries	out	a	key	role	in	mitophagy,	because	interruption	of	fission	reduces	the	
efficiency	 of	 mitophagy,	 suggesting	 that	 fission	 segregates	 mitochondria	 with	 loss	 of	
membrane	potential	(Frank	et	al.,	2012;	Stotland	and	Gottlieb,	2015).	
Fusion	 is	 the	 reverse	 process	 of	 fission,	 when	 the	 inner	 and	 outer	 membranes	 of	 one	
mitochondrion	melt	with	the	respective	membranes	of	another	organelle.	First,	the	OMs	fuse,	
allowing	the	IMs	to	come	into	proximity	for	their	fusion.	In	mammals,	three	proteins	carry	out	
this	event:	 the	mitofusins	MFN1	and	MFN2	for	the	OM	fusion	and	OPA1	for	the	 IM	fusion	
(Chan,	 2012).	 These	 proteins	 belong	 to	 the	 dynamin-like	 protein	 superfamily	 and	 contain	
GTPase	activity	essential	for	their	functions	(Praefcke	and	McMahon,	2004).	MFN1	is	essential	
to	 induce	 OM	 fusion,	 whereas	 the	 role	 of	MFN2	 is	 less	 defined.	MFN2	 can	 form	 hetero-
oligomers	with	MFN1	and	 is	suggested	to	participate	 in	 later	steps	of	mitochondrial	 fusion	
(Ishihara	 et	 al.,	 2004;	 Koshiba	 et	 al.,	 2004).	MFN2	has	 been	 shown	 to	 be	 involved	 also	 in	
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endoplasmic	 reticulum	 interactions,	 bridging	 the	 two	 organelles	 close	 at	 the	 level	 of	
mitochondrial	 associated	membranes	 (MAMs),	 and	 the	 levels	 of	MFN2	 correlate	with	 the	
oxidative	metabolism	of	skeletal	muscle	(Bach	et	al.,	2003;	de	Brito	and	Scorrano,	2008).	OPA1	
is	essential	for	IM	fusion,	but	it	is	also	involved	in	shaping	the	cristae	morphology,	OXPHOS	
efficiency,	 and	mtDNA	maintenance	 (Belenguer	 and	 Pellegrini,	 2013;	 Vidoni	 et	 al.,	 2013).	
OPA1	oligomerization,	tightening	cristae	junctions,	also	controls	the	propensity	to	apoptosis	
by	sequestering	cytochrome	c	within	the	cristae	and	regulating	its	release	in	the	IMS	(Dotto	
et	al.,	2017;	Frezza	et	al.,	2006;	Olichon	et	al.,	2003).	Fusion	is	important	also	for	mitochondrial	
calcium	homeostasis	 (Szabadkai	 et	 al.,	 2006),	 embryonic	 development	 (Chen	et	 al.,	 2003),	
spermatogenesis	and	mtDNA	maintenance	(Chen	et	al.,	2007).	
	
The	mitochondrial	genome:	mtDNA	
The	human	mitochondrial	genome	(mtDNA)	is	a	circular	double-stranded	molecule	of	about	
16.6	kb,	 localized	 in	 the	mitochondrial	matrix,	and	 represents	0,5-1%	of	 the	entire	human	
genome.	The	mtDNA	 is	present	 in	multiple	copies,	 ranging	 from	tens	to	thousand	per	cell,	
according	to	the	cell	type.	The	two	strands	of	mtDNA	can	be	distinguished	into	‘heavy	strand’	
(H-strand)	and	‘light	strand’	 (L-strand),	based	on	their	nucleotide	(GC)	content	(Fernández-
Silva	et	al.,	2003).	The	mtDNA	is	very	compact,	having	none	or	only	a	few	noncoding	bases	
between	 genes	 and	 lacking	 in	 many	 cases	 the	 termination	 codons;	 termination	 is	 post-
transcriptionally	induced	by	polyadenylation	of	mRNAs	(Anderson	et	al.,	1981;	Andrews	et	al.,	
1999).	
The	mtDNA	encodes	for	37	genes:	24	genes	(22	tRNAs	and	2	rRNAs,	12S	and	16S)	are	necessary	
for	transcription	of	13	OXPHOS	subunits,	7	for	complex	I	 (MT-ND1,	MT-ND2,	MT-ND3,	MT-
ND4,	MT-ND4L,	MT-ND5,	MT-ND6),	1	for	complex	III	(MT-CYB),	3	for	complex	IV	(MT-CO1,	MT-
CO2,	MT-CO3)	and	2	for	complex	V	(MT-ATP6,	MT-ATP8)	(Anderson	et	al.,	1981)	(Figure	2).		
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Figure	2.	Map	of	mitochondrial	DNA	(Taylor	and	Turnbull,	2005)	
	
Genes	are	distributed	asymmetrically	between	the	two	strands:	H-strand	encodes	for	most	
genes,	both	rRNAs,	14	tRNAs	and	12	mRNAs	of	13	subunits,	but	ND6	and	8	tRNAs	are	in	L-
strand	(Attardi	and	Schatz,	1988).	Furthermore,	two	non-coding	regions	(NCR)	are	present	in	
the	mtDNA.	D-loop	(Displacement	Loop)	is	a	triple-stranded	region	found	in	the	major	NCR	of	
many	mitochondrial	genomes,	and	 is	 formed	by	stable	 incorporation	of	a	 third,	short	DNA	
strand	known	as	7S	DNA	(Nicholls	and	Minczuk,	2014).	D-loop	is	involved	in	many	function,	
especially	 in	 mtDNA	 replication	 and	 translation,	 but	 also	 in	 mtDNA	 topology,	 mtDNA	
recombination,	membrane	association	and	dNTPs	metabolism	(Nicholls	and	Minczuk,	2014).	
The	second	NCR	contains	the	origin	of	L-strand	replication	(OL)	and	is	located	in	a	cluster	of	
five	tRNA	genes	(MT-TA,	MT-TN,	MT-TC,	MT-TY)	on	L-strand,	between	nucleotides	5512	and	
5903,	around	two	thirds	of	the	mtDNA	length	from	the	OH	(Anderson	et	al.,	1981;	Fernandez-
Silva	et	al.,	2003).	
Similar	 to	 bacterial	 chromosomes,	 mitochondrial	 DNA	 is	 organized	 into	 tightly-packed	
nucleoprotein	 complexes	 called	 nucleoids.	 Nucleoids	 are	 found	 associated	 with	 the	 inner	
mitochondrial	 membrane,	 but	 can	 also	 freely	 diffuse	 through	 the	 mitochondrial	 network	
(Albring	et	al.,	1977;	Brown	et	al.,	2011;	Nicholls	and	Minczuk,	2014).	The	most	thoroughly	
characterized	 nucleoid	 protein	 is	 the	 high-mobility	 group	 box	 protein	 TFAM	 (Parisi	 and	
Clayton,	1991).	
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The	mtDNA	replicates	according	to	the	strand-displacement	model,	with	an	asynchronous	and	
asymmetric	modality.	DNA	 synthesis	occurs	 continuously	on	both	 strands	without	Okazaki	
fragments	 (Clayton,	1991).	 There	are	 two	 specific	origins	of	DNA	 replication,	one	 for	each	
strand,	the	H-strand	origin	(OH)	and	the	L-strand	origin	(OL).	This	is	necessary	to	ensure	correct	
DNA	synthesis	for	both	strands.	Replication	starts	at	OH,	and	DNA	synthesis	proceeds	in	5’-3’	
direction	to	produce	a	new	H-strand.	During	the	synthesis	of	the	new	H-strand,	mtSSB	covers	
the	displaced,	parental	H-strand	and	blocks	POLRMT	transcription	(Miralles	Fusté	et	al.,	2014).	
When	the	replication	machinery	exceeds	OL,	it	becomes	single-stranded	and	folds	into	a	stem-
loop	structure.	The	stem	inhibits	mtSSB	binding	and	leaves	the	single-stranded	loop	region	
accessible	 for	POLRMT,	which	 initiates	primer	synthesis	 from	a	poly-T	stretch	 (Fusté	et	al.,	
2010;	Miralles	Fusté	et	al.,	2014).	After	about	25	nucleotides	of	primer	synthesis,	POLRMT	is	
replaced	by	POLγ,	and	L-strand	DNA	synthesis	begins.	The	replication	of	the	two	strands	 is	
interconnected	because	H-strand	synthesis	is	required	for	the	initiation	of	L-strand	synthesis.	
Once	initiated,	H-	and	L-strand	synthesis	proceed	continuously	in	opposite	directions	until	the	
two	events	reach	a	full	circle	(Gustafsson	et	al.,	2016).	
Besides	 the	 replication	 origin	 of	 H-strand,	 D-loop	 contains	 a	 dedicated	 promoter	 for	 the	
transcription	 of	 each	 strand	 of	 mtDNA,	 the	 L-strand	 promoter	 (LSP)	 and	 the	 H-strand	
promoter	 (HSP).	 Transcription	 initiation	 at	 LSP	 or	 HSP	 produces	 near-genome-length	
polycistronic	 transcripts	 that	encompass	all	of	 the	coding	 information	on	each	strand.	The	
primary	transcripts	are	processed	to	release	the	individual	RNA	molecules.	The	steady-state	
levels	 of	 the	 longer	unprocessed	 transcripts	 are	 low	and,	 therefore,	 processing	 is	 likely	 to	
occur	 co-transcriptionally.	 According	 to	 the	 “tRNA	 punctuation	 model”	 model,	 tRNAs	 are	
specifically	recognized	and	cleaved	in	the	polycistronic	transcripts,	thus	leading	to	the	release	
of	tRNAs,	mRNAs,	and	rRNAs	(Anderson	et	al.,	1981;	Ojala	et	al.,	1981),	which	subsequently	
undergo	 further	 maturation	 by,	 for	 example,	 base	 modifications,	 CCA	 addition,	 and	
polyadenylation	 (Hällberg	 and	 Larsson,	 2014).	 In	mammalian	mitochondria,	 the	 5ʹ	 ends	of	
tRNAs	 are	 cleaved	 in	 the	 polycistronic	 transcript	 by	 an	 all-protein	 version	 of	 ribonuclease	
(RNase)	 P,	 consisting	 of	 three	 subunits	 (MRPP1–3),	 whereas	 the	 3ʹ	 ends	 of	 tRNAs	 are	
processed	by	RNase	Z	(ELAC2)	(Hällberg	and	Larsson,	2014).	
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Mitochondrial	genetics	
The	mitochondrial	genome	differs	from	the	nuclear	one	(nDNA)	in	many	respects.	First,	the	
mtDNA	 genetic	 code	 uses	 only	 two	 stop	 codons:	 AGA	 and	 AGG	 (Temperley	 et	 al.,	 2010)	
(compared	 with	 UAA,	 UGA	 and	 UAG	 in	 nDNA),	 conversely	 UGA	 encodes	 tryptophan.	 To	
compensate	for	this	UAA	codons	have	to	be	introduced	at	the	post-transcriptional	 level.	 In	
addition,	AUA,	isoleucine	in	nDNA,	encodes	for	methionine	in	mtDNA	(Chinnery	and	Hudson,	
2013).	
Second,	mtDNA	is	maternally	inherited.	The	prevailing	theory	of	an	“active	elimination	model”	
for	 paternal	 mtDNA	 suggests	 that	 sperm	 mitochondria	 are	 ubiquitinated	 and	 removed	
through	 different	 routes,	 such	 as	 proteosomal,	 lysosomal	 pathways	 or	mitophagy	 (Carelli,	
2015;	Rojansky	et	al.,	2016;	Sato	and	Sato,	2013;	Sutovsky	et	al.,	1999).	Moreover,	autophagy	
has	 been	 recently	 highlighted	 as	 the	 mechanism	 for	 paternal	 mtDNA	 elimination	 in	
Caenorhabditis	elegans	(Al	Rawi	et	al.,	2011;	Sato	and	Sato,	2011).	Finally,	a	passive	“dilution	
model”	due	to	disproportionate	amount	of	paternal	versus	maternal	mtDNAs	in	mammals	has	
been	proposed.	This	was	observed	in	mice	(Luo	et	al.,	2013),	but	not	confirmed	in	humans	
(Pyle	et	al.,	2015).	Occurrence	of	paternal	mtDNA	transmission	has	also	been	documented	in	
human	(Schwartz	and	Vissing,	2002),	and	more	often	in	animals	(Dokianakis	and	Ladoukakis,	
2014;	Gyllensten	et	al.,	1991;	Zhao	et	al.,	2004).	
Finally,	mtDNA	variants	may	be	present	in	homoplasmy	or	heteroplasmy,	not	in	homozygosity	
or	 heterozygosity.	 Homoplasmy	 occurs	when	 the	 sequence	 of	multiple	mtDNA	 copies	 are	
identical.	 However,	 heteroplasmy	 arises	 when	 a	 variant	 co-exists	 with	 its	 wild-type	
counterpart	 in	 various	 proportions,	 due	 to	 the	 polyploid	 nature	 of	mtDNA	 (Chinnery	 and	
Hudson,	2013;	Payne	et	al.,	2013).	A	heteroplasmic	variant	can	be	inherit	from	mother	to	child	
and	 segregate	 in	 different	 tissue	 with	 varying	 loads,	 according	 to	 the	 ‘mitochondrial	
bottleneck	 theory’.	 During	 oogenesis	 and	 meiosis,	 cells	 incur	 to	 mtDNA	 reduction	 and	
amplification,	leading	to	a	purportedly	random	shift	in	mtDNA	mutational	load	between	cells	
(Chinnery	and	Hudson,	2013;	Schon	et	al.,	2012).		
	
Mitochondrial	haplogroups	
The	 rate	 of	 evolution	 of	 the	 mitochondrial	 genome	 appears	 10-fold	 higher	 than	 nuclear	
genome,	mostly	due	to	an	elevated	mutation	rate	of	mtDNA	(Brown	et	al.,	1979).	Due	to	the	
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high	rate	of	evolution,	mtDNA	is	an	extremely	useful	molecule	to	exploit	for	high-resolution	
analysis	in	a	wide	range	of	fields,	including	evolutionary	anthropology	and	population	history,	
medical	genetics,	as	well	as	forensic	science	(van	Oven	and	Kayser,	2009).	Thus,	the	mtDNA	
sequence	evolved	as	a	result	of	the	sequential	accumulation	of	mutations	along	maternally	
inherited	lineages.	All	mtDNA	types	in	the	human	gene	pool	can	ultimately	be	traced	back	to	
a	common	matrilineal	ancestor	that	lived	approximately	200,000	years	ago	in	Africa	(Behar	et	
al.,	2008;	Macaulay	et	al.,	2005;	Mishmar	et	al.,	2003;	van	Oven	and	Kayser,	2009)	and	by	
migration	colonized	the	world	(Kivisild,	2015).	Haplogroups	are	used	to	represent	the	major	
branch	points	on	the	mitochondrial	phylogenetic	tree	and	the	migrations	(Figure	3).	
	
	
Figure	3	mtDNA	haplogroup	tree	and	distribution	map	(Kivisild,	2015).	
	
The	European	population	origins	from	the	African	haplogroup	L3,	followed	by	emergence	of	
the	major	out-of-Africa	haplogroups	M	and	N	 (and	N’s	descendants,	R)	 in	 the	vicinity	of	a	
putative	 “Gulf	 oasis”	 (Richards	 et	 al.,	 2016),	 subsequently	 followed	 by	 haplogroup	 R	
divergence	(Pinhasi	et	al.,	2012).	
In	 the	 last	 decades,	 the	 possible	 role	 of	mtDNA	haplogroups	 in	modulating	mitochondrial	
function	 and	 pathology	 has	 been	massively	 investigated.	 Interestingly,	many	 studies	 have	
shown	 the	associations	of	haplogroups	with	 IQ	 (Skuder	et	al.,	 1995),	 sperm	motility	 (Ruiz-
Pesini	et	al.,	2000),	ability	to	adapt	to	climatic	conditions	(Ruiz-Pesini	et	al.,	2004),	body	fat	
mass	(Yang	et	al.,	2011)	and	longevity	(Cai	et	al.,	2009;	Santoro	et	al.,	2006).	Furthermore,	this	
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association	 of	 mitochondrial	 haplogroups	 has	 been	 noticed	 in	 some	 pathologies,	 such	 as	
psychosis	in	bipolar	disorder	(Frye	et	al.,	2017),	motor	function	in	long-term	HIV-1	infected	
individuals	 (Azar	 et	 al.,	 2017),	 autism	 spectrum	 disorders	 (Chalkia	 et	 al.,	 2017),	
cardiomyopathy	(Shin	et	al.,	2000),	multiple	sclerosis	(Kalman	et	al.,	1999),	Parkinson's	disease	
(Ghezzi	 et	 al.,	 2005),	 Alzheimer's	 disease	 (Krüger	 et	 al.,	 2010;	 van	 der	Walt	 et	 al.,	 2004),	
Friedreich's	disease	(Giacchetti	et	al.,	2004),	Amyotrophic	Lateral	Sclerosis	(Mancuso	et	al.,	
2004)	and	Leber’s	Hereditary	Optic	Neuropathy	 (LHON)	 (Carelli	et	al.,	2006;	Hudson	et	al.,	
2007).	
	
Leber’s	hereditary	optic	neuropathy	(LHON)	
LHON	(OMIM	#535000)	is	a	blinding	disorder,	maternally	inherited,	characterized	by	acute	or	
subacute	 loss	 of	 central	 vision,	 which	 affects	 predominantly	 young	 males,	 and	 is	 now	
recognized	as	the	most	frequent	mitochondrial	disease	(Carelli	et	al.,	2004,	2016;	Yu-Wai-Man	
et	al.,	2011).	The	prevalence	of	LHON	mutations	in	the	population	may	vary	from	1:10,000	in	
North	East	of	England	to	1:50,000	in	Finland	(Man	et	al.,	2003;	Puomila	et	al.,	2007).	
Clinically,	LHON	is	characterized	by	painless,	rapid	loss	of	central	vision	in	one	eye,	followed	
by	 a	 similar	 involvement	 of	 the	 other	 eye,	 usually	 in	 a	 short	 time	 laps,	 associated	 with	
dyschromatopsia	(Carelli	et	al.,	2004).	In	the	acute	phase,	axonal	loss	in	the	papillo-macular	
bundle	 leads	 to	 temporal	 atrophy	 of	 the	 optic	 nerve,	 and	 the	 endpoint	 of	 the	 disease	 is	
generally	a	full	optic	atrophy	with	permanent	severe	loss	of	central	vision,	but	with	relative	
preservation	of	the	peripheral	visual	field	and	pupillary	light	responses	(Carelli	et	al.,	2004).	
However,	patients	show	occasionally	a	spontaneous	recovery	of	visual	acuity	(Carelli	et	al.,	
2004;	Mackey	and	Howell,	1992;	Pezzi	et	al.,	1998;	Stone	et	al.,	1992).	
The	peculiar	feature	of	LHON	is	the	selective	degeneration	of	a	single	cell	 type,	the	retinal	
ganglion	cells	(RGCs).	Thus,	RGCs	display	somehow	a	unique	sensibility	to	the	mitochondrial	
energy	defect	generated	by	LHON	pathogenic	mutations.	The	1.2	million	axons	that	form	the	
optic	nerve	originate	from	the	RGCs	in	the	inner	retina	(Carelli	et	al.,	2004).	These	axons	do	
not	present	a	saltatory	conduction	of	action	potential	until	past	the	lamina	cribrosa,	due	to	
absence	of	the	myelin	sheet,	in	order	to	maintain	the	optical	transparency	and	consequently	
a	good	visual	resolution	(Howell	et	al.,	2002).	Thus,	the	high	energy	dependence	of	these	cells	
Introduction	
	
	
	
11	
on	mitochondrial	OXPHOS	may	explain	the	particular	sensitivity	of	RGCs	and	the	related	visual	
loss	due	to	mitochondrial	dysfunction	(Carelli	et	al.,	2004).	
LHON	is	maternally	inherited,	due	to	the	presence	of	point	mutations	on	mtDNA.	The	most	
common	 pathogenic	 mutations	 are	 m.11778G>A/MT-ND4,	 m.3460G>A/MT-ND1,	 and	
m.14484T>C/MT-ND6,	characterizing	about	90%	of	LHON	cases	(Howell	et	al.,	1991;	Mackey	
and	Howell,	1992;	Wallace	et	al.,	1988;	Yu-Wai-Man	et	al.,	2011).	These	“primary”	pathogenic	
mutations	 are	 usually	 established	 as	 homoplasmic	 over	 multiple	 generations	 in	 LHON	
maternal	lineages.	However,	two	further	features	remain	peculiar	in	LHON,	i.e.	the	incomplete	
penetrance	and	the	male	prevalence	(Caporali	et	al.,	2017).	Mitochondrial	biogenesis,	which	
is	 boosted	 in	 females	 by	 estrogens	 (Giordano	 et	 al.,	 2011),	 seems	 a	major	 compensatory	
mechanism	 that	 determines	 incomplete	 penetrance	 (Giordano	 et	 al.,	 2014).	 On	 this,	
environmental	 factors,	 such	as	 tobacco	smoke	 (Sadun	et	al.,	2004),	and	genetic	modifiers,	
both	in	nDNA	and	mtDNA,	are	assumed	to	play	a	further	role	(Caporali	et	al.,	2017).	
Besides	the	3	common	“primary”	LHON	mutations,	several	other	rarer	pathogenic	mutations	
have	also	been	reported	in	single	cases	or	families	(Achilli	et	al.,	2012).	Moreover,	additional	
recurrent	 polymorphic	 mtDNA	 variants	 were	 also	 associated	 with	 LHON	 and	 called	
“secondary”	mutations	 (Brown	 et	 al.,	 1992;	 Johns	 and	 Berman,	 1991;	 Johns	 and	Neufeld,	
1991).	The	role	of	these	“secondary	mutations”,	widely	debated	(Mackey	et	al.,	1996),	was	
elucidated	by	 firmly	establishing	 these	variants	as	mtDNA	haplogroup-related	polymorphic	
markers	(Torroni	et	al.,	1996).	Thus,	multiple	research	groups	confirmed	the	association	of	
some	 LHON	 “primary”	 mutations	 with	 a	 specific	 mtDNA	 haplogroup,	 haplogroup	 J,	 as	
penetrance	 enhancer:	 in	 particular,	 this	 association	 is	 observed	 with	 the	 LHON	
m.11778G>A/MT-ND4	and	m.14484T>C/MT-ND6	mutations	(Brown	et	al.,	1997;	Lamminen	et	
al.,	1997;	Torroni	et	al.,	1997).	Over	the	years,	this	association	was	refined	to	specific	clades	
of	haplogroup	J,	the	J1c	and	J2b	clades	characterized	by	accumulation	of	missense	variants	
affecting	both	complex	I	and	III	(Carelli	et	al.,	2006;	Hudson	et	al.,	2007).	This	association	were	
validated	in	large	cohorts	of	LHON	patients	of	European	descent,	but	a	similar	scenario	seems	
to	be	confirmed	also	in	LHON	cohorts	of	Asian	ancestry	(Ji	et	al.,	2008;	Kaewsutthi	et	al.,	2011).	
Furthermore,	the	complete	sequence	analysis	of	mtDNA	carrying	rare	LHON	mutation	allowed	
to	 identifying	 private	 variants	 that	may	 also	 act	 as	 genetic	modifiers	 (Achilli	 et	 al.,	 2012).	
Multiple	reports	on	Chinese	LHON	families	indicated	the	occurrence	of	mtDNA	backgrounds	
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characterized	by	an	unusually	high	or	even	complete	penetrance,	frequently	due	to	coexisting	
pathogenic	mutations	 (Yang	 et	 al.,	 2009;	 Zhang	 et	 al.,	 2012).	Opposite,	 in	 other	maternal	
lineages	it	was	observed	an	extremely	reduced	penetrance	(Qu	et	al.,	2009).	Thus,	different	
combinations	 including	mtDNA	haplotypes	as	defined	by	specific	arrays	of	polymorphisms,	
private	variants	and	co-existing	mutations	may	all	impinge	on	the	pathogenic	potential	and,	
ultimately,	 on	 penetrance	 of	 LHON	 primary	mutations.	 Remarkably,	 the	 role	 of	 the	 same	
mtDNA	variant	may	vary	drastically,	for	example,	from	adaptation	at	high	altitudes,	due	to	an	
environmental	 positive	 selection	 on	 the	 mtDNA	 sequence,	 to	 a	 pathogenic	 potential	
predisposing	 to	 LHON	 in	different	 interacting	environments	 (Caporali	et	al.,	 2017;	 Ji	 et	al.,	
2008).	
Interestingly,	 the	 pathogenic	 role	 of	 the	 m.14484T>C/MT-ND6	 mutation	 was	 initially	 not	
recognized	because	of	the	low	phylogenetic	conservation	of	the	affected	amino	acid	(Howell	
et	al.,	1991;	Mackey	and	Howell,	1992).	Remarkably,	the	m.14484T>C/MT-ND6	change	found	
on	 non-J	 mtDNA	 backgrounds	 displays	 a	 very	 low	 penetrance	 and	 has	 been	 occasionally	
reported	in	genetic	surveys	of	control	populations,	thus	behaving	borderline	and	similarly	to	
a	polymorphic	variant	(A.	Torroni,	unpublished	data)	(Howell	et	al.,	2003a;	Palanichamy	et	al.,	
2004).	Furthermore,	different	sets	of	two	or	more	mtDNA	variants	have	been	postulated	as	
modulators	 of	 penetrance,	 such	 as	 combinations	 of	 multiple	 private	 “weak”	 pathogenic	
mutations	or	combination	of	established	LHON	pathogenic	mutations	with	variants,	already	
known	 as	 markers	 of	 specific	 haplogroups,	 but	 detected	 outside	 the	 usual	 haplogroup	
background	(La	Morgia	et	al.,	2008,	2014a).	
A	few	studies	tackled	the	issue	of	providing	a	functional	evidence	for	the	modifying	role	of	the	
mtDNA	haplotype	and/or	the	private	variants	or	co-existing	mtDNA	mutations.	Initial	studies	
based	 on	 MR-spectroscopy	 were	 unable	 to	 detect	 differences	 between	 LHON	 patients	
carrying	the	m.11778G>A/MT-ND4	mutation	associated	or	not	with	the	mtDNA	haplogroup	J	
(Lodi	 et	 al.,	 2000).	 Exploiting	 the	 cell	 model	 of	 transmitochondrial	 cytoplasmic	 hybrids,	
“cybrids”,	it	has	been	shown	in	vitro	that	different	mtDNA	haplogroups	may	have	slight,	but	
significant	differences	in	bioenergetic	efficiency,	production	of	ROS	and	stability	of	respiratory	
complexes	assembly	(Carelli	et	al.,	2002;	Gómez-Durán	et	al.,	2010,	2012;	Pello	et	al.,	2008),	
thus	substantiating	their	possible	role	as	modifiers	for	LHON	penetrance.	Controversial	results	
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were	instead	provided	by	the	few	studies	on	cases	of	LHON	carrying	double	primary	mutations	
(Brown	et	al.,	2001;	Caporali	et	al.,	2017;	Cruz-Bermúdez	et	al.,	2016;	Jiang	et	al.,	2016).	
	
Dominant	optic	atrophy	(DOA)	
Dominant	optic	atrophy	(DOA,	OMIM#165500),	also	known	as	Kjer’s	optic	atrophy,	is	the	most	
common	 amongst	 hereditary	 optic	 neuropathies,	 with	 an	 estimated	 disease	 prevalence	
varying	 from	 1:10,000	 to	 1:30,000	 (Lenaers	 et	 al.,	 2012).	 In	 year	 2000,	 two	 independent	
groups	identified	pathogenic	mutations	in	the	OPA1	gene	as	causative	for	DOA	(Alexander	et	
al.,	2000;	Delettre	et	al.,	2000).	Nowadays,	about	70%	of	DOA	families	have	been	linked	to	
OPA1	mutations	 and	more	 than	 350	pathogenic	mutations	 have	 been	 submitted	 to	OPA1	
databases,	spread	throughout	the	protein	(Ferré	et	al.,	2015;	La	Morgia	et	al.,	2014b).	The	
50%	 of	 DOA	 patients	 carry	 stop-codon,	 frame-shift	 and	 deletion-insertion,	 leading	 to	
incomplete	 transcription	 and	 decreased	 protein	 content,	 with	 haploinsufficiency	 as	 the	
genetic	mechanism.	The	remaining	patients	present	missense	mutations,	which	are	thought	
to	 act	 through	 a	 dominant	 negative	 mechanism.	 In	 2008,	 a	 particular	 group	 of	 missense	
mutations,	 affecting	 the	GTPase	 domain,	 have	 been	 related	 to	 a	 syndromic	 form	of	DOA,	
associated	 with	 sensorineural	 deafness,	 ataxia,	 late-onset	 chronic	 progressive	 external	
ophthalmoplegia	(CPEO)	and	mitochondrial	myopathy	with	cytochrome	c	oxidase	negative.	
This	 new	 phenotype	 was	 defined	 as	 DOA	 “plus”	 syndrome	 (Amati-Bonneau	 et	 al.,	 2008;	
Hudson	et	al.,	2008;	Yu-Wai-Man	et	al.,	2010).	Importantly,	these	patients	harbored	multiple	
deletions	of	mtDNA	in	their	skeletal	muscles,	confirming	the	OPA1	function	in	mtDNA	stability,	
as	previously	reported	for	its	orthologue	in	Saccharomyces	cerevisiae	(Jones	and	Fangman,	
1992;	Guan	et	al.,	1993).	Thus,	OPA1	has	been	added	to	the	list	of	genes	(ANT1,	Twinkle,	POLG,	
MFN2)	associated	with	human	disorders	characterized	by	mtDNA	deletions	(CPEO	syndromes)	
(DiMauro	 and	 Schon,	 2008;	 Rouzier	 et	 al.,	 2012).	 Recently,	 other	 phenotypes	 have	 been	
reported	within	the	frame	of	the	DOA	“plus”	syndrome,	including	MS-like	features	(Yu-Wai-
Man	 et	 al.,	 2016),	 Behr-like	 spastic	 paraparesis	 (Marelli	 et	 al.,	 2011),	 Parkinsonism	 and	
dementia	(Carelli	et	al.,	2015)	and	cases	with	absent	or	very	mild	ocular	phenotype	(Milone	et	
al.,	2009),	thus	expanding	the	spectrum	of	OPA1	spectrum.	
As	 LHON,	 DOA	 is	 a	 hereditary	 neurodegenerative	 disorder,	 characterized	 by	 a	 tissue	
specificity,	 which	 is	 limited	 to	 RGCs	 and	 their	 axons	 forming	 the	 optic	 nerve,	 with	 a	
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preferential	 involvement	of	the	small	 fibers	belonging	to	the	papillomacular	bundle,	which	
serve	central	vision.	The	main	difference	with	LHON	is	slowly	progressive	course	of	bilateral	
visual	 loss,	 and	 as	 in	 LHON,	 DOA	 is	 usually	 symmetrical,	 associated	 with	 centrocaecal	
scotomas,	 impairment	 of	 color	 vision,	 temporal	 pallor	 of	 the	 optic	 disks	 and	 relative	
preservation	of	the	pupillary	reflex	(Delettre	et	al.,	2002;	Lenaers	et	al.,	2012;	Yu-Wai-Man	et	
al.,	2010).	The	onset	of	DOA	is	usually	during	childhood,	although	the	defect	most	frequently	
is	diagnosed	early	in	adult	life.	However,	this	optic	atrophy	shows	wide	variability	in	clinical	
expression	between	and	within	families,	and	visual	impairment	ranges	from	subclinical	vision	
impairment	to	 legal	blindness	 (Barboni	et	al.,	2014;	Carelli	et	al.,	2009;	Yu-Wai-Man	et	al.,	
2010).	
Postmortem	histologic	studies	showed	diffuse	atrophy	of	the	ganglion	cell	layer	in	the	retina,	
with	loss	of	myelin	and	axons	within	the	optic	nerves	(Johnston	et	al.,	1979),	similar	to	the	
histopathology	of	 LHON	 (Kjer	 et	 al.,	 1983).	Analysis	 of	 the	 retinal	 nerve	 fiber	 layer	 (RNFL)	
thickness	in	DOA	patients	with	optical	coherence	tomography	(OCT),	a	non-invasive	technique	
used	to	obtain	high-resolution	images,	revealed	generalized	loss	of	fibers,	typically	prevalent	
on	 the	 temporal	 sector,	 with	 a	 smaller	 average	 optic	 disk	 size	 compared	 to	 a	 control	
population	(Barboni	et	al.,	2011,	2014;	Milea	et	al.,	2010).	
Due	to	the	variable	clinical	severity	and	incomplete	penetrance	observed	in	DOA,	similar	to	
LHON,	 the	possible	 role	 of	mtDNA	haplogroups	was	 investigated	 in	DOA	patients	 carrying	
OPA1	mutations.	The	two	studies	currently	published	reached	contrasting	conclusions	on	the	
possibility	that	the	mtDNA	background	may	act	as	modifying	factor	for	DOA	penetrance	(Han	
et	al.,	2006;	Pierron	et	al.,	2009).	Both	studies	examined	a	limited	series	of	patients	(29	and	
41	respectively)	and	the	study	design	did	not	take	into	consideration	that	DOA	is	a	dominant	
disorder	where	the	mtDNA	haplogroup	may	be	co-inherited	with	the	OPA1	mutation	from	the	
mother	or,	alternatively,	may	change	when	the	OPA1	mutation	is	inherited	from	the	father.	
As	 a	 consequence,	 a	 study	 design	 just	 considering	 the	 simple	 association	 of	 the	 mtDNA	
haplogroup	with	OPA1	mutations	does	not	take	into	account	for	these	intricacies.	Thus,	only	
further	studies	of	large	cohorts	of	patients,	with	multiple	segregations,	may	lead	to	a	properly	
supported	conclusion	on	the	possible	role	played	by	mtDNA	haplogroups	in	OPA1-related	DOA	
(Caporali	et	al.,	2017).	
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AIMS	
	
The	 two	 most	 common	 inherited	 optic	 neuropathies	 due	 to	 mitochondrial	 dysfunction,	
Leber’s	Hereditary	Optic	Neuropathy	(LHON)	and	Dominant	Optic	Atrophy	(DOA),	are	both	
characterized	by	an	incomplete	penetrance	and	variable	clinical	severity,	and	in	LHON	there	
is	also	a	clear-cut	prevalence	 in	males.	These	 features	 remain	poorly	understood.	 LHON	 is	
genetically	determined	by	missense	point	mutation	in	Complex	I	subunits	genes	encoded	by	
the	mitochondrial	genome,	whereas	DOA	is	mostly	due	to	heterozygous	mutation	in	the	OPA1	
gene,	encoding	a	mitochondrial	fusion	protein.	In	LHON,	90	%	of	patients	carry	one	of	three	
common	 primary	 mutations	 (m.11778G>A/MT-ND4,	 m.3460G>A/MT-ND1,	 and	
m.14484T>C/MT-ND6),	the	remaining	10%	harbor	a	rarer	mutation	(Achilli	et	al.,	2012).	Since	
the	identification	of	the	first	pathogenic	mutation	in	mtDNA	(Wallace	et	al.,	1988),	the	role	of	
the	entire	mitogenome	has	been	investigated	in	many	aspect	of	medicine,	and	particularly	in	
LHON,	suggesting	a	complex	interaction	between	the	pathogenic	mutations,	and	the	adaptive	
and	private	variants.	
The	 first	aim	of	 this	 study	 is	 to	determine	 the	molecular	basis	of	optic	neuropathy	 in	 four	
families,	negative	for	the	common	LHON	pathogenic	mutations,	but	still	characterized	by	a	
clinical	 phenotype	 undistinguishable	 from	 LHON,	 which	 is	 maternally	 inherited	 at	 low	
penetrance.	We	will	carry	out	the	sequence	of	the	entire	mitochondrial	genome	in	each	of	the	
four	 probands	 and	 perform	 confirmatory	 functional	 studies	 by	 assessing	 mitochondrial	
bioenergetics,	 taking	 advantage	 of	 the	 cybrids	 cell	 model	 to	 isolate	 the	 mitogenome	
contribution	to	the	pathogenesis.	
The	 second	aim	of	 this	 study	 is	 a	 large-scale	 analysis	 of	 the	entire	mitogenome	 in	 a	 large	
European	cohort	of	LHON	patients	previously	diagnosed	as	carrying	the	m.14484T>C/MT-ND6	
mutation,	the	less	frequent	of	the	primary	mutations.	This	analysis	is	specifically	carried	out	
to	dissect	the	modifier	role	of	the	mitogenome	genetic	variation.	The	association	of	the	three	
primary	LHON	mutation	with	specific	mitochondrial	backgrounds	is	largely	known	(Carelli	et	
al.,	2006;	Hudson	et	al.,	2007),	and	this	is	particularly	stringent	for	the	m.14484T>C/MT-ND6	
mutation,	but	only	a	few	families	have	been	analyzed	to	date,	and	never	at	the	resolution	level	
of	the	entire	sequence	of	the	mitogenome.	
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Finally,	the	last	aim	is	the	analysis	of	the	mitochondrial	genome	variability	 in	DOA	patients	
carrying	 OPA1	mutations.	 It	 is	 well	 established	 that	 DOA	 patients	 present	 a	 wide	 clinical	
variability	between	and	within	families,	without	a	clear	genotype-phenotype	correlation	with	
the	 OPA1	 mutations.	 In	 previous	 studies,	 the	 association	 with	 the	 mitogenome	 genetic	
variation	was	tested,	but	the	results	of	these	study	were	unclear	due	to	a	faulty	design	(Han	
et	al.,	2006;	Pierron	et	al.,	2009).	Thus,	we	re-consider	the	mitogenome	genetic	variation	as	
possible	modifier	of	patients’	clinical	outcome,	measured	as	retinal	nerve	fibers	layer	(RNFL)	
thickness	 by	 OCT	 (optic	 coherence	 tomography).	 We	 will	 also	 investigate	 the	 possible	
relevance	of	coadaptation	between	the	nuclear	and	mitochondrial	genomes,	by	considering	
the	mother-children	segregations,	where	the	mtDNA	segregates	with	the	OPA1	mutation,	and	
father-children	segregations,	where	the	mtDNA	does	not	segregate	with	the	OPA1	mutation.	
For	each	mitogenome,	we	will	define	the	mtDNA	haplogroup,	highlighting	the	private	
mutations,	not	belonging	to	the	evolutionarily	fixed	changes,	and	predicting	the	effect	by	
integration	of	conservation	analysis	and	on-line	prediction	tools.	
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RESULTS	
	
PART	1	-	Peculiar	combinations	of	individually	non-pathogenic	missense	mitochondrial	DNA	
variants	cause	low	penetrance	Leber’s	hereditary	optic	neuropathy	
	
Pedigrees	investigated	
We	 observed	 three	 multigenerational	 pedigrees	 (Families	 1a,	 b,	 and	 c	 in	 Figure	 4)	 with	
multiple	affected	individuals	fitting	the	clinical	diagnosis	of	LHON	and	with	a	clear	maternal	
transmission	 of	 the	 phenotype.	 Noticeably,	 all	 three	 pedigrees	 were	 from	 the	 same	
geographical	area	of	southern	Italy	(Campania	region).		
	
Figure	4.	Pedigree	of	Family	1	with	the	reconstructed	genealogy	(indicated	by	dashed	lines)	of	
its	three	branches	(a,	b,	c).	Affected	individuals	are	indicated	in	black;	probands	are	indicated	
by	arrows.	
	
A	 fourth	smaller	pedigree	(Family	2;	Figure	5)	 from	northern	 Italy	 (Emilia-Romagna	region)	
was	observed	with	a	single	affected	individual	obeying	the	LHON	clinical	diagnosis.	All	four	
families	tested	negative	for	the	three	common	LHON	mutations	at	positions	m.11778G>A/MT-
ND4,	m.3460G>A/MT-ND1	and	m.14484T>C/MT-ND6.	
	
Figure	5.	Pedigree	of	Family	2.	Affected	individuals	are	indicated	in	black;	proband	is	indicated	
by	arrow.	
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Skeletal	muscle	 investigations	 reveal	 normal	 activity	 of	 respiratory	 chain	 complexes	 but	
increased	mitochondrial	biogenesis	
Histological	analysis	of	skeletal	muscle	biopsies	from	the	probands	of	Families	1a,	1b	and	2	
(Figures	4,	5)	showed	no	overt	signs	of	myopathy	with	minimal	variability	in	ﬁbers	size,	and	
histoenzymatic	stain	showed	normal	COX	activity,	but	some	increase	of	subsarcolemmal	SDH	
reactivity	 (Figure	6A).	Ultrastructure	(TEM)	analysis	confirmed	the	presence	of	proliferated	
mitochondria	 under	 the	 sarcolemma	 and,	 occasionally,	 between	 fibers	 (Figure	 6B).	
Mitochondrial	DNA	copy	number	and	CS	activity	were	both	increased	in	skeletal	muscles	of	
patients	as	compared	to	controls	(Figure	6C-D).	Similarly,	the	specific	oxidoreductase	activities	
of	Complex	I,	Complex	II+III,	Complex	III	and	Complex	IV	were	increased	(Figure	6E),	whereas	
when	normalized	on	citrate	synthase	(CS)	activity	they	were	comparable	to	controls	(Table	1).	
Taken	 together	 these	 data	 indicate	 the	 occurrence	 of	 an	 activated	 compensatory	
mitochondrial	 biogenesis,	 most	 likely	 due	 to	 a	 compensatory	 response	 caused	 by	 a	 mild	
mitochondrial	defect,	as	previously	reported	(Giordano	et	al.,	2014;	Iommarini	et	al.,	2012).	
	
	 CI	 CII+III	 CIII	 CIV	
Controls	(mean	±	SD)	 31.7±20.0	 20.3±18.5	 197.94±119.8	 54.6±23.6	
Family	1a	IV:1	 48.10	 29.32	 202.63	 85.23	
Family	2	IV:2	 31.93	 35.83	 281.37	 68.25	
	
Table	1.	Respiratory	chain	enzyme	activity	on	skeletal	muscle	normalized	for	CS	activity	
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Figure	6.	Morphological,	molecular	and	biochemical	analysis	on	skeletal	muscle	biopsies.	A.	
SDH	staining	of	skeletal	muscle	biopsies	 from	 individuals	 IV:1	 from	Family	1a	 (a),	V:6	 from	
Family	1b	 (b)	and	 IV:2	 from	Family	2	 (c).	B.	Transmission	electron	microscopy	of	 the	same	
muscle	specimens	as	in	A.	Both	SDH	histoenzymatic	staining	(A)	and	ultrastructural	evaluation	
(B)	demonstrate	mitochondrial	proliferation	as	highlighted	respectively	by	subsarcolemmal	
increase	of	SDH	reaction	and	corresponding	accumulation	of	mitochondria.	C.	Assessment	of	
mtDNA	content	per	cell,	presented	as	column	with	mean	±	SD	(n=3;	**p<0.001),	confirms	the	
activation	of	mitochondrial	biogenesis	as	shown	by	the	significant	increase	in	LHON	samples.	
D.	 The	 evaluation	 of	 citrate	 synthase	 activity,	 presented	 as	 scatter	 plot	 with	mean	 ±	 SD,	
parallels	again	the	results	observed	in	C,	with	an	increased	mean	value	in	the	LHON	samples.	
E.	Evaluations	of	Complex	 I,	Complex	 II+III,	Complex	 III,	Complex	 IV	activities,	presented	as	
scatter	plot	with	mean	±	SD,	reveal	an	increase	of	all	activities	in	LHON	samples.	
	
Molecular	investigations,	protein	conservation,	frequency,	and	phylogenetic	analyses	of	the	
identified	variants	
Sequencing	 of	 the	 entire	 mitochondrial	 genome	 (mtDNA)	 from	 each	 of	 the	 probands	
independently	ascertained	for	Families	1a,	1b	and	1c	revealed	the	same	identical	sequence,	
indicating	 that	 they	descend	 from	 the	 same	maternal	 ancestor,	 as	also	 suggested	by	 their	
geographical	proximity.	They	all	shared	the	diagnostic	variants	for	haplogroup	K1a	and	the	
following	 private	mutations:	 non-coding	m.2281A>G/MT-RNR2	 and	m.16129G>A/MT-HV1;	
synonymous	 m.6137T>C/MT-CO1,	 m.6329C>T/MT-CO1,	 m.8994G>A/MT-ATP6,	
m.11038A>G/MT-ND4	and	m.15253A>G/MT-CYB;	 and	missense	m.14258G>A/MT-ND6	and	
m.14582A>G/MT-ND6.	 The	 m.14258G>A/MT-ND6	 mutation	 causes	 the	 amino	 acid	
A B 
a 
b 
c 
E 
** 
a 
c 
b 
C D 
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substitution	p.P139L,	and	the	m.14582A>G/MT-ND6	the	amino	acid	substitution	p.V31A.	Both	
missense	mutations	affect	poorly	conserved	positions	of	the	ND6	subunit	of	Complex	I	and	
are	not	predicted	to	be	damaging	(Figure	7,	Table	2).	However,	the	P139	position	showed	a	
higher	conservation	degree	in	mammals	(37%)	compared	to	eukaryotes	(22%),	being	highest	
in	primates	(66%).	Furthermore,	the	P139	position	in	mammals	sits	two	amino	acidic	residues	
away	from	an	invariant	position	(G141)	and,	 in	primates	 is	contiguous	to	another	 invariant	
position	(D138)	within	a	moderately	conserved	domain	(6	invariant	positions	out	of	21)	(Figure	
7).	The	V31	position	shows	similar	features.	In	eukaryotes	and	mammals,	glycine	is	prevalent	
at	 position	 31	 with	 a	 low	 conservation	 (49%	 and	 46%,	 respectively).	 In	 primates,	 at	 this	
position	valine	becomes	prevalent	with	a	higher	conservation	(77%).	Most	relevantly,	V31	is	
within	a	highly	conserved	domain	(10	invariant	positions	out	of	21)	in	mammals,	and	is	even	
more	conserved	in	primates	(16	invariant	positions	out	of	21)	(Figure	7).	
Complete	mtDNA	sequence	analysis	of	 the	proband	 from	Family	2	showed	all	 the	variants	
diagnostic	 for	 haplogroup	 H5b	 and	 the	 following	 private	 mutations:	 synonymous	
m.10248T>C/MT-ND3;	 missense	 m.9966G>A/MT-CO3,	 m.10680G>A/MT-ND4L,	
m.12033A>G/MT-ND4	 and	 m.14258G>A/MT-ND6.	 Besides	 the	 m.14258G>A/MT-ND6	
nucleotide	 change,	 Family	 2	 also	 harbored	 the	 m.10680G>A/MT-ND4L	 and	 the	
m.12033A>G/MT-ND4	mutations	that	induce	the	amino	acid	changes	p.A71T	in	ND4L	and	the	
p.N425S	 in	 ND4	 subunits	 of	 Complex	 I,	 respectively.	 The	 p.A71T	 change	 affects	 a	 highly	
conserved	ND4L	position	(86%	in	eukaryotes,	97%	in	mammals,	invariant	in	primates),	within	
an	invariant	stretch	of	16	amino	acids	in	primates	(Figure	7,	Table	2).	Conversely,	the	p.N425S	
affects	a	highly	conserved	ND4	position	only	in	primates	(41%	in	eukaryotes,	70%	in	mammals,	
87%	in	primates),	in	a	moderately	conserved	domain	(9	invariant	positions	out	of	21)	(Figure	
7,	Table	2).	Both	variants	were	considered	neutral	 for	 the	protein	 function	by	most	of	 the	
prediction	tools	employed.	
The	 m.14258G>A/MT-ND6	 change,	 found	 in	 both	 Families	 1	 and	 2,	 has	 been	 previously	
reported	according	to	Mitomap	and	HmtDB	in	10	different	haplogroups,	being	diagnostic	for	
haplogroups	U3a1a1	and	H1q3.	Conversely,	the	m.14582A>G/MT-ND6	(Family	1)	variant	has	
been	 previously	 reported	 in	 seven	 different	 haplogroups,	 being	 diagnostic	 for	 haplogroup	
H4a.	In	these	databases,	the	sample	classified	as	GenBank:	KC878720	is	from	our	Family	1	and	
it	was	previously	published	(Costa	et	al.,	2013)	without	considering	the	recurrence	of	a	clinical	
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phenotype	(A.	Torroni,	personal	communication).	The	coexistence	of	m.14258G>A/MT-ND6	
with	the	m.14582A>G/MT-ND6	variants	is,	however,	unique	to	Family	1,	when	compared	to	
all	the	other	reported	cases	(Table	3).	
Concerning	the	m.10680G>A/MT-ND4L	variant,	this	has	been	found	in	14	haplogroups	and	it	
has	been	previously	reported	as	the	only	pathogenic	change	in	three	LHON	families,	arising	as	
independent	mutational	events	in	haplogroups	B4a1e,	M13a1b	and	D6a1	(Zhang	et	al.,	2012;	
Zou	 et	 al.,	 2010).	 In	 addition,	 this	 mutation	 has	 also	 been	 found	 in	 association	 with	 the	
m.14484T>C/MT-ND6	mutation	in	a	further	LHON	family	with	a	haplogroup	B4d1	background	
(Yang	et	al.,	2009).	However,	the	m.10680G>A/MT-ND4L	change	has	also	been	recognized	in	
ten	different	maternal	lineages	with	no	pathology	reported	(Table	4).	
Finally,	the	m.12033A>G/MT-ND4	variant	has	been	reported	in	five	different	haplogroups	in	
the	general	population,	without	being	associated	with	any	pathologic	phenotype.	Overall,	the	
combination	 of	 the	 three	 coexisting	 missense	 changes	 m.10680G>A/MT-ND4L,	
m.12033A>G/MT-ND4	and	m.14258G>A/MT-ND6	is	a	unique	feature	of	Family	2.	
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  m.14528A>G/MT-ND6 
p.V31A 
m.14258G>A/MT-ND6 
p.P139L 
Eukaryotes 
Variants 
H.sapiens 
D.melanogaster 
P.lividus 
G.morhua 
D.rerio 
X.laevis 
A.thaliana 
P.anserina 
C.elegans 
 
20 SSKPSPIYGGLALIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
19 NMIHPLALGLTLLIQTIFVCL 39 
18 FYSLSPYYSALGLVVVSISGC 38 
20 ASNPSPYFAALGLVLVAGVGC 40 
20 ASNPAPYFAAFGLVVVAGVGC 40 
20 ASNPSPFYAALGLVLAAGAGC 40 
18 VRAKNPVHSVLFFILVFCDTS 38 
38 ILTKNPIVSVLFLILLFGGIS 58 
18 INIDPMKSSFFLIFSLLFSMP 38 
              * 
130 EGSGLIREDLIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
119 ----INMNFMENSLSLNKLYN 135 
119 DGGGVSFADFSGVAVFYSCGV 139 
121 IEFSVVAADSGGVALMYSLGG 141 
120 KEFSVIRADVSGVAMMYSSGG 140 
118 LGSYVMRGDWVGVALMYSC-W 137 
119 TTSL---TETLG-NLLYTYYF 135 
141 SEDFIDFNTAIG-NIMYTIYN 160 
94  ------PTTYSSYLGLSGFYY 108 
             * 
Mammals 
H.sapiens 
P.troglodytes 
L.catta 
M.musculus 
O.cuniculus 
E.caballus 
B.taurus 
B.physalus 
P.vitulina 
F.catus 
O.anatinus 
 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
19 SSKPSPIYGGVGLIVSGAVGC 39 
20 ALKPSPIYGGLGLIVSGFVGC 40 
20 SSKPSPIYGGLGLIVSGGVGC 40 
21 SSKPSPIYGGLVLIVSGGVGC 41 
21 SSKPSPIYGGLGLIVSGGVGC 41 
21 SSKPSPIYGGLGLIVGGGVGC 41 
21 SSKPSPIYGGLVLIISGAVGC 41 
21 SSKPSPIYGGFGLIVAGGTGC 41 
20 ASKPSPIYGGLSLVLSGGVGC 40 
              * 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGPGLIREDPIGAGALYDYGR 150 
129 KEGGVIREDSLGVASLYNKAS 149 
129 DDVGVMLEGGIGVAAMYSCAT 149 
130 DEVGLIREDSMGVAALYSYGS 150 
131 GDSGAFSEEIMGAAALYSYGA 151 
131 GDSGFFSEEAMGIAALYSYGT 151 
131 GGSGVFSEEATGIAALYSYGV 151 
131 GDSGFFSEEAMGIAALYSYGT 151 
131 GDSGFFSEEAMGIAALYSYGT 151 
121 GGVEVLGGDYNGVSLLSACGG 141 
             * 
Primates 
H.sapiens 
P.paniscus 
P.troglodytes 
P.abelli 
P.pygmeus 
G.gorilla 
H.lar 
L.Catta 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLIISGAVGC 40 
20 SSKPSPIYGGLVLIISGAVGC 40 
20 SSKPSPIYGGLVLIVSGVVGC 40 
20 SSKPSPIYGGLVLVVSGVVGC 40 
19 SSKPSPIYGGVGLIVSGAVGC 39 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGPGLIREDPIGAGALYDYGR 150 
130 EGPGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDPIGAGALYDYGR 150 
130 EGSGLIREDSIGAGALYDYGR 150 
129 KEGGVIREDSLGVASLYNKAS 149 
	
	
  m.10680G>A/MT-ND4L 
p.A71T 
m.12033A>G/MT-ND4 
p.N425S 
Eukaryotes 
Variants 
H.sapiens 
D.melanogaster 
P.lividus 
G.morhua 
D.rerio 
X.laevis 
A.thaliana 
P.anserina 
C.elegans 
 
60 PIAMLVFAACETAVGLALLVS 80 
60 PIAMLVFAACEAAVGLALLVS 80 
60 SMMFLTFSVCEGALGLSILVS 80 
59 NLLLLTLSACEASIGLSLMVA 79 
60 PMLMLAFSACEASAGLALLVA 80 
60 PMLLLAFSACEASAGLALLVA 80 
60 LYIMLPFAAPEAATGLSLNSD 80 
60 ALLVLTVAAAESAIGLAIFVI 80 
54 AIYIIVVAGAESAIGLGILVA 74 
45 FFYFMCFSVISSILGMVVMVG 65 
              * 
415 QWGSLTHHINSMKPSFTRENT 435 
415 QWGSLTHHINNMKPSFTRENT 435 
402 QHGKLFSGVYSFSSGKIREYL 422 
414 QQGTPTNNINNISLSFSREHL 434 
415 QRGPLPQHMLALPPSYTREHL 435 
415 QRGSIPEHITNLSPSHTREHL 435 
414 QRGMTPEHLNAINPTHTREHT 434 
411 VSGLKPDFLHKFSDLNGREVF 431 
407 AFGFSKFFEENIGDVTKREFF 427 
372 LMGKGYHNFNTWNVGFSAPLV 392 
              * 
Mammals 
H.sapiens 
P.troglodytes 
L.catta 
M.musculus 
O.cuniculus 
E.caballus 
B.taurus 
B.physalus 
P.vitulina 
F.catus 
O.anatinus 
 
60 PIAMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PILLLVFAACEAAVGLALLVT 80 
60 PIT-LVFAACEAAVGLALLVK 79 
60 PIILLVFAACEAAVGLALLVM 80 
60 PIILLVFAACERALGLSLLVM 80 
60 PIILLVFAACEAALGLSLLVM 80 
60 PIILLVFAACEAAIGLALLVM 80 
60 PIILLVFAACEAALGLSLLVM 80 
60 PIILLVFAACEAALGLSLLVM 80 
60 PLILLVFSACEAGVGLALLVK 80 
              * 
415 QWGSLTHHINNMKPSFTRENT 435 
415 QWGSLTHHINSMKPSFTRENT 435 
415 QRGKLTYHSHNLNPSFTRENT 435 
415 QRGKLTNHMINLQPSHTRELT 435 
415 QRGKFTYHTNNISPTFTRENT 435 
415 QRGKYTHHINSIKPSFTRENA 435 
415 QRGKYTYHINNISPSFTRENA 435 
415 QRGKHTHHINNITPSFTREHA 435 
415 QRGKYTYHIKNIKPSFTRENA 435 
415 QRGKYTHHIKNINPSFTRENA 435 
415 QRGKLTSHSLSINPSFTREHM 435 
              * 
Primates 
H.sapiens 
P.paniscus 
P.troglodytes 
P.abelli 
P.pygmeus 
G.gorilla 
H.lar 
L.Catta 
60 PIAMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PITMLVFAACEAAVGLALLAS 80 
60 PITMLVFAACEAAVGLALLAS 80 
60 PITMLVFAACEAAVGLALLVS 80 
60 PVVLLVFAACEAAVGLALLVS 80 
60 PILLLVFAACEAAVGLALLVT 80 
415 QWGSLTHHINNMKPSFTRENT 435 
415 QWGSLTHHINNMKPSFTRENT 435 
415 QWGSLTHHINSMKPSFTRENT 435 
415 QRGTPTHHTNNMKPSFTRENT 435 
415 QRGTPSHHINNMKPSSTRENT 435 
415 QWGPLTHHITNMKPSFTRENI 435 
415 QRGTLTHHIKNMKPSLTRENM 435 
415 QRGKLTYHSHNLNPSFTRENT 435 
	
Figure	7.	Amino	acid	conservation	analysis.	Global	alignment	of	ND1,	ND4L	and	ND6	protein	
sequences	from	a	wide	range	of	eukaryotes,	mammals	and	primates.	The	neighborhoods	(20	
amino	 acids)	 of	m.14582A>G/MT-ND6,	m.14258G>A/MT-ND6,	m.10680G>A/MT-ND4L	 and	
m.12033A>G/MT-ND4	 are	 shown.	 Rectangles	 frame	 these	 specific	 variants.	 Amino	 acid	
residues	with	a	percentage	of	conservation	ranging	between	70.0%	and	79.9%	are	highlighted	
Results	
	
	
	
23	
in	light	grey,	those	between	80.0%	and	99.9%	are	highlighted	in	dark	grey	and	those	invariant	
(100%)	are	highlighted	in	black.	
	
Family	 1,2	 1	 2	 2	
Mutation	 m.14258G>A	 m.14582	A>G	 m.10680	G>A	 m.12033	A>G	
Gene	 MT-ND6	 MT-ND6	 MT-ND4L	 MT-ND4	
AA_change	 p.P139L	 p.V31A	 p.A71T	 p.N425S	
PolyPhen2	 benign	 benign	 benign	 benign	
SIFT	 neutral	 neutral	 neutral	 neutral	
FatHmm	 neutral	 neutral	 neutral	 neutral	
PROVEAN	 neutral	 neutral	 deleterious	 neutral	
MutationAssessor	 neutral_impact	 neutral_impact	 high_impact	 low_impact	
CADD	 deleterious	 neutral	 neutral	 neutral	
PANTHER	 neutral	 neutral	 disease	 neutral	
PhD-SNP	 neutral	 neutral	 disease	 neutral	
MtoolBox	 neutral	 neutral	 neutral	 deleterious	
APOGEE_boost	 N	 N	 N	 N	
GB	 16/32,059	 179/32,059	 14/32,059	 5/32,059	
Frequency	 19/31,735	 188/31,735	 14/31,735	 6/31,735	
Conservation	
Eukaryota	 F	22%	 G	49%	 A	86%	 N	42%	
Vertebrata	 F	32%	 G	69%	 A	97%	 N	54%	
Mammalia		 A	37%	 G	46%	 A	97%	 N	70%	
Local	 63%	 85%	 87%	 77%	
Global	 71%	 71%	 80%	 83%	
Invariants	 -57/+2	 -2/+1	 -11/+3	 -8/+6	
	
Table	2.	Prediction	tools	and	conservation	analysis	
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Table	 3.	Mitogenome	 sequences	 carrying	 the	m.14258G>A/MT-ND6,	 p.P139L,	 in	 common	
databases	
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Table	 4.	Mitogenome	 sequences	 carrying	 the	m.10680G>A/MT-ND4L,	 p.A71T,	 in	 common	
databases	
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Cybrid	studies	
To	 assess	 the	 pathogenic	 potential	 of	 the	 two	peculiar	 combinations	 of	missense	 variants	
found	 in	 Family	 1	 (m.14258G>A/MT-ND6	 and	 m.14582A>G/MT-ND6)	 and	 Family	 2	
(m.10680G>A/MT-ND4L,	 m.12033A>G/MT-ND4	 and	 m.14258G>A/MT-ND6)	 we	 generated	
cybrids	using	enucleated	fibroblasts	derived	from	the	probands	of	Families	1a,	1b	and	2,	as	
cytoplast	donors.	Different	cell	clones	were	obtained	harboring	each	the	two	combinations	of	
homoplasmic	variants	and	used	for	subsequent	investigations.	In	Figure	8,	the	data	obtained	
from	each	LHON	cell	line	were	pooled	together	and	compared	to	control	cybrids,	matched	for	
haplogroup,	having	first	verified	that	they	had	very	similar	functional	profiles.	To	challenge	
the	 mitochondrial	 oxidative	 phosphorylation	 system,	 we	 grew	 cybrids	 in	 a	 glucose-free	
medium	 containing	 galactose;	 under	 these	 conditions,	 the	 rate	 of	 glycolysis	 is	 markedly	
reduced	 and	 cells	 are	 forced	 to	 rely	 on	 oxidative	 phosphorylation	 for	 ATP	 production	
(Robinson	et	al.,	1992).	No	significant	differences	were	found	in	LHON	cell	viability	compared	
to	controls	 (Figure	8A).	Assessment	of	Complex	 I	 redox	activity	displayed	a	non-significant	
reduction	in	LHON	cells	(Figure	8B),	indicating	that	the	combinations	of	variants	did	not	affect	
the	 overall	 Complex	 I	 function.	 However,	 the	 basal	 and	 the	 FCCP-stimulated	 oxygen	
consumption	rate	(OCR)	of	LHON	cells	were	significantly	reduced	(Figure	8C).	LHON	cells	also	
displayed	a	metabolic	shift	toward	glycolysis,	since	they	showed	a	higher	ECAR	and	a	lower	
OCR	when	compared	to	controls	(Figure	8D).	Consistently,	the	CS	normalized	ATP	synthesis,	
driven	by	Complex	 I	 substrates	 (malate	and	glutamate),	was	significantly	 reduced	 in	LHON	
cells,	whereas	ATP	synthesis	was	normal	when	driven	by	Complex	 II	 substrates	 (succinate)	
(Figure	8E).	
Although	LHON	mutations	have	been	reported	to	exert	their	pathogenic	role	by	 increasing	
oxidative	 stress	 (Carelli	 et	 al.,	 2004;	 Yu-Wai-Man	 et	 al.,	 2011),	 we	 failed	 to	 reveal	 any	
difference	 between	mutant	 and	 control	 cells	 in	 terms	 of	 superoxide	 anion	 and	 hydrogen	
peroxide	production	(Figure	9).	Overall,	these	data	indicate	that	combinations	of	polymorphic	
Complex	I	variants	induce	a	mild	bioenergetic	defect.	
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Figure	8.	Biochemical	characterization	of	cybrids	clones.	A.	Cell	viability	after	different	time	
of	 incubation	in	galactose	medium.	Data	are	expressed	as	percentage	of	T0	(n=12;	mean	±	
SEM).	B.	Rotenone	sensitive	redox	activity	of	respiratory	complex	I	normalized	for	CS	activity	
(n=9;	mean	±	SD).	C.	OCR	traces	as	pmol	O2/min,	after	the	injection	of	1µM	oligomycin	(O),	
0.2µM	FCCP	(F),	1µM	rotenone	(R)	and	1µM	antimycin	A	(AA)	(mean	±	SD).	Asterisks	indicate	
statistical	significance	(n=3;	*	p<0.05).	D.	XFe	Metabolic	Phenogram.	Basal	OCR	(pmol/min)	
and	ECAR	(mpH/min)	rates	were	plotted	 in	controls	vs	LHON	cybrids,	showing	a	metabolic	
shift	 in	 LHON	 cybrids	 towards	 glycolysis.	 E.	 ATP	 synthesis	 rates	 normalized	 for	 CS	 activity	
driven	by	complex	I	substrates	(malate/glutamate)	and	complex	II	substrate	succinate	(mean	
±	SD).	Asterisks	indicate	statistical	significance	(n=16;	*	p<0.05).	
	
Figure	 9.	Production	 of	 superoxide	 anion	 and	 hydrogen	 peroxide	 in	 cybrid	 cell	 lines.	A.	
Mitochondrial	superoxide	anion	production	determined	by	epifluorescence	microscopy	using	
MitoSOX™	 fluorescent	 dye.	 Cells	 were	 visualized	 with	 a	 digital	 imaging	 system,	 using	 an	
inverted	epifluorescence	microscope	(magnification	x63/1.4	oil	objective)	at	580nm.	Images	
are	representative	of	3	different	experiments.	B.	Hydrogen	peroxide	 levels	were	measured	
using	H2DCFDA	by	flow	cytometry,	as	described	in	materials	and	methods.	Data	are	mean±SD	
(n=3).	
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Modeling	of	the	identified	variants	on	the	ovine	Complex	I	structure		
In	order	to	define	how	such	peculiar	combinations	of	variants	lead	to	a	mild	Complex	I	defect,	
we	 took	 advantage	 of	 the	 recently	 released	 structure	 of	 mammalian	 enzyme	 at	 3.9 Å	
resolution,	 solved	 by	 cryo-electron	microscopy	 (Fiedorczuk	 et	 al.,	 2016).	We	 analyzed	 the	
position	of	amino	acids	affected	by	the	polymorphic	variants,	namely	m.14258G>A/MT-ND6,	
m.14582A>G/MT-ND6,	 m.10680G>A/MT-ND4L	 and	 m.12033A>G/MT-ND4	 (Figure	 10),	 but	
also	 the	 variants	 in	 three	 LHON	 Chinese	 families,	 with	 m.10680G>A/MT-ND4L	 found	 in	
combination	 with	 m.14484T>C/MT-ND6,	 m.3745G>A/MT-ND1,	 m.3548T>C/MT-ND1	
m.3644T>C/MT-ND1,	respectively	(Yang	et	al.,	2009;	Zhang	et	al.,	2012;	Zou	et	al.,	2010),	and	
the	adaptive	variants	 (m.3745G>A/MT-ND1,	m.4216T>C/MT-ND1,	m.3394T>C/MT-ND1)	 for	
high	altitude	in	Tibet	(Ji	et	al.,	2012;	Kang	et	al.,	2013)	(Figure	11).	
The	variant	m.14258A>G/MT-ND6	shared	by	Families	1	and	2	induces	the	P139L	amino	acid	
change	in	humans,	which	corresponds	to	A140	in	ovine	Complex	I.	Such	amino	acid	is	located	
in	 the	 transversal	a-helix	 5	 of	 ND6.	 The	 variant	 m.14582A>G/MT-ND6	 found	 in	 Family	 1	
generates	the	amino	acid	substitution	p.V31A	in	humans	and	corresponds	to	G32	in	the	ovine	
complex,	affecting	the	transmembrane	a-helix	2	(TM2)	of	ND6.	The	m.10680G>A/MT-ND4L	
variant	harbored	by	Family	2	affects	the	amino	acid	A71	of	ND4L	both	in	human	and	ovine	
Complex	I.	This	amino	acid	lies	in	TM3	of	the	ND4L	subunit.	Lastly,	the	m.12033A>G/MT-ND4	
induces	the	amino	acid	substitution	p.N425S	in	the	loop	between	TM13	and	TM14	of	ND4,	
which	 faces	 the	mitochondrial	 matrix.	 Interestingly,	 with	 the	 only	 exception	 of	 the	 latter	
amino	acid	change,	all	 the	other	variants	affect	positions	around	the	putative	E-channel	of	
Complex	I	(Castellana	et	al.,	2015),	suggesting	that	the	mild	functional	defect	found	in	these	
patients	 may	 arise	 from	 an	 altered	 proton	 pumping	 caused	 by	 the	 two	 peculiar	 mtDNA	
combinations	of	variants	(Figure	10).		
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Figure	10.	Complex	I	model.	Localization	of	polymorphic	variants	on	the	structure	of	the	ovine	
complex	I,	(Fiedorczuk	et	al.,	2016)	using	the	UCSF	Chimera	software.	The	ovine	amino	acids	
Ala140	(corresponding	to	human	p.P139L,	m.14258G>A/MT-ND6),	Gly32	(corresponding	to	
human	 p.V31A,	 m.14582A>G/MT-ND6)	 and	 Ala71	 (corresponding	 to	 human	 p.A71T,	
m.10680G>A/MT-ND4L)	are	shown	as	red-labelled	spheres;	whereas	residues	Glu143/ND1,	
Glu192/ND1,	Glu34/ND4L,	Tyr60/ND6,	the	key	residues	for	the	E-channel	(near	Q	site),	are	
shown	 as	 blue-labelled	 spheres.	 The	 structures	 of	ND1,	ND4L,	ND6	 and	ND3	 subunits	 are	
shown	as	ribbons,	in	green,	blue,	yellow	and	red,	respectively.	The	combination	of	variants	in	
Family	1	(A-B)	and	Family	2	(C-D)	are	displayed	as	front	(A-C)	and	upper	(B-D)	views.	Light	blue	
arrows	indicate	the	proposed	proton	translocation	pathway	(Fiedorczuk	et	al.,	2016).	
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Figure	11.	Combinations	of	mtDNA	variants	from	three	LHON	Chinese	families	and	single	
mtDNA	 variants,	 adaptive	 for	 high	 altitude	 in	 Tibet,	 on	 the	 ovine	 Complex	 I	 structure.	
Positioning	of	the	combinations	of	variants	in	three	LHON	Chinese	families	(A-B)	(Yang	et	al.,	
2009;	Zhang	et	al.,	2012;	Zou	et	al.,	2010)	and	the	adaptive	variants	for	high	altitude	in	Tibet	
(C-D)	 (Ji	 et	 al.,	 2012;	 Kang	 et	 al.,	 2013)	 on	 crystallographic	 structure	 of	 ovine	 Complex	 I	
(Fiedorczuk	et	al.,	2016),	using	the	UCSF	Chimera	software.	In	panels	A	and	B,	the	ovine	amino	
acids	 Ala71	 (corresponding	 to	 human	 p.A71T,	 m.10680G>A/MT-ND4L)	 are	 shown	 as	 red	
labelled	spheres,	and	this	variant	is	associated	in	each	families	with	Met65	(corresponding	to	
human	 p.M64V,	 m.14484T>C	 /MT-ND6),	 Ala147	 (corresponding	 to	 human	 p.A147T,	
m.3745G>A/MT-ND1),	 Leu81	 (corresponding	 to	 human	 p.I81T,	 m.3548T>C/MT-ND1)	 or	
Val113	 (corresponding	 to	 human	 p.V113A,	m.3644T>C/MT-ND1),	 shown	 as	 green	 labelled	
spheres.	 In	 panels	 C	 and	 D,	 the	 ovine	 amino	 acids	 Ala147	 (corresponding	 to	 p.A147T,	
m.3745G>A/MT-ND1),	His304	(corresponding	to	human	p.Y139H,	m.4216T>C/MT-ND1)	and	
Tyr30	 (corresponding	 to	human	p.Y30H,	m.3394T>C/MT-ND1)	are	shown	as	green	 labelled	
spheres.	In	all	panels,	residues	Glu143/ND1,	Glu192/ND1,	Glu34/ND4L,	Tyr60/ND6,	the	key	
residues	for	the	E-channel	(near	Q-site),	are	shown	as	blue	labelled	spheres	(Ji	et	al.,	2012).	
The	backbones	of	ND1,	ND4L,	ND6	and	ND3	are	shown	as	ribbons,	in	green,	blue,	yellow	and	
red,	 respectively.	 The	 variants	 combination	 in	 LHON	 Chinese	 families	 (A-B)	 and	 adaptive	
variants	 for	high	altitude	 in	Tibet	 (C-D)	are	displayed	as	 front	 (A-C)	and	upper	 (B-D)	views.	
Light	blue	arrows	indicate	the	proposed	proton	translocation	pathway.	 	
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PART	2	-	Mitochondrial	DNA	variability	in	Leber’s	hereditary	optic	neuropathy		
	
Mitochondrial	genome	sequencing	and	haplogroup	affiliation	
We	 completely	 sequenced	 mtDNA	 in	 147	 probands,	 affected	 by	 LHON	 carrying	 the	
m.14484T>C/MT-ND6	primary	mutation,	 in	 apparently	 unrelated	 families	 from	Europe	 (52	
from	Italy,	43	from	Germany,	27	from	France,	19	from	UK,	3	from	Spain	and	3	from	US,	but	
with	European	ancestry).	
Out	of	the	entire	cohort	28	probands	were	related	and	in	table	5	the	results	of	119	unrelated	
mitochondrial	genomes	are	shown:	for	each	proband	it	is	indicated	the	haplogroup	affiliation,	
the	private	mutations	not	diagnostic	for	the	haplogroup	and	the	corresponding	amino	acid	
changes.	
Haplotype	 Haplogroup	 Private	variants		
non-coding	
Private	variants	
synonymous	
Private	variants	
missense	
H	 H	 73	A>G	 14968	T>C	 	
H	 H	 16093	T>C	
16258	A>C	
16311	T>C	
	 9055	G>A	
10680	G>A	
H1a1	 H	 	 6959	C>G	 	
H1bm	 H	 1790	A>G		
16171	A>T	
9881	T>C	
10972	A>G	
14582	A>G	
H1e	 H	 	 15518	C>T	 	
H1e1a	 H	 362	insAAAG	
452	T>C	
16093	T>C	
	 14564	A>G	
H3	 H	 	 10121	A>G	
15346	G>A	
15833	C>T	
4639	T>C	
H3c2b1	 H	 	 	 6261	G>A	
7444	G>A	
H3h	 H	 93	A>G	
146	T>C	
	 	
H4a1a	 H	 16362	T>C	 13497	A>G	 	
H4a1a1a	 H	 195	T>C	 15172	G>A	 	
H5	 H	 16368	T>C	 8251	G>A	
9530	T>C	
3368	T>C	
7080	T>C	
H5	 H	 73	A>G	
709	G>A	
5628	T>C	
8251	G>A	
9530	T>C	
	
H5b4	 H	 16145	G>A	 6620	T>C	
12501	G>A	
	
H6a1a	 H	 	 15784	T>C	 	
H7c1	 H	 16093	T>C	 11533	C>T	 	
H14b	 H	 16162	delA	 4086	C>T	
5978	A>G	
	
H26a1	 H	 152	T>C	
5895	insCCC	
8840	A>G	 	
H27	 H	 	 	 3368	T>C	
H56	 H	 	 10235	T>C	 	
H94	 H	 16093	T>C	 9374	A>G	
13227	C>T	
	
HV	 H	 152	T>C	
16311	T>C	
	 	
V1a1	 H	 151	C>T	
16104	C>A	
4065	A>G	 	
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V10b1	 H	 	 	 	
J1b1a1	 J	 146	T>C	 	 	
J1b1a1	 J	 146	T>C	 	 13135	G>A	
J1b1a1	 J	 789	T>C	
10427	G>A	
	 	
J1b1a1	 J	 789	T>C	
10427	G>A	
13743	T>C	 	
J1b1a1	 J	 146	T>C	
657	G>A		
789	T>C		
10427	G>A	
13743	T>C	 	
J1b1a1	 J	 146	T>C	
16311	T>C	
	 	
J1b1a1	 J	 7543	A>G		
16093	T>C	
	 14861	G>A	
J1b1a1b	 J	 15930	G>A		
16256	C>T	
16260	C>T	
15262	T>C	 3535	T>A	
J1b1a1d	 J	 1462	G>A	 	 4659	G>A	
J1b1a1d	 J	 	 	 8557	G>C	
J1b1a1d	 J	 	 	 	
J1c	 J	 1284	T>C		
5788	T>C		
16114	C>T	
16215	A>G	
16265	A>T	
4017	C>T	
9425	A>G	
15394	T>C	
7859	G>A	
13135	G>A	
J1c1d	 J	 10031	T>C	 8383	T>C	 9053	G>A	
J1c1d	 J	 183	A>G	
10031	T>C	
8383	T>C	 9053	G>A	
J1c1d	 J	 	 	 	
J1c2	 J	 	 3375	C>T	 	
J1c2b	 J	 	 	 	
J1c2c1	 J	 	 	 	
J1c2e	 J	 194	C>T	 	 	
J1c2j	 J	 	 	 14279	G>A	
J1c2j	 J	 	 	 4184	T>A	
14279	G>A	
J1c3	 J	 182	C>T	 3372	T>C	 	
J1c3a	 J	 	 	 	
J1c3b	 J	 	 10915	T>C	 10609T>C	
J1c3b1a	 J	 	 	 8989	G>A	
J1c3e2	 J	 16325	T>C	 5147	G>A	 6712	A>T	
9957	T>C	
J1c3e2	 J	 16291	C>T	 	 	
J1c3f	 J	 709	G>A		
16093	T>C	
	 10845	C>T	
J1c3f	 J	 709	G>A		
2181	A>G	
8458	A>G	 10845	C>T	
J1c3g	 J	 188	A>G	
195	T>C	
16243	T>C	
14364	G>A	 	
J1c3j	 J	 	 	 	
J1c4	 J	 	 11260	T>C	 	
J1c4	 J	 	 7271	A>G	
13641	T>C	
	
J1c4	 J	 16189	T>C	 	 	
J1c5	 J	 489	T>C	
16174	C>T	
4209	T>C	
12810	A>G	
	
J1c6	 J	 182	C>T	 	 	
J1c9	 J	 189	A>G	
254	T>C	
16343	A>G	
6602	C>T	
10786	T>C	
12361	A>G	
J1c10	 J	 195	T>C	
198	C>T	
3358	A>G	
12501	G>A	
12648	A>G	
4561	T>C	
13621	C>T	
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J1d1a1	 J	 16093	T>C	
16203	A>G	
15430	C>T	 8812	A>G	
J2a1a1	 J	 198	C>T	
3027	T>C	
	 3316	G>A	
13712	C>T	
J2a1a1a	 J	 16400	C>T	
16497	A>G	
3447	A>G	
5258	A>G	
9137	T>C	
J2a1a1a3	 J	 16189	T>C	 	 7270	T>C	
8843	T>C	
J2a2b1	 J	 185	G>A	
8292	G>A	
16311	T>C	
	 	
J2a2b1	 J	 185	G>A	
8292	G>A	
15409	C>T	 	
J2a2c	 J	 	 14569	G>A	 7269	G>A	
J2a2c	 J	 	 	 7269	G>A	
J2b1	 J	 16265	A>T	 6959	C>G	 4824	A>G	
8953	A>G	
15315	C>T	
J2b1a2	 J	 246	T>C	 3348	A>G	 	
J2b1a3	 J	 709	G>A	 13029	C>T	 	
J2b1a3	 J	 709	G>A	 	 8743	G>A	
J2b1a6	 J	 	 8557	A>C	 9025	G>A	
J2b1a6	 J	 	 13194	G>A	 	
J2b1a6	 J	 	 	 	
J2b1b1	 J	 146	T>C	 10124	T>C	 8711	A>G	
T1a1b	 T	 	 	 	
T1a2	 T	 152	T>C	
204	T>C	
633	A>G		
16185	C>T	
8994	G>A	
9377	A>G	
10876	A>G	
11239	A>G	
8516	T>C		
10398	A>G	
T1a2	 T	 204	T>C	
633	A>G	
8640	C>T	
8994	G>A	
9377	A>G	
10876	A>G	
11239	A>G	
10398	A>G	
T1a2	 T	 204	T>C	
633	A>G	
8994	G>A	
9377	A>G	
10876	A>G	
11239	A>G	
10398	A>G	
T1a2	 T	 633	A>G	 8994	G>A	
9377	A>G	
10876	A>G	
11239	A>G	
10398	A>G	
T2	 T	 490	A>G	 5378	A>G	
12681	T>C	
12819	A>G	
13194	G>A	
3460	G>A		
7440	T>G	
T2	 T	 490	A>G	 5378	A>G	
12681	T>C	
12819	A>G	
13194	G>A	
7440	T>G	
10680	G>A	
T2	 T	 490	A>G	 5378	A>G	
12681	T>C	
12819	A>G	
13194	G>A	
7440	T>G	
T2b	 T	 185	G>A	
16178	T>C	
3828	A>G	 	
T2b	 T	 	 3828	A>G	 	
T2b3b	 T	 	 	 	
T2b25	 T	 16311	T>C	 	 9067	A>G	
10237	T>C	
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T2c1d1	 T	 152	T>C	
182	C>T	
374	A>G	
5565	A>T	
6644	C>T	 13708	G>A	
T2c1d1	 T	 152	T>C	
374	A>G	
5565	A>T	
16092	T>C	
6644	C>T	 13708	G>A	
T2c1d1	 T	 152	T>C	
374	A>G	
5565	A>T	
3645	T>C	
6644	C>T	
13708	G>A	
T2f1a	 T	 8270	ins9	 	 	
U1a1a1	 U	 513insCA	
16168	C>T	
16183	A>C	
16215	A>G	
16325	T>C	
5090	T>C	
6050	T>C	
7257	A>G		
10680	G>A	
11969	G>A	
U3b	 U	 152	T>C	
2833	A>G	
15940	delT	
7660	T>C	
13474	T>C	
3523	A>G	
15221	G>A	
U3b	 U	 152	T>C	
15940	delT	
16172	T>C		
16173	C>T		
16290	C>T	
16390	G>A	
16497	A>G	
3429	C>T	
15784	T>C	
3434	A>G	
13105	A>G	
U5a1a1	 U	 152	T>C	
16231	T>C	
	 11778	G>A	
U5a1a2b	 U	 16082	C>T	 4023	T>C	
10535	T>C	
4160	T>C	
U5a1c1	 U	 15928	G>A	 	 	
U5b1b1	 U	 16093	T>C	 	 	
K1a1b1	 K	 5583	C>T	 	 	
K1a1b1	 K	 16051	A>G	 8053	A>G	 	
K1a8	 K	 152	T>C	
3084	A>G	
9422	A>G	 	
B2	 other	 	 9254	A>G	
9548	G>A	
7119	G>A	
I2a	 other	 	 9758	T>C	 4216	T>C		
5460	G>A	
10320	G>A	
I2d	 other	 152	T>C	
16362	T>C	
	 	
L0F2b	 other	 4456	C>T	 	 	
L1b1a	 other	 200	A>G	
16213	G>A	
8937	T>C	
11452	T>C	
4123	A>G	
4695	T>C	
L1b1a1	 other	 	 3693	G>A	 13105	A>G	
L2a1a1	 other	 1901	C>T		
5774	T>A	
4161	C>T	 14258	G>A	
L2a1l2	 other	 198	C>T	 7492	C>T	 4136	A>G	
L3e1a	 other	 	 	 	
L3e5a	 other	 	 	 5460	G>A	
L3e5a	 other	 16311	T>C	
16362	T>C	
	 9327	A>G	
L3e5a	 other	 3290	T>C	 	 5460	G>A	
8888	T>C	
M1a5	 other	 	 	 	
N1a1a1a3	 other	 143	G>A	
228	G>A	
2955	T>C	
12235	T>C	
4772	T>C	 8448	T>C	
9103	T>C	
15458	T>C	
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X2d1	 other	 16161	TA>T	 	 8400	T>C		
10680	G>A	
	
Table	5.	Mitochondrial	genome	of	LHON	probands	carrying	m.14484T>C/MT-ND6	mutation	
with	haplogroup	affiliation	(according	to	www.phylotree.org	-	build	17)	and	private	changes.	
Missense	 variant	 in	 coloured	 according	 scoring	 criteria	 described	 in	 the	 “materials	 and	
methods”	as	in	table	6.	
	
In	 the	 LHON	 cohort	 of	 probands	 carrying	 the	m.14484T>C/MT-ND6	mutation	we	 found	 a	
statistically	different	frequency	of	mitochondrial	haplogroups	as	compared	to	the	European	
population	(χ2test,	p	<	0,0001)	(Figure	12).	To	understand	which	haplogroup	generated	this	
difference,	all	categories	were	compared	to	each	other	(n=15),	indicating	a	major	role	for	the	
haplogroup	J	and,	less	stringently,	for	haplogroup	T	(χ2test	with	Bonferroni	correction),	both	
over-represented	 and	 stemming	 from	 the	 same	 root.	 On	 the	 contrary,	 haplogroup	H	was	
consistently	under-represented	and	to	a	lesser	extent	haplogroups	K	and	U,	these	latter	two	
sitting	on	the	same	root.	
	
Figure	12.	Frequency	of	European	haplogroups	 in	LHON	cohort	with	m.14484T>C/MT-ND6	
mutation	and	control	population	(n	=10379).	**p<0.001,	*p<0.05.	
	
Taking	advance	of	having	the	entire	mtDNA	genome	sequence	available,	and	in	consideration	
of	 the	 strong	 association	 of	 haplogroup	 J	 with	 the	 m.14484T>C/MT-ND6	 mutation,	 we	
dissected	further	haplogroup	J	 into	the	sub-clades.	Of	relevance,	previous	studies	reported	
the	association	with	specific	clades	of	haplogroup	J,	i.e.	J1c	(Carelli	et	al.,	2006;	Hudson	et	al.,	
2007).	Our	current	 results	 failed	 to	highlight	any	significant	difference	amongst	any	of	 the	
haplogroup	J	sub-clades,	in	particular	between	J1	vs	J2,	or	their	sub-clades,	as	compared	with	
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the	 European	 population	 (χ2test,	 J	 sub-ckades	 p=0.4046,	 J1	 sub-ckades	 p=0.1285,	 J2	 sub-
ckades	p=1.000)	(Figure	13).	
	
Figure	 13.	 Frequency	 of	 J1	 and	 J2	 clades,	 and	 their	 subclades	 in	 55	 LHON	 with	
m.14484T>C/MT-ND6	mutation	on	haplogroup	J	background	and	control	population	(n	=156).	
	
Evaluation	of	private	missense	variants		
We	analysed	all	missense	changes,	which	were	not	diagnostic	for	the	haplogroups,	to	detect	
other	private	variants,	with	some	possible	pathogenic	significance.	For	each	variant,	the	amino	
acid	residue	conservation	and	the	in-silico	prediction	values	of	pathogenicity	were	considered	
(Table	6).		
To	this	end,	the	on-line	 tools	PolyPhen2,	SIFT,	PANTHER	and	PhD-SNP	have	been	used	and	
conservation	analysis	was	carried	out,	as	detailed	in	the	methods.	According	to	the	scoring	
criteria	described	in	the	“materials	and	methods”,	changes	with	a	score	of	0,66-1	points	were	
considered	pathogenic	(red),	with	0,5-0,65	points	were	considered	synergistic	(orange)	and	
with	0-0,49	points	neutral	(black).	
Nucleotide	
change	
Gene	 Amino-	
Acid	
change	
Predictor	tools	 Conservation	(%)	 Invariants	
PolyPhen2	 SIFT	 PANTHER	 PhD-SNP	 Mammals	 Local	 Global	 -	 +	
m.3316G>A	 MT-ND1	 p.A4T	 benign	 neutral	 NA	 neutral	 67	 57	 78	 3	 12	
m.3368T>C	 MT-ND1	 p.M21T	 benign	 neutral	 NA	 neutral	 92	 81	 78	 1	 1	
m.3434A>G	 MT-ND1	 p.Y43C	 benign	 neutral	 neutral	 disease	 82	 86	 78	 2	 1	
m.3460G>A	 MT-ND1	 p.A52T	 probably_damaging	 neutral	 neutral	 disease	 97	 86	 78	 1	 2	
m.3523A>G	 MT-ND1	 p.T73A	 benign	 neutral	 neutral	 neutral	 51	 68	 78	 10	 2	
m.3535T>A	 MT-ND1	 p.L77M	 probably_damaging	 neutral	 neutral	 neutral	 95	 57	 78	 2	 9	
m.4123A>G	 MT-ND1	 p.I273V	 benign	 neutral	 neutral	 neutral	 70	 81	 78	 1	 1	
m.4136A>G	 MT-ND1	 p.Y277C	 probably_damaging	 neutral	 disease	 disease	 99	 86	 78	 3	 1	
m.4160T>C	 MT-ND1	 p.L285P	 probably_damaging	 neutral	 disease	 disease	 100	 100	 78	 1	 1	
m.4184T>A	 MT-ND1	 p.F293Y	 probably_damaging	 neutral	 disease	 neutral	 100	 100	 78	 2	 1	
m.4216T>C	 MT-ND1	 p.Y304H	 benign	 neutral	 neutral	 neutral	 62	 67	 78	 6	 11	
m.4561T>C	 MT-ND2	 p.V31A	 benign	 neutral	 neutral	 neutral	 56	 67	 62	 1	 1	
m.4639T>C	 MT-ND2	 p.I57T	 benign	 neutral	 neutral	 neutral	 86	 76	 62	 6	 2	
m.4659G>A	 MT-ND2	 p.A64T	 benign	 neutral	 disease	 disease	 93	 76	 62	 1	 2	
m.4695T>C	 MT-ND2	 p.F76L	 benign	 neutral	 neutral	 neutral	 73	 57	 62	 9	 8	
m.4824A>G	 MT-ND2	 p.T119A	 benign	 neutral	 disease	 neutral	 94	 81	 62	 1	 1	
m.5460G>A	 MT-ND2	 p.A331T	 benign	 neutral	 neutral	 neutral	 46	 48	 62	 22	 7	
m.6261G>A	 MT-CO1	 p.A120T	 probably_damaging	 neutral	 neutral	 neutral	 100	 100	 95	 1	 1	
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m.6712A>T	 MT-CO1	 p.Y270F	 probably_damaging	 neutral	 disease	 disease	 100	 100	 95	 1	 1	
m.7080T>C	 MT-CO1	 p.F393L	 probably_damaging	 neutral	 neutral	 disease	 100	 100	 95	 1	 2	
m.7119G>A	 MT-CO1	 p.D406N	 benign	 neutral	 neutral	 neutral	 83	 90	 95	 4	 1	
m.7257A>G	 MT-CO1	 p.I452V	 benign	 neutral	 neutral	 neutral	 77	 90	 95	 1	 2	
m.7269G>A	 MT-CO1	 p.V456M	 benign	 neutral	 neutral	 neutral	 77	 86	 95	 1	 1	
m.7270T>C	 MT-CO1	 p.V456A	 benign	 deleterious	 neutral	 neutral	 77	 86	 95	 1	 1	
m.7440T>G	 MT-CO1	 p.S513A	 benign	 neutral	 neutral	 neutral	 33	 55	 95	 5	 -	
m.7859G>A	 MT-CO2	 p.D92N	 benign	 neutral	 neutral	 neutral	 75	 95	 89	 3	 1	
m.8400T>C	 MT-ATP8	 p.M12T	 benign	 neutral	 neutral	 neutral	 55	 62	 46	 3	 39	
m.8448T>C	 MT-ATP8	 p.M28T	 benign	 neutral	 neutral	 neutral	 47	 33	 46	 19	 23	
m.8516T>C	 MT-ATP8	 p.W51R	 probably_damaging	 neutral	 disease	 disease	 100	 48	 46	 42	 4	
m.8557G>C	 MT-ATP6	 p.A11P	 possibly_damaging	 neutral	 neutral	 disease	 68	 67	 77	 2	 1	
m.8557G>C	 MT-ATP8	 p.L64F	 probably_damaging	 neutral	 disease	 neutral	 80	 67	 46	 7	 -	
m.8711A>G	 MT-ATP6	 p.N62S	 benign	 neutral	 neutral	 neutral	 83	 67	 77	 1	 3	
m.8743G>A	 MT-ATP6	 p.V73M	 benign	 neutral	 neutral	 neutral	 44	 71	 77	 2	 2	
m.8812A>G	 MT-ATP6	 p.T96A	 probably_damaging	 neutral	 neutral	 neutral	 98	 95	 77	 1	 1	
m.8843T>C	 MT-ATP6	 p.I106T	 benign	 deleterious	 disease	 neutral	 98	 81	 77	 1	 3	
m.8888T>C	 MT-ATP6	 p.I121T	 benign	 neutral	 neutral	 neutral	 71	 76	 77	 1	 1	
m.8953A>G	 MT-ATP6	 p.I143V	 probably_damaging	 neutral	 neutral	 neutral	 85	 86	 77	 3	 1	
m.8989G>A	 MT-ATP6	 p.A155T	 probably_damaging	 neutral	 neutral	 disease	 93	 95	 77	 2	 2	
m.9025G>A	 MT-ATP6	 p.G167S	 probably_damaging	 deleterious	 disease	 disease	 100	 90	 77	 1	 1	
m.9053G>A	 MT-ATP6	 p.S176N	 benign	 neutral	 neutral	 neutral	 58	 76	 77	 1	 23	
m.9055G>A	 MT-ATP6	 p.A177T	 possibly_damaging	 neutral	 disease	 disease	 90	 71	 77	 2	 22	
m.9067A>G	 MT-ATP6	 p.M181V	 benign	 deleterious	 neutral	 neutral	 90	 57	 77	 6	 18	
m.9103T>C	 MT-ATP6	 p.F193L	 benign	 neutral	 disease	 neutral	 93	 62	 77	 18	 6	
m.9137T>C	 MT-ATP6	 p.I204T	 benign	 neutral	 NA	 neutral	 66	 86	 77	 1	 7	
m.9327A>G	 MT-CO3	 p.T41A	 benign	 neutral	 neutral	 neutral	 42	 71	 92	 5	 1	
m.9957T>C	 MT-CO3	 p.F251L	 benign	 neutral	 neutral	 disease	 100	 100	 92	 1	 1	
m.10237T>C	 MT-ND3	 p.I60T	 probably_damaging	 neutral	 disease	 disease	 100	 100	 69	 3	 1	
m.10320G>A	 MT-ND3	 p.V88I	 benign	 neutral	 neutral	 neutral	 46	 29	 69	 10	 10	
m.10398A>G	 MT-ND3	 p.T114A	 benign	 neutral	 neutral	 neutral	 81	 92	 69	 1	 -	
m.10609T>C	 MT-ND4L	 p.M47T	 benign	 neutral	 neutral	 neutral	 51	 48	 69	 13	 13	
m.10680G>A	 MT-ND4L	 p.A71T	 benign	 neutral	 disease	 disease	 97	 81	 69	 11	 3	
m.10845C>T	 MT-ND4	 p.T29I	 benign	 neutral	 NA	 neutral	 36	 62	 77	 3	 6	
m.11778G>A	 MT-ND4	 p.R340H	 probably_damaging	 deleterious	 disease	 disease	 100	 90	 77	 2	 2	
m.11969G>A	 MT-ND4	 p.A404T	 benign	 neutral	 disease	 disease	 84	 67	 77	 5	 2	
m.12361A>G	 MT-ND5	 p.T9A	 unknown	 neutral	 NA	 neutral	 59	 26	 68	 -	 6	
m.13105A>G	 MT-ND5	 p.I257V	 benign	 neutral	 neutral	 neutral	 59	 86	 68	 1	 1	
m.13135G>A	 MT-ND5	 p.A267T	 benign	 neutral	 disease	 neutral	 56	 67	 68	 4	 12	
m.13621C>T	 MT-ND5	 p.L429F	 benign	 neutral	 disease	 neutral	 67	 62	 68	 4	 6	
m.13708G>A	 MT-ND5	 p.A458T	 benign	 neutral	 disease	 disease	 44	 67	 68	 1	 7	
m.13712C>T	 MT-ND5	 p.A459V	 benign	 neutral	 neutral	 disease	 46	 62	 68	 2	 6	
m.14258G>A	 MT-ND6	 p.P139L	 benign	 neutral	 neutral	 neutral	 37	 38	 52	 57	 2	
m.14279G>A	 MT-ND6	 p.S132L	 benign	 neutral	 neutral	 neutral	 60	 24	 52	 50	 9	
m.14484T>C	 MT-ND6	 p.M64V	 probably_damaging	 neutral	 neutral	 disease	 58	 95	 52	 1	 1	
m.14564A>G	 MT-ND6	 p.V37A	 benign	 neutral	 neutral	 disease	 70	 67	 52	 1	 2	
m.14582A>G	 MT-ND6	 p.V31A	 benign	 neutral	 neutral	 neutral	 47	 86	 52	 2	 1	
m.14861G>A	 MT-CYB	 p.A39T	 benign	 neutral	 neutral	 neutral	 39	 81	 82	 2	 1	
m.15221G>A	 MT-CYB	 p.D159N	 benign	 neutral	 neutral	 disease	 38	 95	 82	 2	 4	
m.15315C>T	 MT-CYB	 p.A190V	 benign	 neutral	 neutral	 disease	 41	 86	 82	 3	 6	
m.15458T>C	 MT-CYB	 p.S238P	 benign	 neutral	 neutral	 disease	 27	 52	 82	 7	 9	
Table	 6.	 Prediction	 tools	 and	 conservation	 analysis	 of	 missense	 private	 variants	 in	 LHON	
probands	carrying	m.14484T>C/MT-ND6	mutation.	
	
This	analysis	confirmed	the	pathogenic	role	of	the	m.14484T>C,	found	in	all	probands.	
We	 detect	 the	 co-presence	 of	 10	 other	 possibly	 pathogenic	 mutations	 in	 10	 different	
pedigrees	(Table	6).	In	2	families,	besides	the	primary	LHON	m.14484T>C	mutation,	a	second	
LHON	primary	mutation	was	found	(m.3460G>A	and	m.11778G>A).	We	also	found	3	possibly	
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pathogenic	 mutations	 in	 MT-ND1	 (m.4136A>G,	 m.4160T>C,	 m.4184T>A),	 1	 in	 MT-ND3	
(m.10237T>C),	 1	 in	 MT-ND2	 (m.4659G>A),	 1	 in	 MT-CO1	 (m.6712A>T),	 1	 in	 MT-CO3	
(m.9957T>C),	1	in	MT-ATP8	(m.8516T>C)	and	2	in	MT-ATP6	(m.8989G>A,	m.9025G>A).	
Furthermore,	 7	 variants	 were	 predicted	 to	 be	 synergistic	 with	 the	 LHON	 m.14484T>C	
mutation:	m.4824A>G	in	MT-ND2,	m.6261G>A	and	m.7080T>C	in	MT-CO1,	m.8557G>C	in	MT-
ATP8,	m.8812A>G	(found	in	2	families),	m.8953A>G	and	m.9055G>A	in	MT-ATP6.	
	
Phylogenetic	analysis	
To	investigate	any	possible	founder	event,	we	reconstructed	the	phylogenetic	tree	starting	
from	control	population	analysis	in	www.phylotree.org	database	(van	Oven	and	Kayser,	2009).	
We	 show	 the	 branches	 of	 haplogruops	 J	 and	 T,	 because	 these	 two	 were	 the	 only	 with	
recurrent	haplotypes	(Figures	14).	
A	possibly	ancient	founder	event	is	recognized	on	J1b1a1,	which	spread	in	central	Europe	with	
3	 families	 in	 Italy,	 2	 in	 France	 and	 6	 in	 Germany.	 Other	 founder	 events	 still	 occurring	 on	
haplogroup	 J	 are	noticed	on	 J1c1d,	 J1c2j,	 J1c3e2,	 J1c3f,	 J1c4	and	 J2b1	 clades,	 but	 also	on	
haplogroup	T,	in	particular	on	T1a2,	T2	and	T2c1d1	clades	(Figure	14).	
J	 	C295T	T489C	A10398G!	A12612G	G13708A	C16069T		 LHON	
	 J1	 	C462T	G3010A		 Family	
	 		 J1b	 	G8269A	G16145A	(C16222T)	C16261T		 		
	 		 		 J1b1	 	G5460A	T13879C		 		
	 		 	 		 J1b1a	 	C242T	T2158C	G8557A	G12007A		 		
	 		 	 	 		 J1b1a1	 	T16172C		 		
	 		 	 	 	 		 T789C	G10427A	 Italy	
	 		 	 	 	 		 		 T13743C	 Italy	
	 		 	 	 	 		 	 		 T146C	G657A	 Italy	
	 		 	 	 	 		 T146C	 France	
	 		 	 	 	 		 	 G13135A	 France	
	 		 	 	 	 	 		 T16311C	 Germany	
	 		 	 	 	 	 A7543G	G14861A	T16093C	 Germany	
	 		 	 	 	 	 J1b1a1b	 	T15067C	 	
	 		 	 	 	 		 		 T3535A	T15262C	G15930A	C16256T	C16260T	 Germany	
	 		 	 	 	 	 J1b1a1d	 	G185A	T6345C	A7299G		 Germany	
	 		 	 	 	 	 		 G1462A	G4659A	 Germany	
	 		 	 	 	 	 		 G8587C	h	 Germany	
	 		 J1c	 	(G185A)	(G228A)	T14798C		 	 	
	 		 		 T1284C	C4017T	T5788C	A9425G	G13135A	T15394C	C16114T	A16215G	A16265T	 Turkey	
	 		 	 J1c1	 	T482C	T3394C	 	
	 		 	 		 J1c1d	 	G16213A	 Germany	
	 		 	 		 	 T8383C	G9053A	T10031C	 Germany	
	 		 	 		 	 	 A183G	 Germany	
	 		 	 J1c2	 	A188G		 	 	
	 		 	 		 		 C3375T	 Germany	
	 		 	 		 J1c2b	 	T4454C		 Germany	
	 		 	 		 J1c2c	 	(T146C!)	G10685A	T13281C	A13933G		 UK	
	 		 	 		 J1c2e	 	C16366T		 	 	
	 		 	 		 	 C194T	 Serbia	
	 		 	 		 J1c2j	 	C8727T	T16362C	G16390A	 		
	 		 	 		 	 G14279A	 Italy	
	 		 	 		 	 	 T4184A	 Italy	
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	 		 	 J1c3	 	C13934T		 	
	 		 		 		 	 C182T	T3372C	 Italy	
	 		 		 		 J1c3a	 	G9548A		 	 Italy	
	 		 		 		 J1c3b	 	C15367T		 	 	
	 		 		 		 		 T10609C	T10915C	 UK	
	 		 		 		 		 J1c3b1	 	G5237A	 	
	 		 		 		 	 		 J1c3b1a	 	G6261A		 	
	 		 		 		 	 	 	 G8989A	 UK	
	 		 		 		 J1c3e	 	G16390A		 	 	
	 		 		 		 		 J1c3e2	 	G8865A	 	
	 		 		 		 	 		 G5147A	A6712T	T9957C	T16325C	 France	
	 		 		 		 	 		 C16291T	 Italy	
	 		 		 		 J1c3f	 	T12477C	T16063C	 	
	 		 		 		 		 G709A	C10845T	 	
	 		 		 		 	 		 T16093C	 US	
	 		 		 		 	 		 A2181G	A8458G	 US	
	 		 		 		 J1c3g	 	G9755A	 	
	 		 		 		 		 A188G	T195C	G14364A	T16243C	 Italy	
	 		 		 		 J1c3j	 	A12358G	T16311C!	 Germany	
	 		 		 J1c4	 	A9632G	T12083g	 	
	 		 		 		 T11260C	 Germany	
	 		 		 		 A7271G	T13641C	 Germany	
	 		 		 		 T16189C	 UK	
	 		 		 J1c5	 	A5198G	 	
	 		 		 		 T489C	T4209C	A12819G	C16174T	 France	
	 		 		 J1c6	 	C4025T	 	
	 		 		 		 C182T	 Germany	
	 		 		 J1c9	 	C6887T	 	
	 		 		 		 C189G	T254C	C6602T	T10786C	A12361G	A16343G	 Germany	
	 		 		 J1c10	 	C5024T	 	
	 		 	 		 T195C	C198T	A3358G	T4561C	G12501A	A12648G	C13621T	 Italy	
	 		 J1d	 	T152C!	G7789A	A7963G	 	
	 	 		 J1d1	 	A16300G	 	
	 	 	 		 J1d1a	 	G1007A	A16309G	 	
	 	 	 	 		 J1d1a1	 	T13392C	 	
	 	 	 	 	 		 A8812G	C15430T	T16093C	A16203G	 Italy	
	
T	 	G709A	G1888A	A4917G	G8697A	T10463C	G13368A	G14905A	A15607G	G15928A	C16294T		 		
		 T1	 	C12633a	A16163G	T16189C!		 		
		 		 T1a	 	C16186T		 		
		 	 		 	T152C!		 		
		 	 	 		 T1a1'3	 	T195C!		 		
		 	 	 		 		 T1a1	 	T9899C		 		
		 	 	 		 	 		 T1a1b	 	G10143A	C14281T		 Germany	
		 	 	 		 T1a2	 	G7853A		 		
		 	 	 	 		 A633G	G8994A	A9377G	A10398G	A10876G	A11239G	 Italy	
		 	 	 	 	 		 T204C	 Italy	
		 	 	 	 	 	 		 C8640T	 Italy	
		 	 	 	 	 	 		 T152C	T8516C	C16185T	 Italy	
		 T2	 	A11812G	A14233G	(C16296T)		 		
	 		 A490G	A5378G	T7440G	T12681C	A12819G	G13194A	 Italy	
	 		 		 G3460A	 Italy	
	 		 		 G10680A	 Italy	
	 		 T2b	 	G930A	G5147A	T16304C		 		
	 		 		 A3828G	 Germany	
	 		 		 		 G185A	T16178C	 Germany	
	 		 		 T2b3	 	A10750G		 		
	 		 		 		 T2b3b	 	A13722G		 France	
	 		 		 T2b25	 	G7521A!	C8934T		 		
	 		 	 		 A9067G	T10237C	T16311C	 Germany	
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	 		 T2c	 	C10822T		 		
	 	 		 T2c1	 	G6261A	C16292T		 		
	 	 		 		 	T146C!		 		
	 	 		 	 		 T2c1d	 	T279C	C5187T	C7873T		 		
	 	 		 	 	 		 T2c1d1	 	G11914A!		 		
	 	 		 	 	 	 		 T152C	A374G	A5565T	C6644T	G13708A	 		
	 	 		 	 	 	 	 		 C182T	 France	
	 	 		 	 	 	 	 		 T16092C	 France	
	 	 		 	 	 	 	 		 T3645C	 Italy	
	 	 		 T2f	 	C8270T	8281-8289d		 		
	 	 	 		 T2f1	 	T195C!	C6489a		 		
	 	 	 	 		 T2f1a	 	T5277C	T5426C	G15043A	T16298C		 		
	 	 	 	 	 		 8970ins9	 Italy	
	
Figure	14.	Phylogenetic	reconstruction	tree	of	LHON	probands	carrying	m.14484T>C/MT-ND6	
on	haplogroups	J	and	T,	based	on	www.phylotree.org		
	
Penetrance	evaluation	on	available	pedigree	
To	 assess	 the	 role	 of	 haplogruop	 J	 on	 incomplete	 penetrance	 and	 male	 prevalence,	 we	
evaluated	the	number	of	affected	versus	unaffected	carriers	on	the	available	reconstruction	
of	the	pedigrees	(14	maternal	lines	on	haplogruop	J,	22	non-J).	The	results	are	summarized	in	
tables	7	and	8.	
	
	 Males	Affected	 Unaffected	
J	 27	(29.0)	 66	(71.0)	
non-J	 42	(24.4)	 130	(75.6)	
All	 69	(26.0)	 196	(74.0)	
	 Females	
	 Affected	 Unaffected	
J	 10	(7.5)	 123	(92.5)	
non-J	 10	(5.7)	 166	(94.3)	
All	 20	(6.4)	 289	(93.6)	
	 Total	
	 Affected	 Unaffected	
J	 37	(16.4)	 189	(83.6)	
non-J	 52	(14.9)	 296	(85.1)	
All	 89	(15.5)	 485	(84.5)	
	
Table	 7.	 Frequency	 of	 affected	 and	 unaffected	 individuals	 within	 haplogroup	 J	 and	 non-J	
maternal	lines,	considering	gender	as	variable.	The	data	are	expressed	as	n	(%).	
	
	
	
	
Results	
	
	
	
43	
RATIO	 Affected	
Male:Female	
Affected:Unaffect
ed	
Male	A:U	 Female	A:U	
J	 2,7	 0,2	 0,4	 0,1	
non-J	 4,2	 0,2	 0,3	 0,1	
All	 3,5	 0,2	 0,4	 0,1	
	
Table	8.	Ratio	of	affected	and	unaffected	individuals	within	haplogroup	J	and	non-J	maternal	
lines,	considering	gender	as	variable.	
	
This	analysis	failed	to	highlight	any	significant	difference.	However,	despite	the	lack	af	a	
strong	evident	effect,	it	remains	a	tendency	towards	higher	penetrance	of	the	m.14484T>C	
mutation	on	the	haplogroup	J	background,	which	applies	to	both	genders	(Tables	7,	8).	 	
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PART	III	-	Mitochondrial	DNA	variability	in	Dominant	Optic	Atrophy	(DOA)	with	mutation	in	
OPA1	gene	
	
Mitochondrial	genome	sequencing	and	haplogroup	affiliation	
We	completely	sequenced	the	mtDNA	in	112	maternally	unrelated	patients	from	85	families	
carrying	a	dominant	OPA1	mutation.	The	haplogroup	affiliations	and	private	variants	are	
summarized	in	Table	9.	
Family	 Relationship	 Haplogroup	 Private	synonimous	 Private	non	coding	 Provate	tRNA/rRNA	 Private	missense	
1	 Proband	 H1	 	 	 	 6253	T>C/MT-CO1	
2	 Proband	 U2e1		 14470	T>C	 228	G>A	 	 	
3	 Proband	 J1d3a	 11061	C>G		 	 	 14551	A>G/MT-ND6	
4	 Proband	 H26	 5096	T>C	 	 	 	
4	 Maternal	granfather	 R1a1	 7055	A>G		12906	C>T	 	 	 	
5	 Proband	 U2e2a1	 	 16183	A>C	16182	A>C	 	
6249	G>A/MT-CO1	
14790	A>G/MT-CYB	
5	 Father	 H5qa	 	 152	T>C	 	 	
6	 Proband	 H	 7630	T>C	11113	T>C	 	 12172	A>G/MT-TH	 	
7	 Proband	 H1j	 	 	 	 	
8	 Proband	 H70	 	 16192	C>T	16209	T>C	 	 	
8	 Father	 T2c1d1	 13056	C>T	14544	G>A	 	 12215	T>C/MT-TS2	 	
9	 Proband	 U1a3	
6023	G>A	
13470	A>G	
9449	C>T	
	 	 	
10	 Proband	 J1c3	 12477	T>C	12696	T>C	 	 	 	
10	 Father	 H10d		 	 15884	G>A	 729	T>C/MT-RNR1	 10398	A>G/MT-ND3	
11	 Proband	 V	 7804	A>G	 	 3290	T>C/MT-TL1	 	
12	 Proband	 N1b1a	 14097	C>T	14323	G>A	 	 	 	
13	 Proband	 H4a1	 8730	A>G	 	 	 4129	A>G/MT-ND1	7853	G>A/MT-CO2	
14	 Proband	 H3b	 	 	 	 	
15	 Proband	 L3b	 10283	A>G	 	 	 12674	A>G/MT-ND5	
16	 Proband	 T1a1l	 14311	T>C	 	 	 	
16	 Father	 K1b1c	 3918	G>A	13470	A>G	 	 1736	A>G/MT-RNR2	 	
18	 Proband	 J1c3	 	 	 	 	
18	 Father	 H10	 7702	G>A	 	 	 8896	G>C/MT-ATP6	14798	T>C/MT-CYB	
19	 Proband	 J1c8	 3657	C>A	14653	C>T	 	 	 13768	T>C/MT-ND5	
20	 Proband	 T2h	 	 	 	 	
21	 Proband	 U2e2a1b	
7235	C>A	
7418	C>T	
7427	C>T	
14788	T>C	
	 	 14180	T>C/MT-ND6	
22	 Proband	 H1c2	 	 	 	 	
23	 Proband	 H	 13641	T>C	 	 2648	T>C/MT-RNR2	 	
23	 Father	 H1u	 	 	 1809	T>C/MT-RNR2	 	
24	 Proband	 H20	 9410	A>G	13656	T>C	
16189	T>C	
16192	C>T	 	 	
25	 Proband	 J1c	 5147	G>A	14296	A>G	 16390	G>A	 	 13145	G>A/MT-ND5	
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26	 Proband	 H65	 	 	 	 4491	G>A/MT-ND2	
27	 Proband	 J2b1a2	 11686	C>T	 	 5774	T>C/MT-TC	 	
28	 Proband	 X2m	 6023	G>A		11944	T>C	 	 15910	C>T/MT-TT	 8866	A>G/MT-ATP6	
28	 Father	 H1q	 5201	T>C	 	 	 	
29	 Proband	 H	
6305	G>A	
7945	C>T	
11203	C>T	
	 	 	
30	 Proband	 H5a	 3744	A>G	 456	C>T	 	 4659	G>A/MT-ND2	
31	 Proband	 H2b	 4092	G>A	 	 4386	T>C/MT-TQ	 12557	C>T/MT-ND5	
32	 Proband	 T2b4	 8146	A>G	 	 	 	
33	 Proband	 HV0e	
9944	T>C	
14260	A>G	
14389	C>T	
	 	 	
33	 Father	 J1b1a	 5201	T>C	 	 	 	
34	 Proband	 K1b1a	
4763	C>T	
6290	C>T	
15877	C>T	
	 	 8084	A>G/MT-CO2	
34	 Father	 H1e	 8251	G>A	 16148	C>T	 15936	A>G/MT-TT	 3316	G>A/MT-ND1	8833	G>A/MT-ATP6	
35	 Proband	 J1b1a3	
3714	A>G	
9156	A>G	
5471	G>A	
188	A>G	
16326	A>G	 	 10188	A>G/MT-ND3	
35	 Father	 U3b		
5417	G>A	
9770	T>C	
12744	C>T	
185	G>A	
16162	A>T	 2707	A>G/MT-RNR2	 	
37	 Proband	 HV0b	 	 16564	A>G	 	 8480	C>T/MT-ATP8	15119	G>A/MT-CYB	
37	 Nephew	 H1	 9932	G>A	11149	G>A	 	 	 	
37	 Nephew	 H	 10232	A>G	16319	T>A	 16319	G>A	 	 	
38	 Proband	 H10a1	 	 	 	 	
38	 Daughter	 K1b1c	
10094	C>T	
11152	T>C	
11719	G>A	
	 	 14258	G>A/MT-ND6	
39	 Proband	 T2b	 11929	T>C	 	 	 	
40	 Proband	 T2a1	 12957	T>C	15265	C>T	 	 	 	
40	 Cousin's	son	 H	 4204	T>C	 	 	 	
40	 Cousin's	son	 H	
3666	G>A	
6293	T>C	
15103	C>T	
	 	 7407	T>C/MT-CO1	
41	 Proband	 U1b2	 6725	C>A	 16042	G>A	 	 	
42	 Proband	 H6a1a	 	 	 5558	A>G/MT-TW	 	
43	 Proband	 N1a3a2	 6743	T>C	 16564	A>G	16565	C>T	 	 	
44	 Proband	 H10a1		 	 16564	A>G	16565	C>T	 2066	C>T/MT-RNR2	 14198	G>A/MT-ND6	
45	 Proband	 H6a1a	 8227	T>C	 	 	 	
46	 Proband	 W1h1	 12927	C>T	 143	G>A	 14727	T>C/MT-TE	 	
47	 Proband	 U5b2a1a1		 14582	A>G	 	 	 	
48	 Proband	 H7	 7340	G>A	 	 	 	
49	 Proband	 H63	 5951	A>G	7094	T>C	 	 	 8701	A>G/MT-ATP6	
51	 Proband	 K1b1c	 	 	 	 	
51	 Son	 H73	 	 	 	 	
52	 Proband	 H1	
6620	T>C	
11929	T>C	
14470	T>C	
	 	 	
53	 Proband	 H13a1a2b	 7397	C>T	 200	A>G	 	 4491	G>A/MT-ND2	8701	A>G/MT-ATP6	
54	 Proband	 U5a2	 	 	 	 	
55	 Proband	 U4c1	 	 	 827	A>G/MT-RNR1	2282	C>T/MT-RNR2	 13327	A>G/MT-ND5	
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56	 Proband	 T1a1	 9275	A>C	 	 	 8896	G>A/MT-ATP6	13879	T>C/MT-ND5	
57	 Proband	 H1a	 4736	T>C	9374	A>G	 	 	 	
58	 Proband	 H	 15682	A>G	 	 	 3511	A>G/MT-ND1	13889	G>A/MT-ND5	
59	 Proband	 K1a	 15466	G>A	 	 15924	A>G/MT-TT	 4917	A>G/MT-ND2	5194	C>T/MT-ND2	
59	 Father	 H	
5426	T>C	
8026	A>G	
14215	T>C	
	 961	T>C/MT-RNR1	 7309	T>C/MT-CO1	7754	G>A/MT-CO2	
60	 Proband	 H7		 	 	 	 	
60	 Father	 U5b3		 4065	A>G	 	 	 3943	A>G/MT-ND1	
61	 Proband	 L3f1b	
5262	G>A	
10373	G>A	
11383	T>C	
15670	T>C	
	 A4343	A>G/MT-TQ	15940	delT/MT-TT	 9957	T>C/MT-CO3	
62	 Proband	 H5b	 7861	T>C	14007	A>G	 	 801	A>G/MT-RNR1	 	
62	 Paternal	grandfather	 H6a1b2	 	 	 	 11150	G>A/MT-ND4	
62	 Father	 H5a	 10172	G>A	 	 	 	
63	 Proband	 T2b	 11929	T>C	 	 2903	T>C/MT-RNR2	12172	A>G/MT-TT	 10398	A>G/MT-ND3	
64	 Proband	 U4b1a	 4703	T>C	12609	T>C	 	 	 13708	G>A/MT-ND5	
64	 Father	 T1a1		 14758	A>G	 	 	 	
65	 Proband	 J1b1a2b		 9968	C>T	 	 	 7407	T>C/MT-CO1	
66	 Proband	 V4	 3849	G>A	 	 1657	C>T/MT-TV	 	
66	 Father	 J2b1	 6959	C>T	10370	T>C	 	
1824	T>C/MT-RNR2	
15894	G>A/MT-TT	
4824	A>G/MT-ND2	
8953	A>G/MT-ATP6	
67	 Proband	 J2a2b2	 	
195	T>C	
16224	T>C	
16276	T>C	
16564	A>G	
16565	C>T	
	 	
68	 Proband	 H1ap	 13194	G>A	 	 2876	G>A/MT-RNR2	 	
69	 Proband	 H13a1a2b	 6959	C>T	 5580	T>C	 	 	
69	 Father	 H	 	 5581	A>T	 	 	
70	 Proband	 I3a1	 13395	A>G	 	 	 	
71	 Proband	 H10aq	 7894	A>G	11314	A>G	
16564	A>G	
16565	A>T	 	 	
72	 Proband	 HV4		 8763	T>C	14515	T>C	
93	A>G	
152	T>C	 	 7805	G>A/MT-CO2	
72	 Father	 U3b		
5264	C>T	
9305	G>A	
14581	T>C	
	
2272	C>T/MT-RNR2	
15940	delT/MT-TT	
15977	C>T/MT-TP	
	
73	 Proband	 T2		 6488	T>C	11944	T>C	 152	T>C	 	
9804	G>A/MT-CO3	
10750	A>G/MT-
ND4L	
74	 Proband	 U5a2d	 6260	G>A	10984	C>T	 16311	T>C	 	
8887	A>G/MT-ATP6	
12663	C>A/MT-ND5	
74	 Father	 H43	 11149	G>A	 	 	 15773	G>A/MT-CYB	
74	 Cousin	 H17a	 7961	T>C	11455	C>T	
16564	A>G	
16565	C>T	 	 	
75	 Proband	 H5a1a	
4086	C>T	
11887	G>A	
13194	G>A	
195	T>C	
513	delCA	 	 14279	G>A/MT-ND6	
76	 Proband	 J2b1a5	 3591	G>A	 	 	 7051	T>C/MT-CO1	
77	 Proband	 H18b	 4736	T>C	 16561	A>T	 	 8519	G>A/MT-ATP8	
78	 Proband	 U5a1a1	 4598	T>C	 	 	 8516	T>C/MT-ATP8	8705	T>C/MT-ATP6	
79	 Proband	 K1b1a	
3714	A>G	
5471	G>A	
14560	G>A	
15877	C>T	
	 	 	
80	 Proband	 T2b	 	 	 	 	
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81	 Proband	 HV4a2	 8763	T>C	14515	T>C	 	 	 	
82	 Proband	 J2a2c		 	 	 15924	A>G/MT-TT	 3508	A>G/MT-ND1	
83	 Proband	 H	 5264	C>T	 	 	 	
83	 Father	 HV1b	 	 	 	 	
84	 Proband	 H	
4823	T>C	
8865	G>A	
11539	C>T	
	 2789	C>T/MT-RNR2	 	
85	 Proband	 H	 13431	C>T	 	 	 	
85	 Father	 R0a1a	 	 	 	 	
85	 Cousin	 T2b	
4823	T>C	
6935	C>T	
13581	T>C	
	 	 14562	C>T/MT-ND6	
	
Table	9.	Mitochondrial	 genome	of	DOA	patients	 carrying	OPA1	mutation	with	haplogroup	
affiliation	(according	to	www.phylotree.org	-	build	17)	and	private	changes.	Missense	variant	
in	coloured	according	scoring	criteria	described	in	the	“materials	and	methods”	as	in	table	10.	
	
In	the	OPA1	mutation	cohort,	as	expected	for	a	dominant	disease,	the	frequency	of	
mitochondrial	haplogroups	was	not	statistically	different	as	compared	to	the	Italian	
population	(χ2test,	p	=5741)	(Figure	15).	
	
Figure	 15.	 Frequency	 of	 European	 haplogroups	 in	 DOA	 cohort	 with	 OPA1	mutations	 and	
control	population	(n	=2495).	**p<0.001,	*p<0.05.	
	
Private	missense	variants	as	phenotype	modifiers	
We	analysed	all	missense	changes,	which	were	not	diagnostic	for	the	haplogroups,	to	detect	
other	 private	 variants,	 with	 some	 possible	modifying	 or	 pathogenic	 significance.	 For	 each	
variant,	 the	 amino	 acid	 residue	 conservation	 and	 the	 in-silico	 prediction	 values	 of	
pathogenicity	 were	 considered	 (Table	 10).	 To	 this	 end,	 the	 on-line	 tools	 PolyPhen2,	 SIFT,	
PANTHER	and	PhD-SNP	have	been	used	and	conservation	analysis	was	carried	out,	as	detailed	
in	the	methods.	According	to	the	scoring	criteria	described	in	the	“materials	and	methods”,	
changes	with	a	score	of	0,66-1	points	were	considered	pathogenic	(red),	with	0,5-0,65	points	
were	considered	synergistic	(orange)	and	with	0-0,49	points	neutral	(black).	
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nt	change	 Gene	 aa	change	
Prediction	tools	 Conservation	 Invariants	
PolyPhen2	 SIFT	 PANTHER	 PhD-SNP	 Mammals	 Local	 Global	 -	 +	
m.3316	G>A	 MT-ND1	 p.A4T	 benign	 neutral	 NA	 neutral	 67	 57	 78	 3	 12	
m.3508	A>G	 MT-ND1	 p.I68V	 benign	 neutral	 neutral	 neutral	 27	 67	 78	 5	 7	
m.3511	A>G	 MT-ND1	 p.T69A	 benign	 neutral	 neutral	 neutral	 37	 67	 78	 6	 6	
m.3943	A>G	 MT-ND1	 p.I213V	 benign	 neutral	 neutral	 neutral	 86	 100	 78	 2	 2	
m.4129	A>G	 MT-ND1	 p.T275A	 benign	 neutral	 neutral	 neutral	 89	 81	 78	 1	 3	
m.4491	G>A	 MT-ND2	 p.V8I	 benign	 neutral	 neutral	 neutral	 54	 39	 62	 5	 8	
m.4659	G>A	 MT-ND2	 p.A64T	 benign	 neutral	 disease	 disease	 93	 76	 62	 1	 2	
m.4824	A>G	 MT-ND2	 p.T119A	 benign	 neutral	 disease	 neutral	 94	 81	 62	 1	 1	
m.4917	A>G	 MT-ND2	 p.N150D	 benign	 neutral	 disease	 disease	 93	 43	 62	 15	 11	
m.5194	C>T	 MT-ND2	 p.P242L	 benign	 neutral	 disease	 neutral	 38	 48	 62	 7	 8	
m.6249	G>A	 MT-CO1	 p.A116T	 benign	 neutral	 neutral	 neutral	 83	 100	 95	 1	 3	
m.6253	T>C	 MT-CO1	 p.M117T	 benign	 neutral	 neutral	 neutral	 85	 100	 95	 2	 2	
m.7051	T>C	 MT-CO1	 p.M383T	 probably_damaging	 deleterious	 neutral	 disease	 100	 100	 95	 1	 1	
m.7309	T>C	 MT-CO1	 p.I469T	 benign	 deleterious	 neutral	 disease	 100	 100	 95	 1	 1	
m.7407	T>C	 MT-CO1	 p.Y502H	 benign	 neutral	 neutral	 neutral	 71	 76	 95	 2	 1	
m.7754	G>A	 MT-CO2	 p.D57N	 benign	 neutral	 NA	 disease	 94	 95	 89	 4	 2	
m.7805	G>A	 MT-CO2	 p.V74I	 benign	 neutral	 NA	 neutral	 85	 90	 89	 2	 2	
m.7853	G>A	 MT-CO2	 p.V90I	 benign	 neutral	 neutral	 neutral	 91	 95	 89	 1	 3	
m.8084	A>G	 MT-CO2	 p.T167A	 benign	 neutral	 neutral	 neutral	 91	 100	 89	 1	 2	
m.8480	C>T	 MT-ATP8	 p.P39S	 probably_damaging	 neutral	 neutral	 neutral	 40	 5	 46	 31	 11	
m.8516	T>C	 MT-ATP8	 p.W51R	 probably_damaging	 neutral	 disease	 disease	 100	 48	 46	 42	 4	
m.8519	G>A	 MT-ATP8	 p.E52K	 probably_damaging	 neutral	 disease	 disease	 80	 48	 46	 1	 3	
m.8701	A>G	 MT-ATP6	 p.T59A	 benign	 neutral	 NA	 neutral	 37	 57	 77	 3	 2	
m.8705	T>C	 MT-ATP6	 p.M60T	 benign	 neutral	 NA	 neutral	 61	 57	 77	 4	 1	
m.8833	G>A	 MT-ATP6	 p.A103T	 probably_damaging	 neutral	 disease	 neutral	 68	 90	 77	 5	 1	
m.8866	A>G	 MT-ATP6	 p.I114V	 benign	 neutral	 disease	 neutral	 54	 76	 77	 5	 2	
m.8887	A>G	 MT-ATP6	 p.I121V	 benign	 neutral	 neutral	 neutral	 71	 76	 77	 1	 1	
m.8896	G>A	 MT-ATP6	 p.A124T	 benign	 neutral	 disease	 disease	 78	 81	 77	 2	 1	
m.8896	G>C	 MT-ATP6	 p.A124P	 benign	 neutral	 disease	 disease	 78	 81	 77	 2	 1	
m.8953	A>G	 MT-ATP6	 p.I143V	 probably_damaging	 neutral	 neutral	 neutral	 85	 86	 77	 3	 1	
m.9804	G>A	 MT-CO3	 p.A200T	 benign	 neutral	 neutral	 disease	 93	 95	 92	 2	 1	
m.9957	T>C	 MT-CO3	 p.F251L	 benign	 neutral	 neutral	 disease	 100	 100	 92	 1	 1	
m.10188	A>G	 MT-ND3	 p.M44V	 benign	 neutral	 neutral	 neutral	 81	 86	 69	 2	 3	
m.10398	A>G	 MT-ND3	 p.T114A	 benign	 neutral	 neutral	 neutral	 81	 92	 69	 1	 -	
m.10750	A>G	 MT-ND4L	 p.N94S	 benign	 neutral	 neutral	 disease	 98	 93	 69	 1	 1	
m.11150	G>A	 MT-ND4	 p.A131T	 benign	 deleterious	 NA	 neutral	 82	 95	 77	 2	 2	
m.12557	C>T	 MT-ND5	 p.T74I	 benign	 neutral	 NA	 neutral	 59	 67	 68	 6	 6	
m.12663	C>A	 MT-ND5	 p.N109K	 benign	 neutral	 neutral	 neutral	 72	 86	 68	 1	 2	
m.12674	A>G	 MT-ND5	 p.N113S	 possibly_damaging	 neutral	 disease	 disease	 36	 81	 68	 1	 4	
m.13145	G>A	 MT-ND5	 p.S270N	 benign	 neutral	 neutral	 neutral	 92	 71	 68	 7	 9	
m.13327	A>G	 MT-ND5	 p.T331A	 probably_damaging	 neutral	 disease	 disease	 95	 90	 68	 1	 1	
m.13708	G>A	 MT-ND5	 p.A458T	 benign	 neutral	 disease	 disease	 44	 67	 68	 1	 7	
m.13768	T>C	 MT-ND5	 p.F478L	 benign	 neutral	 disease	 neutral	 77	 48	 68	 4	 3	
m.13879	T>C	 MT-ND5	 p.S515P	 benign	 neutral	 neutral	 neutral	 23	 29	 68	 18	 7	
m.13889	G>A	 MT-ND5	 p.C518Y	 benign	 neutral	 disease	 neutral	 38	 38	 68	 21	 4	
m.14180	T>C	 MT-ND6	 p.Y165C	 probably_damaging	 neutral	 neutral	 disease	 26	 45	 52	 5	 4	
m.14198	G>A	 MT-ND6	 p.T159M	 probably_damaging	 neutral	 neutral	 neutral	 63	 38	 52	 1	 1	
m.14258	G>A	 MT-ND6	 p.P139L	 benign	 neutral	 neutral	 neutral	 37	 38	 52	 57	 2	
m.14279	G>A	 MT-ND6	 p.S132L	 benign	 neutral	 neutral	 neutral	 60	 24	 52	 50	 9	
m.14562	C>T	 MT-ND6	 p.V38I	 benign	 neutral	 neutral	 neutral	 72	 67	 52	 2	 1	
m.14790	A>G	 MT-CYB	 p.N15S	 benign	 neutral	 disease	 disease	 99	 76	 82	 3	 5	
m.14798	T>C	 MT-CYB	 p.F18L	 benign	 neutral	 neutral	 neutral	 89	 81	 82	 6	 2	
m.15119	G>A	 MT-CYB	 p.A125T	 benign	 neutral	 disease	 disease	 99	 86	 82	 1	 1	
m.15773	G>A	 MT-CYB	 p.V343M	 probably_damaging	 neutral	 disease	 disease	 99	 76	 82	 4	 3	
	
Table	 10.	 Prediction	 tools	 and	 conservation	 analysis	 of	 missense	 private	 variants	 in	DOA	
patients	carrying	OPA1	mutation	
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In	order	to	understand	the	influence	of	mitochondrial	genome	on	the	phenotype	severity	in	
patients	with	OPA1	gene	mutation,	we	have	analyzed	the	thickness	of	retinal	nerve	fiber	layer	
(RNFL),	measured	by	OCT	(Optical	Coherent	Tomography),	as	marker	of	clinical	outcome.	
As	 a	 first	 step,	 we	 assessed	 the	 possible	 influence	 of	 private	 and	 putative	 pathogenic	
mutations	(Table	10)	disregarding	the	haplogroup	affiliation	on	the	RNFL	thickness	in	OPA1	
patients	 carrying	or	not	 carrying	 such	 variants.	We	 failed	 to	detect	 any	differences	 in	 this	
comparison,	 considering	 the	 average	 RNFL	 thickness	 or	 sector	 by	 sector,	 i.e.	 temporal,	
superior,	nasal,	inferior	(Figures	15,	16).	
	
Figure	 15.	 Scatter	 plot	with	mean±SD	 of	 average	 RNFL	 thickness	 in	 DOA	 patients	with	 or	
without	putative	pathogenic	mutations	and	synergistic	variants	in	mtDNA.	
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Figure	16.	Scatter	plot	with	mean±SD	of	RNFL	thickness,	split	 in	four	quadrants	(Temporal,	
superior,	nasal,	inferior),	in	DOA	patients	with	or	without	putative	pathogenic	mutations	and	
synergistic	variants	in	mtDNA	
	
Mitochondrial	haplogroups	as	phenotype	modifier	
Next,	 we	 investigated	 the	 variability	 of	 the	 RNFL	 thickness	 according	 to	 the	 different	
haplogroup	affiliation	of	OPA1	patients,	thus	assessing	the	role	of	ancient	mtDNA	variation,	
selected	 and	 fixed	 during	 evolution	 as	 adaptive	 response	 to	 environmental	 pressure.	 The	
results	are	shown	in	Figures	17	and	18.	
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Figure	17.	Scatter	plot	with	mean±SD	of	average	RNFL	thickness	in	DOA	patients	with	different	
mtDNA	haplogroups.	
	
	
Figure	18.	Scatter	plot	with	mean±SD	of	RNFL	thickness,	split	 in	four	quadrants	(Temporal,	
superior,	nasal,	inferior),	in	DOA	patients	with	different	mtDNA	haplogroups.	*p<0.01	
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The	only	statistically	significant	difference	emerges	for	the	temporal	RNFL	thickness	(ANOVA,	
p=0.0270),	 thus	 revealing	 a	 putative	 protective	 role	 for	 haplogroup	 U	 and	 damaging	 for	
haplogroup	H	(Uncorrected	Fisher’s	LSD,	p=0.0053)	(Figure	18).	
Finally,	 we	 investigated	 the	 interaction	 between	 the	mitochondrial	 and	 nuclear	 genomes,	
assuming	that	there	could	be	a	coadaptation	between	the	two	genomes	and	changes	may	
influence	the	clinical	outcome.	To	analyze	this	interaction,	we	evaluated	the	severity	of	the	
disease	as	a	function	of	OPA1	mutation	co-segregating	or	not	with	the	mtDNA	genome.	 In	
short,	given	the	different	inheritance	of	the	two	traits,	an	individual	always	inherits	mtDNA	
from	the	mother,	while	the	OPA1	mutation	can	be	inherited	from	each	of	the	two	parents.	
Based	 on	 this	 last	 criterion,	 we	 identified	 35	 parent-child	 segregations.	 These	 were	 then	
divided	into	two	groups:	
-	19	OPA1	segregations	"without”	mtDNA	change	(mother-children	segregation);	
-	15	OPA1	segregations	"with”	mtDNA	change	(father-children	segregation).	
We	have	thus	analyzed	the	difference	in	RNFL	thickness	between	the	two	generations	of	each	
segregation	 group	 to	 evaluate	 the	 severity	 of	 the	 clinical	 outcome.	 Interestingly,	 in	 the	
mother-children	segregation	group	there	was	a	significantly	 increased	severity	of	fiber	 loss	
(lower	RNFL	thickness)	 in	children	for	the	average	and	 inferior	quadrant	RNFL	comparison,	
with	a	similar	tendency	for	all	other	quadrants	(paired	t-test,	p=0.0186,	0.0071,	respectively)	
(Figure	19).	Noticeably,	the	infero-temporal	fibers	belong	to	the	papillomacular	bundle,	which	
is	 the	 main	 target	 of	 the	 neurodegenerative	 process.	 Concerning	 the	 father-children	
segregation	 group,	 the	 only	 significant	 difference	 was	 found	 for	 the	 temporal	 quadrant	
(paired	t-test,	p=0.0172)	(Figure	19).	
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Figure	19.	Scatter	plot	with	mean±SD	of	differences	in	RNFL	thickness	from	mother-children	
segregations	and	father-children	segregations.	*p<0.05	
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DISCUSSION	
	
Peculiar	combinations	of	individually	non-pathogenic	missense	mitochondrial	DNA	variants	
cause	low	penetrance	Leber’s	hereditary	optic	neuropathy	
LHON	is	now	well	established	that	is	a	disease	determined	by	a	very	mild	complex	I-dependent	
respiratory	 chain	 dysfunction,	 somehow	 borderline	 between	 functional	 and	 pathological	
variability,	which	is	certainly	dependent	on	the	presence	of	a	major	predisposing	pathogenic	
mtDNA	 mutation	 (“primary”	 mutation),	 but	 also	 largely	 modulated	 by	 the	 mitogenome	
sequence	 variation	 (mtDNA	haplogroup	with	 “secondary”	 and	private	mutations)	 (Gómez-
Durán	et	al.,	 2010,	2012).	 Furthermore,	 the	 respiratory	defect	and	pathogenic	mechanism	
seem	also	highly	modulated	by	environmental	(Ghelli	et	al.,	2009)	and	nuclear	DNA	factors	
(Carelli	et	al.,	2003).	Thus,	to	date,	by	definition	in	a	LHON	family	it	has	always	been	recognized	
a	 clearly	 pathogenic	 “primary”	 mutation,	 possibly	 modulated	 by	 other	 private	 or	 mildly	
deleterious	variants,	which	were	usually	defined	as	“secondary”	mutations	 (Caporali	et	al.,	
2017).	
In	this	study,	for	the	first	time	we	provide	a	clear	evidence	that	in	the	cluster	of	Families	1a,	
1b	and	1c,	all	belonging	to	the	same	maternal	lineage	and	carrying	the	previously	unreported	
combination	 of	 m.14258G>A/MT-ND6	 and	 m.14582A>G/MT-ND6	 variants	 on	 a	 K1a	
haplogroup	background	(Table	3),	there	was	no	clearly	“primary”	pathogenic	mutation.	Thus,	
the	 only	 variants	 we	 could	 assign	 a	 possible	 pathogenic	 role	 were	 the	missense	 changes	
affecting	the	ND6	subunit	of	complex	I,	here	found	in	a	previously	unreported	combination,	
otherwise	individually	present	in	the	known	public	datasets,	but	on	different	mitogenomes	
(www.mitomap.org).	 On	 the	 clinical	 ground,	 it	 is	 worth	 noting	 that	 all	 affected	members	
(n=14)	 of	 this	 very	 large	 family	 are	males,	 indicating	 that	most	 likely	 the	 combination	 of	
missense	 variants	 on	 the	 K1	 mitogenome	 characterizing	 Families	 1a,	 1b	 and	 1c	 was	 not	
sufficient	 to	 cross	 the	 threshold	 for	 triggering	 LHON	 in	 females.	 Furthermore,	 general	
penetrance	of	these	14	affected	members	was	13%	over	the	total	number	of	individuals	on	
the	maternal	 line,	 and	25%	over	 the	 total	number	of	males.	 This	 latter	percentage	 is	well	
below	the	usual	quote	of	average	50%	penetrance	in	males	reported	in	literature	(Carelli	et	
al.,	2004;	Yu-Wai-Man	et	al.,	2011).	
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It	is	also	interesting	to	note	that	the	mitogenomes	of	both	Families	1	and	2	had	in	common	
the	m.14258G>A/MT-ND6	change,	a	mutation	previously	not	recognized	as	associated	with	
LHON.	 The	 other	 variant	m.10680G>A/MT-ND4L	 found	 in	 Family	 2	 has	 been	 either	 found	
alone	in	pedigrees	segregating	cases	of	LHON	on	the	maternal	line	(Zhang	et	al.,	2012;	Zou	et	
al.,	2010),	or	in	association	with	known	LHON	primary	mutations	(Yang	et	al.,	2009).	Moreover,	
the	mtDNA	 sequence	 variants	 of	 these	 previously	 reported	 cases	 of	 Chinese	 ancestry	 are	
found	in	combination	with	other	missense	changes	in	Complex	I	subunits	genes,	in	particular	
in	 the	ND1	subunit	 (m.3644T>C/MT-ND1;	m.3745G>A/MT-ND1;	m.3548T>C/MT-ND1)	or	 in	
the	ND6	subunit	(m.14484T>C/MT-ND6),	which	are	closely	assembled	with	ND4L	according	to	
the	 currently	 proposed	 Complex	 I	 crystal	 structure	 (Figure	 11,	 Table	 4)	 (Fiedorczuk	 et	 al.,	
2016).	Thus,	at	least	the	m.14258G>A/MT-ND6	(in	the	present	study)	and	m.10680G>A/MT-
ND4L	variants	have	been	recurrently	associated	with	LHON,	either	in	combination	with	other	
polymorphic	 variants	 or	 associated	with	 other	 primary	mutations.	However,	 both	 variants	
alone	are	also	reported	 in	the	normal	population,	remarking	their	non-pathogenicity	when	
isolated	(Tables	3,	4).	
To	validate	on	the	functional	ground	the	pathogenic	role	of	the	two	combinations	of	variants	
found	in	Families	1	and	2,	the	only	recognized	method	is	to	demonstrate	a	functional	defect	
of	mitochondrial	respiratory	chain	 in	the	cybrid	cell	model,	where	only	the	patient-derived	
mtDNA	is	transferred.	We	observed	that	ATP	synthesis	driven	by	Complex	I	substrates	and	
respiration	 as	 measured	 by	 OCR	 were	 significantly	 defective	 in	 cybrids	 harboring	 the	
mitogenomes	from	Families	1	and	2	compared	to	haplogroup-matched	controls.	Remarkably,	
similar	to	the	other	LHON	primary	mutations	with	the	exception	of	m.3460G>A/MT-ND1,	the	
Complex	 I	 specific	 activity	 was	 not	 reduced	 in	 cybrids	 carrying	 the	 two	 combinations	 of	
variants	(Carelli	et	al.,	1997,	1999).	Thus,	even	if	other	reports	proposed	that	combinations	of	
different	 variants	might	 exert	 the	 equivalent	 pathogenic	 role	 of	 the	 single	 primary	 LHON	
mutation	(Zhang	et	al.,	2012;	Zou	et	al.,	2010),	we	here	provide	for	the	first	time	experimental	
evidence	of	the	respiratory	chain	impairment	from	a	functional	point	of	view.	Interestingly,	
the	now	available	 crystal	 structure	of	 Complex	 I	 revealed	 that	 the	 large	majority	 of	 these	
variants,	either	those	found	in	the	Italian	Families	1	and	2,	as	well	as	those	reported	in	Chinese	
families	(Zhang	et	al.,	2012;	Zou	et	al.,	2010)	are	located	in	close	proximity	to	the	predicted	E-
channel	for	proton	translocation	(Figures	10,	11),	contributed	by	all	three	ND6,	ND4L	and	ND1	
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subunits.	 Genetic	 variation	 along	 this	 pathway	 may	 alter	 the	 efficiency	 of	 proton	
translocation,	ultimately	affecting	the	energy	conserving	function	of	Complex	I.		
These	results	substantially	change	the	general	criteria	used	to	date	for	the	diagnosis	of	LHON,	
and,	more	in	general,	for	the	assessment	of	pathogenicity	of	mtDNA	variants.	In	the	case	of	
the	three	branches	of	Family	1,	we	performed	complete	mtDNA	sequencing	because	there	
was	a	clear	evidence	of	maternal	recurrence	of	a	phenotype	undistinguishable	from	classic	
LHON	 despite	 the	 absence	 of	 the	 three	 common	 LHON	 mutations.	 However,	 also	 the	
sequencing	of	the	entire	mitogenome	in	our	entire	cohort	of	Italian	LHON	families	revealed	
the	 presence	 of	 multiple	 variants	 potentially	 relevant	 for	 LHON	 pathogenesis,	 beside	 the	
known	primary	LHON	mutations.	Therefore,	we	propose	complete	mitogenome	sequencing	
as	the	gold	standard	for	LHON	diagnosis,	to	disclose	possible	unique	combinations	of	variants,	
or	double/triple	mutants.	In	brief,	the	definition	of	a	pathogenic	mtDNA	mutation	becomes	
blurrier	 than	 ever,	 and	 only	 the	 accurate	 consideration	 of	 population-dependent	 mtDNA	
structure,	combined	with	functional	analyses	using	the	cybrid	cell	model,	may	lead	to	its	final	
validation.	A	good	example	for	such	a	scenario	is	the	m.3394T>C/MT-ND1,	which	might	act	as	
an	adaptive	variant	selected	for	high	altitudes	in	Tibet,	while	exerting	a	pathogenic	effect	on	
other	mtDNA	backgrounds	and	predisposing	to	LHON	in	China	(Ji	et	al.,	2012).	Closely	similar,	
other	 two	 adaptive	 variants	 for	 high	 altitude	 in	 Tibet,	 i.e.	 m.3745G>A/MT-ND1	 and	
m.4216T>C/MT-ND1,	were	also	implicated	in	LHON	(Kang	et	al.,	2013).	The	m.3745G>A/MT-
ND1	was	in	fact	found	in	combination	with	m.10680G>A/MT-ND4L	in	a	Chinese	LHON	Family	
(Yang	 et	 al.,	 2009),	whereas	 the	m.	 4216T>C/MT-ND1	 variant	 is	 at	 the	 shared	 root	 of	 the	
Western	 Eurasian	 haplogroups	 J	 and	 T,	 both	 possibly	 affecting	 the	 E-channel	 for	 proton	
pumping	(Figure	11).	
	
Mitochondrial	DNA	variability	in	Leber’s	hereditary	optic	neuropathy	
The	 background	 mitogenome	 variability	 may	 be	 associated	 as	 a	 modifying	 factor	 to	 the	
“primary”	mutations	 in	 LHON,	 this	being	particularly	evident	 for	 the	m.14484T>C/MT-ND6	
mutation.	In	fact,	according	to	the	current	literature	the	mitochondrial	haplogroup	J	is	well	
established	to	be	a	modifier	of	penetrance	for	this	mutation,	with	the	strongest	association	
compared	 with	 the	 other	 LHON	 primary	 mutations,	 whereas	 non-J	 mtDNA	 backgrounds	
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display	a	very	reduced	penetrance	for	the	m.14484T>C/MT-ND6	mutation	(Carelli	et	al.,	2006;	
Howell	et	al.,	2003a;	Hudson	et	al.,	2007;	Palanichamy	et	al.,	2004).		
However,	 all	 previous	 studies	 on	 LHON	 cohorts	 did	 not	 analyze	 the	 entire	 sequence	 of	
mitogenomes,	but	only	a	few	SNPs,	which	are	diagnostic	markers	of	haplogrups,	or	at	best	
included	 in	 some	 studies	 the	 sequence	 of	 the	 control	 region,	 with	 only	 a	 few	 pedigrees	
analyzed,	i.e.	6	and	33	respectively	(Carelli	et	al.,	2006;	Hudson	et	al.,	2007).	Thus,	we	decided	
to	collect	all	available	LHON	families	carrying	the	m.14484T>C/MT-ND6	mutation	in	Europe	
and	 perform	 the	 complete	 sequence	 analysis	 of	 the	mitogenomes,	 to	 dissect	 the	 genetic	
variability	and	its	relevance	for	this	specific	LHON	primary	mutation.	We	collected,	thanks	to	
a	relevant	international	effort	and	collaborations,	and	analyzed	147	probands	from	apparently	
unrelated	families.	Our	results	confirmed	the	strong	association	with	haplogroup	J.	The	45%	
of	 this	 LHON	 cohort,	 carrying	 the	 m.14484T>C/MT-ND6	 mutation,	 had	 a	 haplogroup	 J	
background	as	compared	to	the	9%	in	controls,	further	reproducing	the	results	reported	by	
previous	studies	(Carelli	et	al.,	2006;	Hudson	et	al.,	2007;	Torroni	et	al.,	1997).	However,	in	
our	hands	the	association	was	weaker	than	in	previous	reports:	in	the	first	report	(Torroni	et	
al.,	1997)	the	patients	analyzed	were	only	two,	both	with	J	haplogroup,	whereas	a	following	
study	 found	a	 66.7%	 (4	out	 6)	 of	mutational	 events	on	 J	 haplogroup	 (Carelli	 et	 al.,	 2006).	
Finally,	the	largest	study	ever	by	Hudson	and	colleagues	reported	a	haplogroup	J	frequency	of	
99%	 in	851	 LHON	carrying	m.14484T>C/MT-ND6	mutation,	but	 this	 figure	was	 reached	by	
considering	all	individuals	on	the	33	available	maternal	lineages	(Hudson	et	al.,	2007).		
Furthermore,	the	other	difference	we	have	observed	between	haplogroups	T	and	H	 in	our	
cohort	 may	 be	 due	 to	 the	 reduced	 frequency	 of	 haplogroup	 H,	 as	 counterpart	 of	 the	 J	
predominance,	 or	 to	 a	 milder	 modifier	 role	 of	 haplogruop	 T,	 which	 shares	 the	 common	
phylogenetic	root	as	haplogroup	J.	This	 latter	 interpretation	 is	corroborated	by	the	normal	
distribution	we	have	found	by	dissecting	the	haplogroup	J	sub-clades,	compared	to	controls,	
failing	to	confirm	the	previously	proposed	preferential	association	of	 the	J1	clade	with	the	
m.14484T>C/MT-ND6	mutation	(Carelli	et	al.,	2006;	Hudson	et	al.,	2007).	
A	 side	 result	 of	 our	 sequencing	 analysis	 of	 such	 a	 large	 number	 of	 mitogenomes	 is	 the	
correction	of	previous	haplogroup	affiliation	in	some	families,	which	was	wrong.	The	previous	
analysis	was	carried	out	by	RFLP,	considering	only	a	limited	number	of	diagnostic	variants	for	
each	 haplogroup.	 In	 particular,	 the	 presence	 of	 the	 change	 m.10398A>G/MT-ND3	 was	
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discriminating	between	haplogroup	 J	and	haplogroup	T,	while	 the	change	m.4216T>C/MT-
ND1	was	at	the	root	of	haplogroups	J	and	T.	From	our	new	analysis,	however,	these	changes	
were	private	variants,	outside	the	canonical	mtDNA	background,	confirming	the	complexity	
of	the	mitogenome	variation.	
The	assessment	of	a	possible	functional	impact	of	the	missense	private	variants,	besides	the	
m.14484T>C/MT-ND6	mutation,	was	based	on	amino	acid	conservation	and	on-line	prediction	
tools,	and	revealed	in	some	instances	double	mutants	and	synergistic	changes.	
In	 2	 independent	 families,	 besides	 the	 primary	 LHON	 m.14484T>C/MT-ND6	 mutation,	 a	
second	 LHON	 “primary”	mutation	was	 found	 (m.3460G>A/MT-ND1	 and	m.11778G>A/MT-
ND4).	 This	 kind	 of	 event,	 though	 rare,	 was	 already	 reported	 in	 one	 family	 with	 both	
m.3460G>A	and	m.11778G>A	and	6	families	with	both	m.14484T>C	and	m.11778G>A	(Brown	
et	al.,	2001;	Catarino	et	al.,	2017;	Cruz-Bermúdez	et	al.,	2016;	Howell	et	al.,	2002;	Riordan-Eva	
et	 al.,	 1995;	 Tonska	 et	 al.,	 2008).	Most	 cases	 carried	 the	 second	 “primary”	mutation	 in	 a	
heteroplasmic	state,	besides	one	primary	homoplasmic	changes,	and	the	coexistence	of	two	
primary	mutations	did	not	apparently	modify	the	phenotype,	most	cases	displaying	a	classic	
LHON	(Catarino	et	al.,	2017).	Only	in	two	families	the	double	mutation	seemed	to	increase	the	
proportion	of	 affected	 females,	 impacting	on	 the	male:female	 ratio	 (Catarino	et	 al.,	 2017;	
Howell	et	al.,	2002).	
Other	variants	 in	CI	 subunits	genes	were	predicted	 to	be	pathogenic:	 the	m.4136A>G/MT-
ND1,	m.4160T>C/MT-ND1,	m.4184T>A/MT-ND1,	m.10237T>C/MT-ND3.	The	m.4160T>C/MT-
ND1	(p.L285P)	was	already	associated	with	LHON	in	an	Australian	family	(Queensland	family)	
carrying	also	the	m.14484T>C/MT-ND6	and	affected	by	a	complex	multisystemic	neurological	
disorder	 compatible	 with	 the	 definition	 of	 LHON	 “plus”	 (Howell	 et	 al.,	 1991,	 1995).	 The	
sequence	analysis	of	this	family	was	limited	to	the	CI	subunits	genes	only,	and	based	on	the	
reported	 data	 (Howell	 et	 al.,	 1991)	 the	 haplogroup	 affiliation	 of	 this	 Australian	 family	 is	
compatible	 with	 haplogroup	 U,	 carrying	 some	 diagnostic	 variants	 for	 this	 haplogroup	
(m.14647A>G/MT-ND6	and	m.12372G>A/MT-ND6,	both	in	MT-ND6).	The	family	carrying	the	
same	combination	of	variants	(m.4160T>C/MT-ND1	+	m.14484T>C/MT-ND6)	identified	in	our	
cohort	 is	originally	from	France	and	showed	the	same	haplogroup,	U5a1a12b,	suggesting	a	
possible	founder	event	or	a	migration	of	a	female	in	Australia,	even	though	the	Queensland	
family	 was	 thought	 to	 be	 originally	 from	 Scotland.	 Furthermore,	 in	 a	 branch	 of	 the	 large	
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Australian	pedigree	there	was	a	third	m.4136A>G/MT-ND1	variant,	which	was	proposed	as	an	
intragenic	 suppressor,	 ameliorating	 the	 complex	 neurological	 phenotype	 associated	 with	
complex	I	deficiency	(Howell	et	al.,	1991).		
The	 m.4160T>C/MT-ND1	 was	 also	 reported	 in	 patients	 with	 thymidine	 phosphorylase	
deficiency,	as	somatic	mtDNA	point	mutation	(Nishigaki	et	al.,	2003)	and	in	a	healthy	control	
(Lippold	et	al.,	2014).	Thus,	the	specific	pathogenic	role	of	this	change	affecting	a	conserved	
position	remains	uncertain.	
The	m.4136A>G/MT-ND1	 (p.Y277C)	 variant	 was	 found	 in	 49	 controls,	 on	 26	 independent	
mtDNA	backgrounds,	but	never	on	L2a1l2	(www.mitomap.org),	as	in	our	French	proband,	and	
it	was	also	previously	found	associated	to	m.11778G>A/MT-ND4	LHON	mutation	in	Italy,	with	
a	possible	synergic	role	(La	Morgia	et	al.,	2008).		
The	m.4184T>A/MT-ND1	(p.F293Y)	variant	has	never	been	found	 in	the	control	population	
(www.mitomap.org);	moreover,	 the	 same	position,	but	with	a	different	nucleotide	 change	
T>G	causing	a	different	amino	acid	substitution	(p.F293C),	was	found	mutated	in	a	Russian	
LHON	family	carrying	also	the	m.3460G>A/MT-ND1,	on	haplogroup	T1	(Povalko	et	al.,	2005).		
The	 m.10237T>C/MT-ND3	 (p.I60T)	 was	 found	 in	 54	 controls,	 on	 20	 independent	 mtDNA	
backgrounds,	but	never	on	the	haplogroup	T2b25	sub-clade	(www.mitomap.org),	as	 in	our	
German	proband.	The	same	mutation	was	found	in	a	Hungarian	LHON	patient	not	carrying	the	
common	primary	mutations	(Horvath	et	al.,	2002).		
The	 m.4659G>A/MT-ND2	 (p.A64T)	 was	 found	 in	 57	 controls,	 on	 27	 independent	 mtDNA	
backgrounds,	but	never	on	the	haplogroup	J1b1a1d	sub-clade	(www.mitomap.org),	as	in	our	
German	proband.	This	variant	was	postulated	 to	 increase	 the	 risk	of	developing	Parkinson	
disease	(Khusnutdinova	et	al.,	2008),	and	it	also	is	a	marker	of	haplogroup	H2a1n.	
Other	 putative	 “secondary”	 pathogenic	 mutations	 were	 found	 in	 CIV	 and	 CV	 subunits:	
m.6712A>T/MT-CO1,	 m.8516T>C/MT-ATP8,	 m.8989G>A/MT-ATP6,	 m.9025G>A/MT-ATP6	
and	 m.9957T>C/MT-CO3.	 All	 these	 variants	 are	 rare,	 found	 a	 few	 times	 in	 the	 normal	
population	(1,	4,	10,	24,	27,	respectively),	and	never	associated	with	pathologic	phenotypes	
(www.mitomap.org).	 The	 only	 exception	 is	 the	 m.9957T>C/MT-CO3	 variant,	 previously	
associated	 with	 several	 forms	 of	 mitochondrial	 encephalomyopathy:	 mitochondrial	
encephalomyopathy,	lactic	acidosis	and	stroke-like	episodes	(MELAS)	(Manfredi	et	al.,	1995),	
chronic	 progressive	 external	 ophthalmoplegia	 (CPEO)	 (Liu	 et	 al.,	 2011),	 and	 non-arteritic	
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ischemic	 optic	 neuropathy	 (Abu-Amero	 et	 al.,	 2005).	 A	 cell	 study	 on	 cybrids	 carrying	 this	
mutation	showed	a	normal	respiration,	but	increased	ROS	production	(Lenaz	et	al.,	2004).	
The	 putative	 synergistic	 variants	 (m.4824A>G/MT-ND2,	 m.6261G>A/MT-CO1,	
m.7080T>C/MT-CO1,	 m.8557G>C/MT-ATP8,	 m.8812A>G/MT-ATP6,	 m.8953A>G/MT-ATP6,	
m.9055G>A/MT-ATP6)	 were	 found	 in	 57,	 1052,	 253,	 40,	 18,	 46,	 4,	 1769,	 27	 controls,	
respectively.	All	variants	were	not	associated	with	any	neurological	conditions,	except	for	the	
m.6261G>A/MT-CO1	 and	m.9055G>A/MT-ATP6	 variants.	 The	m.6261G>A/MT-CO1	 variant,	
besides	being	found	in	cancer	as	a	somatic	mutation,	was	also	associated	with	a	LHON-like	
optic	neuropathy	in	a	patient	negative	for	primary	LHON	mutations,	on	haplogroup	T2	(Abu-
Amero	 and	 Bosley,	 2006).	 Moreover,	 this	 variant	 is	 a	 marker	 of	 several	 haplogroups	
(www.phylotree.org),	which	lowers	its	possible	pathogenic	role	as	a	primary	mutation.	The	
m.9055G>A/MT-ATP6,	in	the	frame	of	an	association	study	of	mitochondrial	haplogroups	and	
Parkinson	disease,	was	assigned	a	putative	protective	effect	for	women	(van	der	Walt	et	al.,	
2003).	 The	 same	 variant	 was	 studied	 in	metabolic	 disease,	 failing	 to	 find	 any	 association	
(Saxena	et	al.,	2006).	After	all	considered,	the	m.9055G>A/MT-ATP6	is	a	marker	of	haplogroup	
K	(www.phylotree.org),	and	was	found	on	the	haplogroup	H	in	our	case.	
The	phylogenetic	analysis	showed	that	some	families	cluster	into	a	common	origin,	suggesting	
founder	events.	 In	particular,	11	probands,	apparently	 independent	 from	the	geographical	
point	of	view,	share	the	common	J1b1a1	root,	and	diverged	in	at	least	5	separate	branches,	
which	were	country-related.	There	were	similar	events	on	J1c1d	in	Germany,	on	J1c2j,	T1a2,	
T2	in	Italy,	on	T2c1d1	in	both	Italy	and	France.	All	these	cases	may	be	the	result	of	a	founder	
effect,	assuming	that	the	m.14484T>C/MT-ND6	mutational	event	occurred	early	during	the	
evolution	and	became	 fixed.	Alternatively,	 the	 LHON	mutational	 events	might	have	arisen	
independently,	 suggesting	 that	 some	 mitogenomes	 could	 predispose	 to	 mutagenesis	 at	
position	m.14484T.	According	 to	Carelli	 and	 colleagues	 (Carelli	 et	 al.,	 2006),	 the	 six	 Italian	
LHON	 families	 originally	 studied	 in	 their	 previous	 report	 carried	 the	m.14484T>C/MT-ND6	
mutation	on	independent	mitochondrial	backgrounds,	thus	the	preferential	association	of	the	
m.14484T>C/MT-ND6	 LHON	 mutation	 with	 haplogroup	 J1	 was	 interpreted	 as	 not	 due	 to	
founder	events	but	to	a	true	mtDNA	background	effect.	It	was	also	proposed	that	the	specific	
combination	of	amino	acid	changes	in	the	cytochrome	b	is	the	possible	cause	of	the	mtDNA	
background	 effect,	 and	 that	 this	may	 occur	 affecting	 the	 supercomplex	 formation,	 by	 co-
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assembling	 respiratory-chain	 complexes	 I	 and	 III	 (Carelli	 et	 al.,	 2006).	However,	differently	
from	the	Italian	population,	a	clear	major	founder	event	that	might	have	occurred	900–1,800	
years	 ago	 has	 been	 recognized	 in	Northern	 Europe	 (Dutch	 and	 French	 population)	 and	 in	
Canada	 (French-Canadian	 population)	 on	 haplogroup	 J1c1d	 (Howell	 et	 al.,	 2003b).	 The	
association	 of	 m.14484T>C/MT-ND6	 mutation	 with	 haplogroup	 J	 does	 not	 apply	 to	 non-
European	population:	for	example,	a	study	of	an	Indian	LHON	cohort	showed	an	association	
with	 different	 mtDNA	 backgrounds	 (F1c1,	 M31a,	 U2a,	 M*,	 I1,	 M6,	 M3a1,	 and	 R30a),	 as	
independent	mutational	events	(Khan	et	al.,	2013).	
Finally,	on	the	clinical	ground,	penetrance	in	LHON	families	carrying	the	m.14484T>C/MT-ND6	
mutation	 on	 haplogroup	 J	 was	 higher	 than	 those	 on	 non-J	 haplogroups.	 This	 was	 a	 non-
significant	 tendency	 that	 applied	 to	 both	 genders.	 Unfortunately,	 besides	 the	 association	
studies	there	are	no	published	data	on	this	issue,	with	the	actual	calculation	of	penetrance	in	
in	 large	 cohorts	 of	 families,	 except	 for	 a	 few	 maternal	 lineages	 (Caporali	 et	 al.,	 2017).	
Moreover,	as	reported	in	literature,	the	ratio	between	affected	males	and	females	was	7.7:1	
(Macmillan	et	al.,	1998;	Yu-Wai-Man	and	Chinnery,	2016).	In	our	cohort,	this	ratio	is	about	
half	(3.5:1),	and	in	the	haplogroup	J	background	families	 it	decreases	to	2.7:1,	while	 in	the	
non-J	was	4.2:1.	Thus,	the	contribution	of	haplogroup	J	seems	to	be	limited	to	a	slight	increase	
of	penetrance,	especially	true	in	females	carrying	the	m.14484T>C/MT-ND6	mutation.		
	
Mitochondrial	DNA	variability	in	Dominant	Optic	Atrophy	(DOA)	with	OPA1	mutations		
Hypothetically,	 the	mtDNA	background	may	 be	 also	 a	modifier	 in	DOA	 families	 carrying	 a	
mutation	in	the	OPA1	gene,	considering	the	consolidated	role	of	mitogenome	variability	 in	
LHON	 and	 the	 clinical	 and	 pathophysiological	 similarities	 between	 DOA	 and	 LHON.	 The	
mitochondrial	haplogroups	have	been	already	investigated	in	DOA,	and	these	studies	failed	to	
reveal	 any	 association	 (Han	 et	 al.,	 2006;	 Pierron	 et	 al.,	 2009).	 Our	 results	 confirmed	 this	
finding,	as	expected	for	a	dominantly	inherited	disorder	(Figure	15).	We	used	the	same	mtDNA	
sequencing	approach	 for	DOA	as	 for	 the	m.14484T>C/MT-ND6	LHON	cohort,	and	we	have	
analyzed	 all	 private	 missense	 changes	 to	 detect	 the	 presence	 of	 putative	 pathogenic	
mutations	or	synergistic	variants,	besides	the	normal	population-specific	variability	(Table	10).	
This	analysis	revealed	10	changes	with	a	possible	pathogenic	role.	Most	of	them	are	reported	
as	 rare	 population	 polymorphisms	 (www.mitomap.org).	 Both	 the	 m.4659G>A/MT-ND2	
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(p.A64T)	and	m.9957T>C/MT-CO3	variants	were	already	found	in	our	m.14484T>C/MT-ND6	
LHON	cohort,	as	well	as	associated	to	other	neurological	disorders.	The	m.4659G>A/MT-ND2	
was	postulated	 to	 increase	 the	 risk	of	developing	Parkinson	disease	 (Khusnutdinova	et	al.,	
2008),	and	is	also	a	marker	of	haplogroup	H2a1n.	As	commented	in	the	previous	paragraph,	
the	m.9957T>C/MT-CO3	was	found	in	27	individuals,	healthy	controls	and	patients,	and	was	
previously	associated	with	several	form	of	mitochondrial	encephalomyopathy	(Abu-Amero	et	
al.,	2005;	Liu	et	al.,	2011;	Manfredi	et	al.,	1995)	and	its	pathogenicity	evaluated	on	cybrids	
(Lenaz	et	al.,	2004).	However,	the	pathogenic	role	of	this	mutation	is	now	questioned	based	
on	our	current	results.	Next,	the	m.15773	G>A/MT-CYB	(p.V343M)	was	found	in	39	controls,	
in	28	independent	backgrounds,	but	never	on	H43	haplogroup,	and,	in	particularly,	was	found	
associated	with	the	m.11778G>A/MT-ND4	LHON	mutation,	with	a	possible	synergic	role	(La	
Morgia	et	al.,	2008)	supporting	a	putative	role	in	modulating	neurodegeneration.	
Furthermore,	 the	 putative	 synergic	 variants	 m.4824	 A>G/MT-ND2,	 m.7754	 G>A/MT-CO2,	
m.7805	G>A/MT-CO2,	m.8896	G>A/MT-ATP6,	m.8953	A>G/MT-ATP6,	m.12674	A>G/MT-ND5,	
m.14180	T>C/MT-ND6,	found	in	the	DOA	cohort,	were	also	found	in	1052,	19,	334,	28,	4,	11,	
138	controls	respectively,	and	never	associated	with	a	pathological	condition.	
We	thus	 investigated	the	mitogenome	variability	as	a	possible	modifier	 in	 the	DOA	clinical	
outcome,	evaluating	the	haplogroup	association	with	the	RNFL	thickness,	as	evaluated	by	OCT	
and	 reliable	 readout	 of	 disease	 severity.	 First,	 we	 analyzed	 the	 effect	 of	 the	 putative	
pathogenic	 mutations	 and	 synergistic	 variant	 found	 in	 mtDNA.	 These	 mutations	 did	 not	
impinge	on	the	clinical	outcome	of	DOA	patients	(Figures	15,	16).		
Second,	we	evaluated	the	mitogenomes	variability,	fixed	by	evolution	(Figures	16,	17),	finding	
that	 DOA	 patients	 on	 the	 haplogroup	 U	 background	maintain	 a	 significantly	 higher	 RNFL	
thickness	 on	 the	 temporal	 quadrant	 as	 compared	 with	 those	 carrying	 haplogroup	 H.	
Remarkably,	the	specificity	for	the	temporal	fibers,	which	are	the	main	disease	target,	possibly	
indicates	a	real	protective	role.	Noticeably,	haplogroup	H	is	the	most	frequent	in	Europe	and	
often	 found	to	be	more	prevalent	 in	healthy	control	 subjects	 than	 in	patient	study	groups	
(Mueller	 et	 al.,	 2012),	 but	 sometime	was	 also	 associated	 as	 risk	 factor,	 i.e.	 for	 late	 onset	
Alzheimer's	disease	 (Santoro	et	al.,	2010).	Haplogroup	U	 is	 the	second	most	 frequent,	and	
haplogroup	K	stems	from	it	as	sub-clade.	Haplogroup	U	has	also	been	associated	with	several	
clinical	conditions,	i.e.	psychosis	in	bipolar	disorder	(Frye	et	al.,	2017),	reduction	of	physical	
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performance	(Arjmand	et	al.,	2017),	or	severe	progression	of	knee	osteoarthritis	(Rego-Pérez	
et	al.,	2008).	However,	this	haplohgroup	as	a	whole,	or	in	association	with	its	sub-clade	K,	has	
also	been	assigned	a	protective	role	for	Parkinson	disease,	a	neurodegenerative	disorder	with	
a	clear	involvement	of	mitochondrial	dysfunction,	particularly	of	complex	I,	in	its	pathogenesis	
(Giannoccaro	et	al.,	2017).	This	latter	observation	further	supports	that	OPA1-related	DOA,	
which	has	a	documented	complex	I	defect	(Zanna	et	al.,	2008),	may	benefit	of	a	protective	
effect	from	the	association	with	haplogroup	U,	in	analogy	with	Parkinson	disease.	
Last,	 we	 evaluated	 the	 effect	 of	 the	 interaction	 between	 the	 mitochondrial	 and	 nuclear	
genomes.	This	approach	is	based	on	the	widely	discussed	issue	of	preferntial	coadaptation	
between	the	nuclear	and	mitochondrial	genomes,	thus	 involving	 in	the	clinical	outcome	of	
DOA	the	co-inheritance	of	mtDNA	changes	with	the	OPA1	mutation	(Figure	18).	To	this	end,	
we	compared	the	clinical	severity,	assessed	as	RNFL	thickness	in	the	two	possible	segregations	
mother-child	 (same	mitogenome)	vs	 father-child	 (change	of	 the	mitogenome	haplogroup).	
This	 analysis	 revealed	 that	 the	 mother-children	 segregations	 displayed	 a	 statistically	
significant	 worsening	 of	 the	 clinical	 outcome,	 particularly	 on	 the	 average	 and	 inferior	
quadrant	RNFL	thickness,	with	the	other	quadrants	(temporal,	superior	and	nasal)	presenting	
the	 same	 trend.	 On	 the	 contrary,	 the	 only	 significant	 difference	 in	 the	 father-children	
segregations	was	on	the	temporal	quadrant,	with	a	similar	outcome	on	the	other	quadrants	
and	 on	 the	 average	 assessment.	 These	 results	 strongly	 indicate	 that	 the	 nuclear	 genome	
variation	seems	to	play	the	major	role	on	severity	of	DOA	carrying	dominant	OPA1	mutations,	
as	exemplified	in	the	mother-child	segregations	where	the	mitogenome	remains	the	same.	
	
Common	features	between	LHON	and	DOA	
Interestingly,	the	otherwise	normal	variants	found	in	the	peculiar	pathogenic	combination	in	
the	two	 independent	LHON	families,	were	also	 found	 in	both	LHON	and	DOA	cohorts.	The	
m.14258G>A/MT-ND6	was	found	in	one	proband	of	the	m.14484T>C/MT-ND6	LHON	cohort,	
on	 a	 L2a1a1	 mtDNA	 background,	 and	 in	 one	 patient	 with	 OPA1	 mutation,	 on	 a	 K1a	
background.	The	m.10680G>A/MT-ND4L	variant	was	found	in	4	families	on	H,	T2,	U1a1a1	and	
X2d1	haplogroups,	only	in	the	LHON	cohort.	The	m.14582A>G/MT-ND6	variant	was	found	in	
1	case	on	H1bm	haplogroup,	while	the	m.12033A>G/MT-ND4	was	not	found	in	any	proband	
of	the	two	LHON	and	DOA	cohorts.	These	findings	confirm	the	association	of	these	variants	
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with	 LHON,	 especially	 the	 m.10680G>A/MT-ND4L,	 and	 their	 relative	 frequency	 in	 the	
population,	although	rare.	
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CONCLUSIONS	
	
The	 current	 study	 provides	 genetic	 and	 functional	 evidence	 that	 specific	 and	 previously	
unreported	combinations	of	missense	mtDNA	variants,	which	individually	obey	the	definition	
of	population	polymorphisms,	may	exert	a	sufficient	pathogenic	potential	for	being	causative	
of	low-penetrance	LHON.	
This	finding	seems	to	be	the	extreme	end	of	a	wide	and	complex	molecular	landscape	clearly	
implicating	the	interaction	of	the	haplogroup-specific	variants,	as	well	as	the	private	variants,	
with	 the	 clearly	 pathogenic	 mutations,	 as	 in	 the	 case	 of	 the	 LHON	 cohort	 carrying	 the	
m.14258G>A/MT-ND6	mutation.	This	 interaction	seems	to	be	very	strong	also	in	the	LHON	
cohort	 carrying	 the	 primary	 m.14484T>C/MT-ND6	 mutation.	 The	 association	 with	 the	
haplogroup	 J	 root	 highlights	 this	 complex	 interplay,	 revealing	 also	 the	 importance	 of	
geographic	 mitogenome	 stratification	 with	 the	 occurrence	 of	 multiple	 founder	 events	 in	
Europe,	as	well	as	the	possibility	that	certain	mitogenomes	may	predispose	to	mutagenesis,	
which	becomes	eventually	fixed	during	evolution.	
More	 complex	and	 still	 completely	open	 is	 the	 scenario	 in	DOA,	where	we	documented	a	
minor	effect	that	could	be	ascribed	to	the	mitogenome	variation,	as	compared	with	what	it	
seems	a	stronger	role	of	nDNA	modifying	effect.	
Overall,	this	study	highlights	the	complexities	of	mtDNA	sequence	variability,	 introducing	a	
perspective	 that	will	 necessarily	 change	 the	approach	 for	 assigning	 the	pathogenic	 role	 to	
single	or	peculiar	combinations	of	mtDNA	variants,	and	modifying	the	criteria	for	diagnostics	
in	mitochondrial	human	diseases	(Montoya	et	al.,	2009).	
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MATERIALS	AND	METHODS	
	
Patients	
Total	DNA	was	extracted	by	standard	methods	from	blood	cells,	urinary	sediment	epithelium	
and	 skeletal	muscle	 after	 informed	 consent	 and	 approval	 of	 the	 internal	 review	 board	 at	
University	of	Bologna	for	Italian	patients.		
For	the	Europen	LHON	cohort	carrying	m.14484T>C/MT-ND6	mutation	the	informal	consent	
was	approved	by	local	review	board	and	total	DNA	was	extract	from	blood.	
The	LHON	cohort	are	composed	by	147	probands:	52	from	Italy	(Prof.	Carelli,	University	of	
Bologna,	Institute	of	Neurological	Sciences;	Prof.	Federico,	University	of	Siena;	Dr.	Garavaglia	
and	 Dr.	 Zeviani,	 Besta	 Institute,	 Milan),	 43	 from	 Germany	 (Prof.	 Wissinger,	 University	 of	
Tubingen;	 Prof.	 Klopstok,	 University	 of	 Munich),	 27	 from	 France	 (Dr.	 Amati	 Bonneau,	
University	 of	Angers),	 19	 from	UK	 (Prof.	 Cinnery,	University	 of	 Chambridge),	 3	 from	Spain	
(Prof.	Montoya,	University	of	Saragozza)	and	3	from	US	(Prof.	Sadun,	Doheny	Eye	Centers-
UCLA),	but	with	European	ancestry.	
The	dominant	optic	atrophy	(DOA),	carrying	OPA1	mutations,	are	composed	by	85	families	
with	 112	 maternally	 unrelated	 patients.	 The	 variants	 are	 described	 according	 to	 OPA1	
transcript	 variant	 1	 (RefSeq:	NM_015560.2)	 (Table	 11).	 All	 patients	were	 referred	 to	 Prof.	
Valerio	Carelli,	at	Neurophthamology	Clinic	(IRCCS	Institute	of	Neurological	Science,	University	
of	Bologna).		
	
Family	 Mutation	 Effect	 Family	 Mutation	 Effect	
1	 c.1334G>A	 p.R445H	 44	 c.1899_90del	 p.E630FfsX2	
2	 c.889C>T	 p.Q297X	 45	 c.2771_2773del	 p.K924del	
3	 c.1212+1G>A	 Splice	defect	 46	 c.2733_2734del	 p.E912GfsX7	
4	 c.1807G>C	 p.D603H	 47	 c.931G>C	 p.A311P	
5	 c.1516+1G>A	 Splice	defect	 48	 c.2825_2828del	 p.V942EfsX25	
6	 c.815T>C	 p.L272P	 49	 c.1212+5G>C	 Splice	defect	
7	 c.2708_2711del	 p.V903GfsX3	 50	 c.1334G>A	 p.R445H	
8	 c.1146A>G	 p.I382M	 51	 c.2713C>T	 p.R905X	
9	 c.1516+1G>A	 Splice	defect	 52	 c.1669C>T	 p.R557X	
10	 c.1516+1G>C	 Splice	Defect	 53	 c.2713C>T	 p.R905X	
11	 c.2708_2711del	 p.V903GfsX3	 54	 c.2215C>T	 p.Q739X	
12	 c.2569C>T	 p.R857X	 55	 c.2825_2828del	 p.V942EfsX25	
13	 c.1724_1725del	 p.E575fsX576	 56	 c.1410_1443+5del	 p.D470fsX	
14	 c.1770G>A	 Exon	Skipping	 57	 c.1346_47insC	 p.T449fsX	
15	 c.2470C>T	 p.R824X	 58	 c.1462A>G	 p.G488R	
16	 c.751delG	 p.D251MfsX13	 59	 c.2708_2711del	 p.V903GfsX3	
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17	 c.631_634del	 p.D211KfsX16	 60	 c.2708_2711del	 p.V903GfsX3	
18	 c.2729T>A	 p.V910D	 61	 c.984+3A>T	 Splice	Defect	
19	 c.703C>T	 p.R235X	 62	 c.984+3A>T	 Splice	Defect	
20	 c.2825_2828del	 p.V942EfsX25	 63	 c.2825_2828del	 p.V942EfsX25	
21	 c.2708-2A>T	 Splice	Defect	 64	 c.1334G>A	 p.R445H	
22	 c.2482delG	 p.V828X	 65	 c.2771_2773del	 p.K924del	
23	 c.2819-2A>C	 Exon	Skipping	 66	 c.2726del	 p.N909MfsX58	
24	 c.2341C>T	 p.R781W	 67	 c.869G>A	 p.R290Q	
25	 c.1444-1G>C	 Splice	defect	 68	 c.869G>A	 p.R290Q	
26	 c.2341C>T	 p.R781W	 69	 c.870+5G>A	 Splice	Defect	
27	 c.1196T>A	 p.L399X	 70	 c.2331C>A	 p.Y777X	
28	 c.2708_2711del	 p.V903GfsX3	 71	 c.1484C>T	 p.A495V	
29	 c.893G>A	 p.S298N	 72	 c.113_130del	 p.R38_S43del	
30	 c.2496+1G>A	 Splice	defect	 73	 c.869G>A	 p.R290Q	
31	 c.1609del	 p.H537fs540X	 74	 c.1778T>C	 p.L593P	
32	 c.869G>A	 p.R290Q	 75	 c.2671_2694dup	 p.891_898dup8	
33	 c.751delG	
c.2341C>T	
p.D251MfsX13	
p.R781W	
76	 del	exons21-23	 -	
34	 c.2131C>T	 p.R711X	 77	 c.2825_2828del	 p.V942EfsX25	
35	 c.1212+3A>T	 Splice	defect	 78	 c.889C>T	 p.Q297X	
36	 c.869G>A	 p.R290Q	 79	 c.2331C>A	 p.Y777X	
37	 c.1462A>G	 p.G488R	 80	 del	exons2-11	 -	
38	 c.2708_2711del	 p.V903GfsX3	 81	 c.703C>T	 p.R235X	
39	 c.751delG	 p.D251MfsX13	 82	 c.784-21_784-
22InsAluYb8	
Exon	Skipping	
40	 c.1587del	 p.L529fs534X	 83	 c.1316G>T	 p.G439V	
41	 c.869G>A	 p.R290Q	 84	 c.1187T>G	 p.L396P	
42	 c.869G>A	 p.R290Q	 85	 c.2815del	 p.L939Sfs28	
43	 del	exon19	 -	 	 	 	
Table	11.	OPA1	mutation		
The	RNFL	(retinal	nerve	fibers	layer)	thickness	was	evaluated	in	91	patients,	from	49	families,	
by	 the	 Stratus	 OCT	 (Optical	 Coherent	 Tomography),	 at	 Prof.	 Valerio	 Carelli’s	
Neurophthamology	Clinic	(IRCCS	Institute	of	Neurological	Science,	University	of	Bologna)	and	
Dr.	Piero	Barboni’s	clinic	(Studio	Oculistico	d'Azeglio,	Bologna).	Data	are	shown	in	Table	12.	
Family	 Relationship	 OD	 OS	AVG	 T		 S	 N	 I	 AVG	 T	 S	 N	 I	
3	 Proband	 52	 38	 77	 48	 46	 48	 29	 73	 45	 43	
4	 Brother	 64	 33	 66	 71	 85	 43	 36	 53	 41	 43	
4	 Maternal	granfather	 75	 35	 93	 77	 95	 83	 35	 98	 96	 105	
4	 Mother	 87	 38	 123	 63	 123	 95	 35	 142	 73	 128	
4	 Proband	 46	 33	 71	 33	 48	 55	 26	 80	 48	 67	
5	 Father	 55	 35	 71	 46	 67	 49	 24	 74	 40	 50	
5	 Proband	 66	 30	 100	 58	 75	 65	 34	 87	 60	 79	
7	 Proband	 59	 26	 92	 55	 61	 64	 28	 95	 61	 71	
8	 Father	 84	 77	 102	 51	 106	 87	 57	 118	 64	 111	
8	 Proband	 89	 44	 101	 98	 116	 85	 42	 106	 82	 109	
10	 Proband	 73	 27	 106	 75	 84	 70	 34	 109	 60	 78	
12	 Proband	 62	 32	 88	 57	 71	 59	 31	 90	 51	 63	
13	 Sister	 100	 64	 130	 79	 125	 73	 26	 89	 53	 122	
14	 Proband	 61	 24	 94	 65	 60	 57	 28	 88	 46	 64	
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18	 Father	 56	 34	 65	 51	 74	 62	 35	 85	 47	 80	
18	 Proband	 68	 39	 83	 56	 95	 71	 35	 113	 47	 88	
18	 Paternal	aunt	 59	 38	 88	 51	 61	 60	 36	 88	 55	 63	
19	 Proband	 59	 32	 86	 60	 60	 60	 60	 91	 31	 59	
22	 Brother	 98	 49	 131	 97	 114	 115	 61	 146	 118	 134	
22	 Mother	 85	 45	 122	 79	 92	 91	 45	 120	 103	 95	
22	 Maternal	Granmother	 89	 76	 90	 61	 131	 75	 55	 95	 55	 96	
22	 Proband	 71	 26	 123	 67	 67	 73	 27	 131	 63	 70	
23	 Father	 66	 40	 94	 64	 68	 65	 31	 85	 56	 90	
23	 Proband	 82	 34	 105	 99	 90	 73	 26	 102	 81	 82	
23	 Sister	 65	 36	 94	 68	 64	 64	 34	 88	 60	 73	
26	 Mother	 92	 81	 115	 64	 110	 95	 71	 133	 62	 116	
26	 Proband	 59	 26	 100	 50	 59	 62	 34	 107	 47	 62	
27	 Proband	 67	 30	 91	 67	 78	 74	 40	 95	 69	 93	
27	 Sister	 78	 49	 106	 64	 94	 77	 42	 103	 71	 91	
28	 Father	 76	 45	 101	 62	 97	 86	 52	 103	 91	 97	
28	 Proband	 73	 51	 101	 59	 82	 69	 52	 73	 56	 95	
29	 Proband	 46	 34	 59	 33	 59	 40	 42	 42	 27	 50	
30	 Proband	 93	 43	 125	 94	 110	 93	 34	 134	 94	 111	
32	 Mother	 57	 38	 76	 54	 61	 74	 68	 77	 98	 55	
32	 Proband	 61	 29	 88	 65	 61	 62	 41	 87	 60	 59	
32	 Proband	 61	 48	 76	 56	 64	 58	 42	 79	 59	 54	
32	 Maternal	aunt	 65	 25	 99	 61	 76	 67	 31	 102	 57	 80	
35	 Father	 63	 36	 86	 54	 75	 58	 33	 84	 51	 62	
35	 Proband	 57	 28	 95	 49	 57	 54	 31	 83	 46	 57	
36	 Proband	 52	 45	 60	 45	 59	 42	 29	 47	 35	 55	
37	 Nephew	 58	 27	 83	 49	 73	 59	 33	 91	 41	 69	
37	 Nephew	 103	 68	 128	 93	 124	 106	 71	 122	 105	 127	
37	 Proband	 69	 48	 81	 60	 88	 65	 45	 83	 47	 86	
38	 Daughter	 49	 27	 69	 50	 51	 57	 32	 81	 63	 52	
38	 Proband	 62	 30	 87	 63	 69	 60	 28	 99	 49	 62	
39	 Sister	 60	 31	 84	 53	 71	 54	 30	 82	 39	 64	
40	 Son	 72	 47	 89	 61	 95	 72	 54	 90	 57	 89	
40	 Proband	 48	 23	 72	 47	 48	 49	 27	 75	 42	 51	
45	 Proband	 69	 54	 86	 58	 79	 73	 53	 92	 48	 98	
48	 Mother	 68	 29	 90	 74	 80	 70	 31	 93	 67	 89	
48	 Proband	 54	 27	 71	 63	 56	 60	 38	 82	 59	 61	
52	 Proband	 66	 35	 101	 50	 80	 72	 32	 112	 68	 79	
54	 Brother	 75	 28	 118	 79	 74	 82	 34	 92	 99	 102	
54	 Cousin	 63	 46	 102	 55	 49	 50	 27	 76	 45	 53	
54	 Proband	 80	 41	 105	 77	 95	 92	 73	 112	 66	 118	
55	 Proband	 74	 57	 85	 70	 83	 61	 38	 88	 60	 57	
57	 Mother	 78	 33	 104	 64	 112	 82	 29	 114	 64	 123	
57	 Proband	 53	 26	 94	 43	 50	 61	 34	 106	 48	 56	
57	 Sister	 74	 40	 112	 69	 77	 70	 34	 108	 45	 91	
60	 Father	 83	 43	 106	 81	 102	 82	 44	 126	 63	 96	
60	 Proband	 66	 29	 80	 74	 82	 67	 29	 88	 73	 79	
61	 Brother	 54	 47	 42	 49	 77	 56	 44	 76	 43	 60	
61	 Mother	 60	 31	 80	 60	 68	 56	 35	 69	 55	 63	
61	 Proband	 54	 41	 64	 42	 71	 na	 na	 na	 na	 na	
62	 Father	 61	 38	 89	 51	 67	 55	 25	 77	 50	 68	
62	 Paterna	granfather	 46	 28	 53	 50	 53	 51	 35	 71	 51	 49	
62	 Proband	 56	 27	 80	 48	 70	 55	 24	 91	 48	 58	
62	 Sister	of	paternal	granfather	 40	 25	 55	 36	 46	 48	 39	 60	 38	 54	
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64	 Father	 43	 36	 45	 38	 52	 48	 32	 62	 48	 48	
64	 Proband	 59	 57	 56	 41	 83	 63	 39	 75	 52	 86	
66	 Father	 na	 na	 na	 na	 na	 66	 42	 111	 46	 63	
66	 Proband	 41	 26	 68	 34	 36	 46	 27	 69	 39	 49	
68	 Mother	 50	 47	 63	 34	 55	 42	 37	 56	 27	 47	
68	 Proband	 50	 35	 70	 39	 58	 50	 30	 63	 43	 65	
68	 Sister	 59	 33	 89	 44	 69	 63	 44	 91	 53	 65	
69	 Proband	 70	 34	 108	 66	 72	 71	 35	 95	 69	 87	
70	 Mother	 62	 26	 84	 62	 77	 60	 28	 78	 59	 74	
70	 Proband	 66	 38	 100	 61	 66	 56	 34	 87	 41	 63	
72	 Paternal	aunt	 84	 55	 108	 54	 120	 86	 58	 109	 50	 127	
73	 Proband	 59	 33	 64	 47	 93	 53	 30	 65	 36	 79	
74	 Proband	 44	 36	 63	 38	 38	 42	 31	 55	 39	 45	
74	 Sister	 39	 30	 54	 29	 41	 43	 31	 54	 39	 47	
75	 Proband	 78	 29	 123	 79	 81	 80	 42	 121	 66	 94	
78	 Brother	 62	 41	 87	 59	 60	 60	 36	 87	 53	 63	
78	 Proband	 57	 35	 76	 50	 66	 63	 34	 78	 61	 80	
79	 Proband	 76	 46	 94	 57	 94	 61	 39	 86	 47	 72	
81	 Proband	 65	 33	 89	 62	 74	 59	 38	 65	 64	 70	
82	 Proband	 51	 28	 74	 42	 58	 50	 33	 86	 36	 46	
83	 Father	 51	 59	 44	 33	 68	 na	 na	 na	 na	 na	
83	 Proband	 44	 38	 44	 44	 48	 na	 na	 na	 na	 na	
85	 Father	 75	 50	 93	 64	 92	 72	 51	 94	 55	 86	
Table	12.	RNFL	thickness	by	OCT	of	DOA	patient	carrying	OPA1	muations	
OD:	Right	eye,	OS:	Left	eye;	AVG:	average;	T:	temporal;	S:	superior;	N:	nasal;	I:	inferior.	
	
Sanger	mtDNA	sequencing	
Direct	 sequence	 analysis	 of	 the	 entire	mtDNA	molecule	was	 performed	 on	 total	 DNA,	 by	
Sanger	(Torroni	et	al.,	2001).	The	protocol	consists	in	11	amplicons	(Table	13).	The	PCR	mixture	
contained	50	ng	of	DNA,	0.5U	GoTaq®	G2	Flexi	DNA	Polymerase	5U/µl	(Promega),	1x	Colorless	
GoTaq®	 Flexi	 Buffer	 5X	 (Promega),	 200	 µM	 PCR	 nucleotides	 mix	 (Life	 Technologies),	 200	
µMeach	primers	(Sigma-Aldrich),	in	a	final	volume	of	25	µl.	The	cycle	conditions	were	94°C	for	
5	min,	30	cycles	of	30	sec	at	94°C,	30	sec	at	55°C,	72°C	for	30	sec,	and	a	final	extensionof	7	min	
at	72°C.		
	
Primer	 Position	(mtDNA)	 Sequence	(5’	→3’)	 Length	product	(bp)	
1F	 14900	 149191	 GCCATGCACTACTCACCAGA	 1760	
1R	 90	 71	 AATGCTATCGCGTGCATACC	
2F	 16458	 16477	 CCCATAACACTTGGGGGTAG	 1682	
2R	 1570	 1549	 TGTAAGTTGGGTGCTTTGTGTT	
3F	 1404	 1425	 ACTTAAGGGTCGAAGGTGGATT	 1832	
3R	 3235	 3214	 CTTAACAAACCCTGTTCTTGGG	
4F	 2932	 2951	 GGGATAACAGCGCAATCCTA	 1607	
4R	 4538	 4519	 GCTTAGCGCTGTGATGAGTG	
5F	 4366	 4387	 AAAATTCTCCGTGCCACCTATC	 1659	
5R	 6024	 6003	 TTATGTTGTTTATGCGGGGAAA	
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6F	 5871	 5892	 GCTTCACTCAGCCATTTTACCT	 1747	
6R	 7617	 7596	 TCTTGTAGACCTACTTGCGCTG	
7F	 7356	 7379	 GTAGAAGAACCCTCCATAAACCTG	 1822	
7R	 9177	 9154	 TAGAAGTGTGAAAACGTAGGCTTG	
8F	 8896	 8914	 GCCCTAGCCCACTTCTTACC	 1740	
8R	 10728	 10708	 GGCCATATGTGTTGGAGATTG	
9F	 10466	 10485	 CCAAATGCCCCTCATTTACA	 1774	
9R	 12240	 12221	 GGGGCATGAGTTAGCAGTTC	
10F	 12014	 12035	 CTCACCCACCACATTAACAACA	 1816	
10R	 13829	 13808	 AGTCCTAGGAAAGTGACAGCGA	
11F	 13504	 13525	 TACTCCAAAGACCACATCATCG	 1804	
11R	 15307	 9184	 GAAGGGCAAGATGAAGTGAAAG	
Table	13.	11	amplicons	primer	list	for	mitochondrial	genome	amplification	
	
PCR	product	was	displayed	through	electrophoretic	run	on	agarose	gel	(1%),	with	the	addition	
of	GelStar	(Lonza)	at	UV	light,	using	as	size	marker	GeneRuler	100	bp	Plus	DNA	Ladder	(Thermo	
Scientific).	PCR	products	were	purified	with	magnetic	beads	(AMPure	XP,	Beckman	Coulter)	
following	the	manufacturer	instructions.		
The	 sequencing	 reaction	 mixture	 contained	 100-200	 ng	 of	 DNA	 template,	 0.5%	 DMSO	
(dimethyl	 sulfoxide),	 1.5μl	 of	 Sequencing	 Buffer	 5X,	 200μM	 of	 Primer,	 1μl	 of	 BigDye	
Terminator	3.1	Cycle	Sequencing	Kit	(Life	Techonologies),	in	a	final	volume	of	10μl		
The	cycle	conditions	were	25	cycles	of	10	sec	at	96°C,	5	sec	at	50°C,	4	min	at	60°C.	For	each	
amplicon	three	primers	were	used	to	sequence	and	their	details	are	shown	in	Table	14.	
	
Amplicon	 Position	(mtDNA)	 Sequence(5'-3')	
1	 14948	 14967	 CACATCACTCGAGACGTAAA	
1	 15564	 15583	 ATTTCCTATTCGCCTACACA	
1	 58	 39	 AATACCAAATGCATGGAGAG	
2	 16522	 16541	 TAAAGCCTAAATAGCCCACA	
2	 584	 603	 TAGCTTACCTCCTCAAAGCA	
2	 1060	 1079	 AAGACCCAAACTGGGATTAG	
3	 1445	 1464	 GAGTGCTTAGTTGAACAGGG	
3	 2047	 2066	 TTTAAATTTGCCCACAGAAC	
3	 2509	 2528	 ATCACCTCTAGCATCACCAG	
4	 3067	 3088	 TGAGTTCAGACCGGAGTAAT	
4	 3540	 3561	 TCTCACCATCGCTCTTCTAC	
4	 4010	 4029	 ACACCCTCACCACTACAATC	
5	 4410	 4429	 CAGCTAAATAAGCTATCGGG	
5	 5014	 5033	 CCTCAATTACCCACATAGGA	
5	 5544	 5563	 TCAAAGCCCTCAGTAAGTTG	
6	 6041	 6060	 CCTTCTAGGTAACGACCACA	
6	 6473	 6492	 CACAGCAGTCCTACTTCTCC	
6	 7027	 7046	 CCCACTTCCACTATGTCCTA	
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7	 7416	 7435	 TTCGAAGAACCCGTATACAT	
7	 7987	 8006	 ACTCCTTGACGTTGACAATC	
7	 8505	 8524	 ATAACAAACCCTGAGAACCA	
8	 8975	 8992	 TCATTCAACCAATAGCCC	
8	 9589	 9608	 AAGTCCCACTCCTAAACACA	
8	 10147	 10166	 ACATAGAAAAATCCACCCCT	
9	 10498	 10519	 TAGCATTTACCATCTCACTTCT	
9	 11081	 11100	 ATAACATTCACAGCCACAGA	
9	 11644	 11663	 CCTCGTAGTAACAGCCATTC	
10	 12114	 12132	 ACATCATTACCGGGTTTTC	
10	 12611	 12630	 ATTCATCCCTGTAGCATTGT	
10	 13134	 13153	 AGCAGAAAATAGCCCACTAA	
11	 13596	 13615	 CGCCTATAGCACTCGAATAA	
11	 14115	 14134	 CCCACTCATCCTAACCCTAC	
11	 14646	 14665	 CACTCAACAGAAACAAAGCA	
Table	14.	Primer	list	for	mitochondrial	genome	sequencing	
	
Sequence	 analysis	 was	 performed	 using	 the	 Sequencer	 4.10	 software	 (Gene	 Codes),	
comparing	with	the	reference	mitochondrial	DNA	sequence,	rRCS	(NC_012920)	(Andrews	et	
al.,	1999).	
	
NGS	mtDNA	sequencing	
The	Next	Generation	Sequencing	(NGS)	protocol	consists	in	two	long	PCR	amplicons	(9.1	kb	
and	11.2	kb)	(Stawski,	2013)	and	we	amplified	using	Q5	High-Fidelity	DNA	Polymerase	(with	
fidelity	280	times	higher	than	Taq)	(New	England	Biolabs).	The	PCR	mixture	contained	50	ng	
of	DNA,	1U	Q5	High-Fidelity	DNA	Polymerase	(New	England	Biolabs),	1x	Q5	Reaction	Buffer	
(New	England	Biolabs),	200	µM	PCR	nucleotides	mix	(Life	Technologies),	500	µM	each	primer	
(Sigma-Aldrich),	in	a	final	volume	of	25	µl.	The	cycle	conditions	were	94°C	for	5	min,	30	cycles	
of	30	sec	at	94°C,	30	sec	at	55°C,	72°C	for	30	sec,	and	a	final	extensionof	7	min	at	72°C	(Table	
15).	
Primer	 Position	(mtDNA)	 Sequence	(5’-3’)	 Length	product	(	bp)	
MTL-F1	 9397	 9416	 AAAGCACATACCAAGGCCAC	 9064	
MTL-R1	 1892	 1873	 TTGGCTCTCCTTGCAAAGTT	
MTL-F2	 15195	 15214	 TATCCGCCATCCCATACATT	 11170	
MTL-R2	 9796	 9773	 AATGTTGAGCCGTAGATGCC	
Table	15.	NGS	primer	list	for	mitochondrial	genome	amplification	
	
PCR	product	was	displayed	through	electrophoretic	run	on	agarose	gel	(1%),	with	the	addition	
of	GelStar	(Lonza)	at	UV	light,	using	as	size	marker	EZ	Load™	1	kb	Molecular	Ruler	(Bio-Rad).	
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PCR	products	were	purified	with	magnetic	beads	(AMPure	XP,	Beckman	Coulter)	following	the	
manufacturer	instructions.		
The	library	was	constructed	by	Nextera	XT	DNA	Library	Preparation	Kit	(Illumina,	San	Diego,	
CA).	 After	 fluorimetric	 quantification,	 using	Quantus	 Fluorometer	with	Quantifluor	 dsDNA	
System	(Pomega),	the	target	DNA	were	diluted	to	the	final	concentration	of	0,4	ng	µL.	The	
first	 step	 is	 tagmentation	 reaction,	 using	 “NexteraXT	 Transposome”,	which	 fragment	DNA	
adding	simultaneously	DNA	adapters	ends.	The	reaction,	in	a	final	volume	of	20	µl,	contains	2	
ng	of	DNA,	10	µl	TD	(Tagment	DNA	Buffer),	5	µl	of	ATM	(Amplicon	Tagment	Mix),	incubated	
at	 55°C	 for	 5	 min,	 and	 immediately	 added	 5	 µl	 of	 NT	 (Neutralize	 Tagment	 Buffer)	 and	
incubated	at	25°C	for	5	min.	
Then,	a	PCR	amplification	 (Limited-Cycle	PCR)	added	 the	 Index	1	 (i7),	 Index	2	 (i5),	and	 full	
adapter	sequences	to	the	tagmented	DNA	from	the	previous	step.	Every	sample	had	a	unique	
index	combination,	to	be	distinguished	in	the	sequences	reaction.	15	µL	of	NPM	(Nextera	PCR	
Master	Mix),	5	µL	of	index	1	primers	(N7XX)	and	5	µL	of	index	primers	2	(S5XX)	are	added.	
Themalcycler	program	is	72°C	for	3	min,	95°C	for	30	sec,	12	cycles	at	95°C	for	10	sec,	55°C	for	
30	sec,	72°C	for	30	sec,	final	extention	at	72°C	for	5	min	and	hold	at	10°C.		
The	 PCR	 product	 were	 purified	 using	 magnetic	 beads,	 AMPure	 XP	 (Beckman-Coulter),	
following	 the	manufacturer	 instructions,	and	quantified	with	 fluorimetric	method	Quantus	
Fluorometer	with	Quantifluor	dsDNA	System	(Promega).	The	normalized	DNA	were	pooled.	
The	pool	where	quantified	and	concentration	is	converted	from	ng/	µL	to	nM,	according	with	
this	formula:	
	
(concetration	in	ng/µl)	/	(660	g⁄mol	x	average	library	size)	x	106	=	concentration	in	nM	
	
where	 660g/mol	 represents	 the	mean	 value	 of	 the	molar	mass	 of	 a	 pair	 of	 dsDNA	bases,	
assuming	that	average	size	of	the	bases	is	650	bp.	Pool	were	diluted	to	a	final	concentration	
of	4	nM.	
5	µL	of	the	4nM	library	are	added	to	5	µL	of	fresh	NaOH	0,2	N,	mixed	and	incubated	at	room	
temperature	for	5	min	for	DNA	denaturation.	A	volume	of	990	µL	of	cold	Hybridization	Buffer	
are	added	to	obtain	a	library	final	concentration	of	20	pM.	Simultaneously,	the	PhiX	control	
library,	mixing	mtDNA	library	with	1%	of	PhiX	in	600	µL	final	volume,	was	carried	out	on	the	
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MiSeq	(Illumina)	sequencer.	
The	sequencing	parameters	consisted	in	150	cycles	in	Paired	End	(2x150)	on	MiSeq	Reagent	
Kit	v3,	600	cycles	(Illumina).		
Sequence	output	given	 from	sequencer	 is	a	 file	 in	FASTAQ	format,	where	each	base	call	 is	
associated	to	a	“quality	score”.	Through	 instrument	software	 (MiSeq	Reporter),	 sequences	
are	 aligned	 to	 the	 mitochondrial	 genome	 reference	 sequence,	 rCRS	 (	 revised	 Cambridge	
Reference	 Sequence),	 creating	 the	 alignment	 file	 (BAM)	 and	 identifying	 also	 sequences	
variants	(	variant	calling),	listing	in	a	VCF	file	(	Variant	Call	File).	
Population	frequencies	of	missense	mutations	and	the	mtDNA	backgrounds	on	which	they	
were	 observed	 were	 recovered	 from	 two	 public	 databases,	 Mitomap	
(http://www.mitomap.org)	 and	 HmtDB	 (http://www.hmtdb.uniba.it)	 (Lott	 et	 al.,	 2013;	
Rubino	 et	 al.,	 2012).	 Haplogroup	 affiliations	 of	 mitogenomes	 were	 assigned	 according	 to	
PhyloTree	(www.phylotree.org)	(van	Oven	and	Kayser,	2009).	
	
Protein	conservation	analysis	and	homology	modelling	
Protein	conservation	analysis	and	pathogenicity	prediction	were	carried	out	considering	 in	
silico	 protocol	 (Polyphen2,	 SIFT,	 FatHmm,	 PROVEAN,	 MutationAssessor,	 CADD,	 PANTHER,	
PhD-SNP,	 MtoolBox,	 APOGEE_boost)	 (Achilli	 et	 al.,	 2012),	 available	 on	 MitImpact	 2.7	
databases	 (mitimpact.css-mendel.it)	 (Castellana	 et	 al.,	 2015),	 and	 conservation	 analysis	 on	
mammals,	evaluating	the	amino	acid	residue	conservation	(>	70%),	local	conservation	value	>	
global	storage	value,	invariant	residue	included	in	“-4/+4”	range.	An	average	score	(0-1)	for	
each	missense	variant	has	been	calculated	and	changes	with	a	score	of	0,66-1	points	were	
considered	pathogenic,	with	a	score	of	0,5-0,65	points	were	considered	synergistic	and	with	
0-0,49	points	neutral.	
Positioning	of	amino	acid	changes	on	the	3D	structure	of	respiratory	Complex	I	was	performed	
using	UCSF	Chimera	1.11.2	(www.cgl.ucsf.edu/chimera/)	using	as	a	template	the	molecular	
model	of	ovine	respiratory	Complex	I	(PDB	file	5LNK)	(Fiedorczuk	et	al.,	2016).	
	
mtDNA	copy	number	quantification	
Absolute	quantification	of	mtDNA	relative	to	nuclear	DNA	(nDNA)	was	performed	by	a	real-
time	PCR	based	method	using	the	LightCycler480	(Roche).	This	method	is	a	multiplex	assay	
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based	on	hydrolysis	probe	chemistry.	A	mtDNA	fragment	(ND2	gene)	and	a	nDNA	fragment	
(FasL	 gene)	 were	 co-amplified	 by	 multiplex	 polymerase	 chain	 reaction	 according	 to	 the	
primers,	 probes	 and	 conditions	 previously	 published	 (Cossarizza	 et	 al.,	 2003).	 These	 two	
fragments	were	cloned	tale	to	tale	in	a	vector	and	serial	dilutions	were	used	to	construct	a	
standard	 curve,	 obtaining	 a	 ratio	 of	 1:1	 of	 the	 reference	 molecules.	 Primers	 and	 probes	
sequences	and	PCR	conditions	are	available	on	request.	
	
Skeletal	muscle	investigation	
Tibialis	anterior	muscle	biopsy	was	carried	out	and	routine	histological	and	histoenzymatic	
analysis,	 including	 cytochrome	 c	 oxidase	 (COX)	 and	 succinic	 dehydrogenase	 (SDH)	 activity	
staining,	were	performed	 (Dubowitz	et	al.,	 2013).	Respiratory	 chain	 complexes	and	citrate	
synthase	(CS)	redox	enzymatic	activities	were	determined	on	skeletal	muscle	homogenates	as	
previously	 reported	with	minor	modifications	 (Caporali	 et	 al.,	 2013;	 Trounce	 et	 al.,	 1996).	
Measurements	were	performed	at	37°C	by	using	a	dual-wavelength	spectrophotometer	(V550	
Jasco	Europe,	Italy),	under	constant	stirring	of	the	samples	diluted	in	the	assay	buffer	(50	mM	
KH2PO4	(pH	7.6),	1	mM	EDTA,	2.5	mg/ml	BSA).	For	Complex	I	NADH:DB:DCIP	oxidoreductase	
activity	was	assessed	in	the	presence	of	60	µM	DCIP	(λmax:	600	nm;	εDCIP:	mM-1	cm-1),	70	µM	
DB,	 0.3	mM	KCN	and	200	μM	NADH	 (Janssen	 et	 al.,	 2007),	 after	 the	 subtraction	of	 1	 µM	
rotenone-insensitive	 activity.	 The	 antimycin	 A-sensitive	 ubiquinol:cytochrome	 c	 reductase	
activity	of	Complex	III	was	determined	in	the	presence	of	50	µM	decylbenzoquinol	(DBH2),	0.3	
mM	KCN	and	20	µM	bovine	heart	cytochrome	c	(λmax:	550–540	nm;	εcytc	=	19.1	mM-1	cm-1).	
The	Complex	II+	III	activity	was	measured	as	the	succinate:cytochrome	c	reductase	activity	in	
the	presence	of	5	mM	succinate,	0.3	mM	KCN	and	20	µM	bovine	heart	cytochrome	c,	after	
the	subtraction	of	5	mM	malonate-	and	1	µM	antimycin	A-insensitive	activity.	The	Complex	IV	
activity	 was	 determined	 adding	 60	 μM	 of	 reduced	 bovine	 heart	 cytochrome	 c,	 after	
subtraction	 of	 0.3	 mM	 KCN-insensitive	 activity.	 Data	 were	 corrected	 for	 citrate	 synthase	
activity	 (Trounce	et	al.,	1996)	and	protein	content	measured	with	Bradford	assay.	Skeletal	
muscle	 biopsies	 also	 underwent	 transmission	 electron	 microscopy	 (TEM)	 analyses	 using	
standard	procedures.	
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Generation	and	maintenance	of	cybrids	
Cybrid	 cell	 lines	 were	 generated	 in	 Dr.	 Monica	 Montopoli’s	 Laboratory	 (Department	 of	
Pharmaceutical	 and	 Pharmacological	 Sciences,	 University	 of	 Padova)	 from	 patient’s	 skin	
fibroblasts	and	143B.Tk-	cells,	as	previously	described	(King	and	Attardi,	1996).	Cybrids	were	
grown	in	Dulbecco’s	modified	Eagle	medium	(DMEM)	supplemented	with	10%	fetal	calf	serum	
(South	America	source	from	Gibco,	Life	Technologies),	2	mM	L-glutamine,	100	U/ml	penicillin,	
100	μg/ml	streptomycin,	in	an	incubator	with	a	humidified	atmosphere	of	5%	CO2	at	37	°C.	
	
Cell	viability	assessment	
For	viability	experiments,	cells	(4x104	cells/cm2)	were	seeded	in	24	well	plates	and	incubated	
for	different	times	in	glucose-free	DMEM	supplemented	with	5	mmol/L	galactose,	5	mmol/L	
Na-pyruvate	and	5%	FBS	(DMEM-galactose).	Viability	was	determined	using	the	colorimetric	
sulforhodamine	B	(SRB)	assay	(Scarlatti	et	al.,	2003).	Briefly,	at	the	end	of	 incubation	time,	
cells	were	fixed	with	50%	trichloroacetic	acid	(TCA)	for	1	hour	at	4°C,	washed	5	times	with	H2O	
and	dried	for	1	hour	at	room	temperature.	Cells	were	then	stained	with	SRB	0.4%	diluted	in	
1%	acetic	acid	for	1	hour	at	room	temperature,	washed	4	times	with	1%	acetic	acid.	SRB	was	
solubilized	with	10	mM	Tris-HCl	pH	9.8.	The	absorbance	of	SRB	was	detected	by	measuring	
the	SRB	absorbance	at	570	nm	with	a	VICTOR3	Multilabel	Plate	Counter	(PerkinElmer	Life).	
	
Oxygen	consumption	rate	
Oxygen	consumption	rate	(OCR)	and	extracellular	acidification	rate	(ECAR)	were	measured	in	
adherent	cells	with	an	XFe24	Extracellular	Flux	Analyzer	(Seahorse	Bioscience,	Billerica,	MA,	
USA),	as	previously	described	(Iommarini	et	al.,	2014).	OCR	and	ECAR	were	measured	under	
basal	 conditions	 and	 after	 the	 sequential	 addition	 of	 1μM	 oligomycin,	 0.2	 μM	 FCCP	
(carbonylcyanide-p-trifluoromethoxyphenyl	 hydrazone,	 Sigma-Aldrich,	 Milan,	 Italy),	 1	 μM	
rotenone	and	1	μM	antimycin	A.	Data	were	normalized	on	SRB-based	cell	quantification	and	
expressed	either	as	rate	(pmol	O2/min	or	mpH/min)	or	as	percentage	of	OCR	compared	to	
non-mitochondrial	residual	OCR.	
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ATP	synthesis	
The	 rate	 of	mitochondrial	 ATP	 synthesis	was	measured	 in	 digitonin-permeabilized	 cybrids	
using	the	previously	described	luciferin/luciferase	assay,	with	minor	modifications	(Giorgio	et	
al.,	2012).	Briefly,	after	trypsinization,	cells	were	resuspended	(10x106/mL)	in	buffer	A	(10	mM	
KCl,	25	mM	Tris-HCl,	2	mM	EDTA,	0.1%	bovine	serum	albumin,	10	mM	potassium	phosphate,	
0.1	mM	MgCl2	(pH	7.4)),	kept	for	15	minutes	at	room	temperature,	and	then	incubated	with	
50	μg/mL	digitonin	 for	 1	minute.	After	 centrifugation,	 the	 cells	 pellet	was	 resuspended	 in	
buffer	A	and	aliquots	were	taken	to	measure	ATP	synthesis,	protein	content,	and	CS	activity.	
Aliquots	of	cells	were	 incubated	with	5	mM	malate	plus	5	mM	pyruvate	(complex	 I–driven	
substrates)	in	the	presence	or	absence	of	10	μg/mL	oligomycin,	or	with	10	mM	succinate	plus	
2	μg/mL	rotenone	(Complex	II–driven	substrate),	and	0.2	mM	ADP	for	1	and	3	minutes.	The	
amount	of	ATP	was	measured	as	described	(Zanna	et	al.,	2005).	Adenosine	5ʹ-triphosphate	
(ATP)	Bioluminescent	Assay	Kit	was	 from	Sigma	Aldrich.	Data	were	normalized	on	protein	
content	measured	by	Bradford	assay	and	the	rate	of	ATP	synthesis	was	expressed	as	a	ratio	
on	CS	activity	(Trounce	et	al.,	1996).	
	
Reactive	oxygen	species	(ROS)	assessment	
Mitochondrial	superoxide	production	was	determined	by	fluorescent	microscopy	incubating	
cells	with	2.5	μm	MitoSOX™	(Life	Technologies)	for	30	min	at	37°C.	MitoSOX-Red	fluorescence	
was	determined	at	580	nm	with	a	digital	imaging	system	using	an	inverted	epifluorescence	
microscope	 with	 63X/1.4	 oil	 objective	 (Nikon	 Eclipse	 Ti-U,	 Nikon,	 Japan).	 Images	 were	
captured	with	a	back-illuminated	Photometrics	Cascade	CCD	camera	system	(Roper	Scientific)	
with	500	ms	exposure	 time	and	elaborated	with	Metamorph	acquisition/analysis	 software	
(Universal	Imaging	Corp.).	
Hydrogen	 peroxide	 was	 determined	 after	 incubation	 with	 5	 μM	 of	 2,7-
dichlorodihydrofluorescein	 diacetate	 (H2DCFDA,	 Life	 Technologies).	 H2DCFDA	 fluorescence	
was	measured	at	535	nm	using	a	multilabel	counter	Wallac	1420	(PerkinElmer,	Turku,	Finland).		
	
Statistical	analyses	
Statistical	analysis	was	performed	using	the	Prism	6	software	(GraphPad),	choosing	ordinary	
one-way	ANOVA	with	multiple	comparison,	applying	Tukey	test,	as	correction	test,	or	χ2	tests	
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were	performed,	corrected	with	Bonferroni	test.	Data	were	considered	significantly	different	
for	p-values	<	0.05.	
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